Entries |
Document | Title | Date |
20080199483 | LONG LASTING FUSION PEPTIDE INHIBITORS OF VIRAL INFECTION - Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component. | 08-21-2008 |
20080220002 | MODIFIED TRANSFERIN-ANTIBODY FUSION PROTEINS - Modified fission proteins of transferrin and therapeutic proteins or peptides, preferably antibody variable regions, with increased serum half-life or serum stability are disclosed. Preferred fusion proteins include those modified so that the transferrin moiety exhibits no or reduced glycosylation, binding to iron and/or binding to the transferrin receptor. | 09-11-2008 |
20080220003 | C5a Receptor Antagonists - The present invention is related to a compound, preferably a C5a receptor antagonist, having the following structure, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21 and R22 are individually and independently selected from the group comprising H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, heteroarylalkyl, substituted heteroarylalkyl, alkoxyl, substituted alkoxyl, aryloxy, substituted aryloxy, arylalkyloxy, substituted arylalkyloxy, acyloxy, substituted acyloxy, halogen, hydroxyl, nitro, cyano, acyl, substituted acyl, mercapto, alkylthio, substituted alkylthio, amino, substituted amino, alkylamino, substituted alkylamino, bisalkyl amino, substituted bisalkyl amino, cyclic amino, substituted cyclic amino, carbamoyl (—CONH | 09-11-2008 |
20080220004 | Use of VEGF inhibitors for treatment of eye disorders - Modified chimeric polypeptides with improved pharmacokinetics and improved tissue penetration are disclosed useful for treating eye disorders, including age-related macular degeneration and diabetic retinopathy. | 09-11-2008 |
20080220005 | Comb Polymers - The present invention provides a process for producing a comb polymer comprising the steps of: a) providing: (i) (w+z) molar equivalents of a monomer; (ii) one molar equivalent of an initiator compound of formula (IX), wherein B | 09-11-2008 |
20080226656 | RG1 antibodies and uses thereof - The present invention relates to antibodies, and antigen-binding antibody fragments, directed against an RG1 polypeptide. The invention further relates to methods for utilizing the antibodies, and antibody fragments, for diagnostic and therapeutic applications. | 09-18-2008 |
20080233135 | Cobalamin taxane bioconjugates - The present invention is directed to methods and compositions including a taxane covalently bonded to the cobalt atom of a cobalamin. The composition can be delivered by any effective route, but is particularly useful as an oral anti-cancer or antiangiogenic compound. The anti-cancer/anti-angiogenic compound can be used in various chemotherapies including anti-angiogenic chemotherapies, alone or in combination with other anti-cancer/anti-angiogenic compounds. | 09-25-2008 |
20080241169 | IMMUNIZATION AGAINST AMYLOID PLAQUES USING DISPLAY TECHNOLOGY - A strategy for immunizing against amyloid plaques using display technology. The strategy includes methods, agents, and pharmaceutical compositions for vaccination against plaque forming diseases (e.g., Alzheimer's disease) that rely upon presentation of an antigen or epitope on a display vehicle. The strategy further includes methods, agents, and pharmaceutical compositions for vaccination against plaque forming diseases (e.g., Alzheimer's disease) that rely upon presentation of an antibody, or an active portion thereof, on a display vehicle. Whether antigens or antibodies are employed, desegregation of plaques results from the immunization. | 10-02-2008 |
20080241170 | Vaccines Based on Targeting Antigen to DCIR Expressed on Antigen-Presenting Cells - The present invention includes compositions and methods for increasing the effectiveness of antigen presentation using a DCIR-specific antibody or fragment thereof to which an antigen is attached that forms an antibody-antigen complex, wherein the antigen is processed and presented by a dendritic cell that has been contacted with the antibody-antigen complex. | 10-02-2008 |
20080248050 | Meta-specific vaccine, method for treating patients immunized with meta-specific vaccine - A meta-specific vaccine particle is provided. Also provided is a method for inducing an immune response in a human ( | 10-09-2008 |
20080248051 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS - Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo. | 10-09-2008 |
20080248052 | Multi-Drug Ligand Conjugates - Described herein are compounds, pharmaceutical compositions and methods for treating pathogenic cell populations in a patient. The compounds described herein include conjugates of a plurality of cytotoxic drugs and vitamin receptor binding ligands. The plurality of drugs may be the same or different. Similarly, the vitamin receptor binding ligands may be the same or different. The conjugates also include a linker that is formed from one or more spacer linkers, heteroatom linkers, and releasable linkers. | 10-09-2008 |
20080254044 | Multivariable Antigens Complexed with Targeting Humanized Monoclonal Antibody - The present invention includes compositions and methods for designing, making and using modular recombinant antibodies or fragments thereof with one half of a cohesin-dockerin pair that permits the rapid assembly of multivariant antigen conjugates. | 10-16-2008 |
20080254045 | Modulation of NKT Cell Activity with Antigen-Loaded CD1d Molecules - The invention is directed to methods of modulating an immune response in an animal, comprising administering a composition comprising one or more soluble CD1d complexes, in particular non-specific soluble CD1d complexes. Soluble CD1d complexes comprise a soluble CD1d polypeptide, a β2-microglobulin polypeptide, and a ceramide-like glycolipid antigen bound to the CD1d antigen binding groove, and in certain embodiments, an immunogen. The administration of compositions of the present invention affects the activity of CD1d-restricted NKT cells, and in particular, allows for multiple administrations without causing CD1d-restricted NKT cell anergy. | 10-16-2008 |
20080260755 | Proteolytically cleavable fusion proteins with high molar specific activity - The invention relates to therapeutic fusion proteins in which a coagulation factor is fused to a half-life enhancing polypeptide, and in which both are connected by a linker peptide that is proteolytically cleavable. The cleavage of such linkers liberates the coagulation factor from activity-compromising steric hindrance caused by the half-life enhancing polypeptide and thereby allows the generation of fusion proteins may show relatively high molar specific activity when tested in coagulation-related assays. Furthermore, the fact that the linker is cleavable can enhance the rates of inactivation and/or elimination after proteolytic cleavage of the peptide linker compared to the rates measured for corresponding therapeutic fusion proteins linked by the non-cleavable linker having the amino acid sequence GGGGGGV. | 10-23-2008 |
20080260756 | Peptide Inhibitors of iASPP - The invention relates to a polypeptide or part thereof which inhibits the apoptotic activity of the tumor suppressor protein p53, and includes screening methods to identify agents which interfere with the activity of the polypeptide. | 10-23-2008 |
20080267980 | Complement Receptor 2 Targeted Complement Modulators - Modulation of the complement system represents a therapeutic modality for numerous pathologic conditions associated with complement activation. In a strategy to prepare complement inhibitors that are targeted to sites of complement activation and disease, compositions comprising a complement inhibitor linked to complement receptor (CR) 2 are disclosed. The disclosed are compositions can be used in methods of treating pathogenic diseases and inflammatory conditions by modulating the complement system. | 10-30-2008 |
20080286290 | Anti-Cd14 Antibody Fusion Protein - A protein comprising (I) an anti-CD14 antibody or its active fragment, or a derivative thereof and (II) an inhibitor for a protease, or its active fragment, or a derivative thereof is provided. | 11-20-2008 |
20080292645 | Antibody or Antibody Fragment Coupled with an Immunogenic Agent - An immunogenic conjugate includes a target cell-specific circulating molecule and at least one immunogenic agent, the immunogenic agent being coupled by any appropriate means with the circulating molecule. Also described is a method for preparing the immunogenic conjugate and its use for treating cancers or autoimmune diseases. | 11-27-2008 |
20080292646 | RECOMBINANT FUSION PROTEIN AND POLYNUCLEOTIDE CONSTRUCT FOR IMMUNOTOXIN PRODUCTION - The present invention relates to a polynucleotide construct encoding a fusion protein consisting of a domain which binds the immunoglobulin Fc region, genetically fused to a truncated form of | 11-27-2008 |
20080299136 | WNT ANTAGONISTS AND THEIR USE IN THE DIAGNOSIS AND TREATMENT OF WNT-MEDIATED DISORDERS - The present invention provides for chimeric Wnt antagonists comprising a Frz domain component derived from a Frizzled protein, a secreted Frizzled related protein or Ror protein and an Fc immunoglobulin component, and their use in the treatment and diagnostic detection of cellular Wnt signaling and Wnt-mediated disorders, including cancer. | 12-04-2008 |
20080299137 | Fusion Proteins That Bind Effector Lymphocytes And Target Cells - Novel fusion proteins that comprise a first portion that corresponds to an antibody-like protein that is specific for an activating receptor on an effector lymphocyte or a variant thereof and a second portion that corresponds to a portion of a cell membrane protein and that binds to a cell-associated target are provided, as are methods of producing such fusion proteins, uses and methods involving such fusion proteins, and compounds and compositions related to such fusion proteins. | 12-04-2008 |
20080299138 | Toll-Like Receptor 3 Modulators and Uses Thereof - Modulators of TLR3 activity and their use are disclosed. | 12-04-2008 |
20080299139 | MAMMALIAN CYTOKINES; RELATED REAGENTS AND METHODS - Nucleic acids encoding mammalian, e.g., primate, IL-1ζ, purified IL-1ζ polypeptides and fragments thereof. Binding proteins, e.g., antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are provided. | 12-04-2008 |
20080305119 | Modified Bacteriophage Vectors and Uses Thereof - Provided herein are modified phage surface polypeptides, phages with modified surface polypeptides, nucleic acids that encode the modified surface polypeptides, and related vectors and phages comprising the vectors. The provided phage surface polypeptides optionally comprise one or more modifications, including, for example, one or more modifications to enhance targeting to an antigen-presenting cell and one or more modifications that destabilize a viral capsid. Further provided herein are methods of making a lambda phage with a modified surface polypeptide and methods of making a lambda phage with a plurality of modified surface polypeptides. Also provided herein are antigen delivery systems comprising the modified phages of the invention and methods of promoting an antigenic response in a subject by administering to the subject the antigen delivery system of the invention, alone or in combination with other immunization modalities. | 12-11-2008 |
20080311132 | Human Complement C3 Derivates with Cobra Venom Factor-Like Function - A modified human complement C3 protein (C3) is disclosed comprising a substitution of a portion of a human C3 protein, with a corresponding portion of a Cobra Venom Factor protein (CVF) which results in a human C3 protein with CVF functions, but with substantially reduced immunogenicity. Advantageously, the C3 protein can be manipulated to contain at least one of the following CVF functions: increased stability of the C3 convertase and increased resistance to the actions of factors H and/or I. A large number of hybrid C3 proteins containing substitutions in the C-terminal portion of the alpha chain of C3 are presented and tested for the above functions. Methods of treatment of diseases such as reperfusion injury, autoimmune diseases, and other diseases of increased complement activation are presented as well as methods of increasing the effectiveness of gene therapeutics and other therapeutics. | 12-18-2008 |
20080311133 | METHODS OF USING MULTIVALENT MHC CLASS II-PEPTIDE CHIMERAS - The present invention provides a multimeric complex of at least two chimeric molecules, wherein the chimeric molecules comprise an immunoglobulin constant region element and two MHC elements wherein each MHC element is associated with a peptide, and wherein the chimeric molecules are covalently linked through a carbohydrate residue of the immunoglobulin constant region element by a polyalkylene glycol linker. Methods of making and using the multimeric complexes are also provided. | 12-18-2008 |
20080311134 | CYSTEINE ENGINEERED ANTI-MUC16 ANTIBODIES AND ANTIBODY DRUG CONJUGATES - Cysteine engineered anti-MUC16 antibodies are engineered by replacing one or more amino acids of a parent anti-MUC16 antibody with non cross-linked, reactive cysteine amino acids. Methods of design, preparation, screening, and selection of the cysteine engineered anti-MUC16 antibodies are provided. Cysteine engineered anti-MUC16 antibodies (Ab) are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered anti-MUC16 antibody-drug conjugates having Formula I: | 12-18-2008 |
20080311135 | IMMUNE COMPLEX VACCINATION AS A STRATEGY TO ENHANCE IMMUNITY IN THE ELDERLY AND OTHER IMMUNE COMPROMISED POPULATIONS - The present invention generally concerns methods and compositions for improving the immune system of an individual that is an immune-compromised individual. In particular aspects, the immune-compromised individual is elderly or is immunosuppressed, such as from chemotherapy or immunosuppressants following organ or tissue transplantation. In specific embodiments, the invention relates to delivery to the immune-compromised individual of immune complexes harboring an antigen and an antibody that immunologically recognizes the antigen. The antigen may be viral, bacterial, or fungal, for example. | 12-18-2008 |
20080317765 | Method for Removal of Toxins from Mucosal Membranes - The present invention provides novel mucoadhesive compounds useful in the prevention of diseases and disorders of or which arc associated with the mucosal membrane. | 12-25-2008 |
20080317766 | Costimulatory Molecules and Uses Thereof - The invention relates to a novel costimulatory pathway mediated by a member of the semaphorin protein family, Sema4A, which is selectively expressed on the surface of dendritic cells. In addition, the invention relates to the use of Sema4A protein and protein derivatives in a method for the identification of immunomodulatory substances and to therapeutic applications making use thereof. | 12-25-2008 |
20090022742 | COMPOUNDS AND METHODS FOR DIAGNOSIS AND IMMUNOTHERAPY OF TUBERCULOSIS - Compounds and methods for diagnosing tuberculosis or for inducing protective immunity against tuberculosis are disclosed. The compounds provided include polypeptides that contain at least one immunogenic portion of one or more | 01-22-2009 |
20090022743 | Peptides Effective in the Treatment of Tumors and Other Conditions Requiring the Removal or Destruction of Cells - The invention is directed to methods of treating conditions requiring removal or destruction of harmful or unwanted cells in a patient, such as benign and malignant tumors, using compounds containing or based on peptides comprising a part of the amino acid sequence of a neural thread protein. | 01-22-2009 |
20090022744 | Modified Fc molecules - The present invention concerns compositions of matter, for example, but not limited to, modified antibodies, in which one or more biologically active peptides are incorporated into a loop region of a non-terminal domain of an immunoglobulin Fc domain. | 01-22-2009 |
20090028880 | Serum albumin binding proteins - The present invention relates to amino acid sequences that are capable of binding to serum albumin, which sequences do not significantly reduce or inhibit the binding of serum albumin to FcRn or significantly reduce the half-life of serum albumin. It further relates to proteins and polypeptides comprising or essentially consisting of such amino acid sequences; to nucleic acids that encode such amino acid sequences, proteins or polypeptides; to compositions, and in particular pharmaceutical compositions, that comprise such amino acid sequences, proteins and polypeptides; and to uses of such amino acid sequences, proteins and polypeptides. | 01-29-2009 |
20090028881 | Conjugate of an antibody against CCR5 and an antifusogenic peptide - The current invention is related to a conjugate comprising one or more antifusogenic peptides and an anti-CCR5 antibody (mAb CCR5) characterized in that one to eight antifusogenic peptides are each conjugated to one terminus of the heavy and/or light chains of said anti-CCR5 antibody and to the pharmaceutical use of said conjugate. | 01-29-2009 |
20090028882 | Methods of inhibiting binding of beta-sheet fibril to rage and consequences thereof - This invention provides a method of inhibiting the binding of beta-sheet fibril to RAGE on the surface of a cell which comprises contacting the cell with a binding-inhibiting amount of a compound capable of inhibiting binding of beta-sheet fibril to RAGE so as to thereby inhibit binding of beta-sheet fibril to RAGE. | 01-29-2009 |
20090028883 | Novel P-selectin Ligand Protein - A novel P-selectin ligand glycoprotein is disclosed, comprising the amino acid sequence set forth in SEQ ID NO:2 or by the amino acid sequence set forth in SEQ ID NO:4. DNA sequences encoding the P-selectin ligand protein are also disclosed, along with vectors, host cells, and methods of making the P-selectin ligand protein. Pharmaceutical compositions containing the P-selectin ligand protein and methods of treating inflammatory disease states characterized by P-selectin- and E-selectin-mediated intercellular adhesion are also disclosed. | 01-29-2009 |
20090028884 | OLIGOMERIC RECEPTOR LIGAND PAIR MEMBER COMPLEXES - This invention concerns an oligomeric receptor-ligand pair member complex which includes (i) an oligomeric core, said core comprising at least two chimeric proteins, said chimeric proteins comprising a first section including at least one domain forming part of a first member of a complementary binding pair and a second section comprising an oligomerising domain derived from an oligomer-forming coiled-coil protein, wherein formation of the oligomeric core occurs by oligomerisation at the oligomerising domain of the chimeric proteins; and (ii) at least two receptor-ligand pair member peptides derived from a receptor-ligand pair member peptide chain or a functional part thereof, wherein each receptor-ligand pair member peptide further comprises attached thereto a second member of said complementary binding pair capable of binding to the first complementary binding pair member as defined in (i). Each receptor-ligand pair member peptide is bound to the core via binding of the first and second members of the complementary binding pair. At least two of the receptor-ligand pair member peptides in the complex are derived from the same receptor-ligand pair member peptide chain. In one embodiment, the oligomerising domain in the second section in at least one of the chimeric proteins is derived from the pentamerisation domain of the human cartilage oligomeric matrix protein (COMP). The invention further concerns related pharmaceutical and diagnostic compositions and processes. | 01-29-2009 |
20090035323 | IMMUNE RESPONSE MODIFIER CONJUGATES - The present invention provides IRM conjugates that includes an IRM moiety and a second active moiety covalently linked to the IRM moiety in which the covalent link does not depend on UV irradiation. | 02-05-2009 |
20090041789 | Monoclonal Antibodies and Single Chain Antibody Fragments Against Cell-Surface Prostate Specific Membrane Antigen - Isolated monoclonal antibodies or an antigen binding portion thereof which bind to prostate specific membrane antigen in its native form occurring on the surface of tumor cells characterized in that it is linked to a label or a cytotoxic agent or constructed as a part of a bispecific antibody or a recombinant diabody. | 02-12-2009 |
20090041790 | Methods for treating cardiovascular disease using a soluble CTLA4 molecule - The present invention relates to compositions and methods for treating cardiovascular system diseases by administering to a subject soluble CTLA4 molecules that block endogenous B7 molecules from binding their ligands. | 02-12-2009 |
20090053246 | IMMUNOGLOBULIN FC FRAGMENT MODIFIED BY NON-PEPTIDE POLYMER AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME - Disclosed are an Fc fragment modified by a non-peptide polymer, a pharmaceutical composition comprising the Fc fragment modified by the non-peptide polymer as a carrier, a complex of the Fc fragment and a drug via a linker and a pharmaceutical composition comprising such a complex. The Fc fragment modified by a non-peptide peptide according to the present invention lacks immunogenicity and effector functions. Due to these properties, the Fc fragment maintains the in vivo activity of a drug conjugated thereto in high levels, remarkably increases the serum half-life of the drug, and remarkably reduces the risk of inducing immune responses. | 02-26-2009 |
20090053247 | BIOLOGICAL MATERIALS AND USES THEREOF | 02-26-2009 |
20090060925 | Rage Fusion Proteins and Methods of Use - Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to an immunoglobulin CH2 domain. Such fusion proteins may provide specific, high affinity binding to RAGE ligands. Also disclosed is the use of the RAGE fusion proteins as therapeutics for RAGE-mediated pathologies. | 03-05-2009 |
20090060926 | MEDICINE FOR TREATMENT OF CARCINOMA - A medicine for treatment of a carcinoma which can be supplied to the carcinoma via the circulatory system, contains two active components coupled to one another. The first active component is formed of at least one coupling molecule that specifically tethers to a target molecule formed by the cancer tissue. The second active component is formed of at least one signal molecule typical to inflammation, or of at least originating molecule encoding such a signal molecule. | 03-05-2009 |
20090068203 | Methods for treating cardiovascular disease using a soluble CTLA4 Molecule - The present invention relates to compositions and methods for treating cardiovascular system diseases by administering to a subject soluble CTLA4 molecules that block endogenous B7 molecules from binding their ligands. | 03-12-2009 |
20090068204 | Morinda citrifolia Based Formulations for Regulating T cell Immunomodulation in Neonatal Stock Animals - Both liquid and dry form | 03-12-2009 |
20090068205 | ErbB4 antagonists - The present invention concerns methods and means for controlling excessive proliferation and/or migration of smooth muscle cells, and in particular for treating stenosis, by using antagonists of a native ErbB4 receptor. The invention further concerns a method for the identification of ErbB4 agonists and antagonists capable of inhibiting or enhancing the proliferation or migration of smooth muscle cells. | 03-12-2009 |
20090081242 | METHODS OF THERAPY FOR B-CELL MALIGNANCIES USING ANTAGONIST ANTI-CD40 ANTIBODIES - Methods of therapy for B-cell malignancies are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity when the antibody binds a CD40 antigen on a normal human B cell, exhibits antagonist activity when the antibody binds a CD40 antigen on a malignant human B cell, and can exhibit antagonist activity when the antibody binds a CD40 antigen on a normal human B cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of malignant human B cells. | 03-26-2009 |
20090098147 | Antibody fragment-polymer conjugates and uses of same - Described are conjugates formed by an antibody fragment covalently attached to a non-proteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD. The conjugates exhibit substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the underivatized parental antibody fragment. Also described are conjugates directed against human vascular endothelial growth factor (VEGF), human p185 receptor-like tyrosine kinase (HER2), human CD20, human CD18, human CD11a, human IgE, human apoptosis receptor-2 (Apo-2), human tumor necrosis factor-α (TNF-α), human tissue factor (TF), human α | 04-16-2009 |
20090098148 | HIGH EFFICIENCY TISSUE-SPECIFIC COMPOUND DELIVERY SYSTEM USING STREPTAVADIN-PROTEIN A FUSION PROTEIN - The present invention relates to methods and compositions that can be employed to introduce toxins and nucleic acids into the cytoplasm or nucleus of a eukaryotic cell, particularly a cell of a higher vertebrate. The invention particularly concerns the use of a fusion protein of streptavidin and protein A sequences to form a non-covalent complex of a toxin or nucleic acid and an antibody. | 04-16-2009 |
20090104210 | Peptide compounds for treating obesity and insulin resistance - Compounds comprising an angiopoietin-like protein 6 (Angptl6) peptide for use in the treatment of metabolic syndrome, in particular, obesity and insulin resistance are described. | 04-23-2009 |
20090117133 | POLYMERIC IMMUNOGLOBULIN FUSION PROTEINS THAT TARGET LOW AFFINITY FCyRECEPTORS - The present invention concerns a family of nucleic acids, polypeptides and cloning vectors which direct expression of fusion proteins that can mimic aggregated IgG (AIG) and immune complex function with respect to their interactions with FcγR and which allow for the inclusion and targeting of a second protein domain to cells expressing FcγR. This was accomplished by expressing multiple linear copies of the hinge and CH2 domains (HCH2) of human IgG | 05-07-2009 |
20090117134 | Truncated EGF Receptor - The present invention relates to truncated EGF receptor molecules that exhibit increased binding affinities for EGFR ligands such as EGF and TGF1. The present invention also relates to methods of screening for EGF receptor ligands and methods of treatment which involve the use of these molecules. | 05-07-2009 |
20090117135 | VACCINE COMPRISING AN ANTIGEN CONJUGATED TO LOW VALENCY ANTI-CD40 OR ANTI-CD28 ANTIBODIES - We describe a conjugate comprising an antibody and antigen wherein said conjugate has low antibody valency and including methods to prepare said conjugate. | 05-07-2009 |
20090123485 | Antigen Antibody Complexes as HIV-1 Vaccines - The present relation relates to antigen-antibody complexes for use as prophylactic and therapeutic vaccines for infectious diseases of AIDS. The present invention encompasses the preparation and purification of immunogenic antibody-antigen complexes which are formulated into the vaccines of the present invention. | 05-14-2009 |
20090136525 | Immunoglobulins Comprising Predominantly a Glcnacman3Glcnac2 Glycoform - Compositions and methods for producing compositions comprising immunoglobulins or immunoglobulin fragments having an N-linked glycosylation pattern consisting predominantly of the GlCNAcMan | 05-28-2009 |
20090142359 | Antibody-induced apoptosis - Anti-Her2 antibodies which induce apoptosis in Her2 expressing cells are disclosed. The antibodies are used to “tag” Her2 overexpressing tumors for elimination by the host immune system. Also disclosed are hybridoma cell lines producing the antibodies, methods for treating cancer using the antibodies, and pharmaceutical compositions. | 06-04-2009 |
20090142360 | USE OF FERRITIN TO TREAT IRON DEFICIENCY DISORDERS - The present inventors have demonstrated the presence of H-ferritin receptors on endothelial cells in culture and on rat brain rat brain microvasculature, identifying H-ferritin as a means for transporting iron across the blood brain barrier. The present invention provides a method for treating an iron deficiency disorder in a patient, comprising administering to a patient in need thereof a therapeutically effective amount of a ferritin-iron complex. In an embodiment of the invention, the ferritin-iron complex comprises H-ferritin. In another embodiment, the iron deficiency disorder comprises an iron deficiency in the brain. The present invention also provides a method for delivering iron to the brain, comprising administering iron in the form of a ferritin-iron complex to a patient, whereby said iron is transported across the blood-brain barrier and delivered to the brain; a method for using H-ferritin as a targeting moiety, comprising attaching H-ferritin to a liposome, whereby said liposome is targeted to the brain and/or cells within the brain; and a method for treating an iron overload disorder in a patient, comprising administering to a patient in need thereof a therapeutically effective amount of a multi subunit ferritin complex, wherein said multi subunit ferritin complex is at less than 100% iron binding capacity. | 06-04-2009 |
20090155289 | FURIN-CLEAVABLE PEPTIDE LINKERS FOR DRUG-LIGAND CONJUGATES - Disclosed are certain peptide linkers for conjugating drugs to ligands, and the resulting drug-linker-ligand molecules and compositions thereof. The conjugated molecules useful for the targeted delivery of drugs to the desired cells, and allow for the intracellular release of the drug in cases where the targeted antigen is internalized via the trans Golgi network and not the lysosomal pathway. | 06-18-2009 |
20090155290 | Antigen - The present invention relates to a novel method for the delivery of agents to tumour cells. In particular it relates to a method for the specific delivery of agents to the interior of tumour cells. Uses of the method are also described. | 06-18-2009 |
20090175886 | MONOCLONAL ANTIBODIES AGAINST CD30 LACKING IN FUCOSYL AND XYLOSYL RESIDUES - The invention pertains to anti-CD30 antibodies that lack fucosyl and xylosyl residues. The antibodies of the invention exhibit increased antibody-dependent cellular cytotoxicity (ADCC) activity, including the ability to lyse CD30-expressing cell lines that are not lysed by the fucosylated and xylosylated form of the antibodies. The invention also provides host cells that express the anti-CD30 antibodies that lack fucosyl and xylosyl residues, wherein the host cells are deficient for a fucosyltransferase and a xylosyltransferase. Methods of using the antibodies to inhibit the growth of CD30 cells, such as tumor cells, are also provided. | 07-09-2009 |
20090175887 | ANTIBODIES DIRECTED TO THE DELETION MUTANTS OF EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREOF - The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided. | 07-09-2009 |
20090186040 | DOSING METHODS FOR TREATING AUTOIMMUNE DISEASES USING A TACI-Ig FUSION PROTEIN SUCH AS ATACICEPT - In various embodiments, the present invention provides methods, compositions, dosing, and administration schedules for treatment of autoimmune diseases, including systemic erythematosus (SLE), for example, comprising administering to a patient in need of such treatment a TACI-Ig fusion molecule such as atacicept. In one embodiment, the TACI-Ig fusion molecule is administered in amount sufficient to slow, suppress or inhibit proliferation-inducing functions of BLyS and APRIL, in particular the use of multiple administrations of the fusion molecule at relatively low dose over the course of the treatment. | 07-23-2009 |
20090191222 | Metastatic human tumor associated molecule, methods to detect both activated gene and protein and to interfere with gene expression - This disclosure characterizes the function and the expression of the human protein encoded by tm9sf4. The protein is highly expressed in malignant tumor cells and therefore is a novel marker for malignancy. Moreover, the protein is involved in the phagocytotic character of tumor cells. This disclosure provides methods and tools to diagnose and follow up malignancy of tumors. Furthermore, means to inhibit phagocytotic character of tumor cells as well as means to treat cancer are provided. | 07-30-2009 |
20090191223 | Peptides that selectively home to heart vasculature and related conjugates and methods - The present invention provides a variety of isolated peptides and peptidomimetics, which can be useful, for example, in constructing the conjugates of the invention or, where the peptide itself has biological activity, in unconjugated form as a therapeutic for treating any of a variety of cardiovascular diseases as described below. Thus, the present invention provides an isolated peptide or peptidomimetic which has a length of less than 60 residues and includes the amino acid sequence CRPPR (SEQ ID NO: 1) or a peptidomimetic thereof. The invention further provides an isolated peptide or peptidomimetic which has a length of less than 60 residues and includes the amino acid sequence CARPAR (SEQ ID NO: 5) or a peptidomimetic thereof, or amino acid sequence CPKRPR (SEQ ID NO: 6) or a peptidomimetic thereof. | 07-30-2009 |
20090191224 | Nucleolin-Mediated Cancer Diagnostics and Therapy - The present invention provides for diagnostic kits for identifying cancer patients who are more susceptible to cancer therapies employing endostatin and other angiogenesis inhibitors, based upon the discovery that Nucleolin is a specific receptor for Endostatin. In particular, the diagnostic kits include antibody molecules against Nucleolin, DNA or RNA molecules that specifically bind to nucleic acid molecules encoding Nucleolin. The present invention also discloses methods of screening for angiogenesis inhibitors which specifically interact with Nucleolin, and act as angiogenesis inhibitors in an analogous manner as Endostatin. In addition, the present invention discloses methods of inhibiting the proliferation of endothelial cells or angiogenesis of tumor by administering an anti-nucleolin antibody linked to a cytotoxic agent such as tumor necrosis factor alpha to the endothelial cells. | 07-30-2009 |
20090202571 | Bioreductively-activated prodrugs - A compound of formula (1), or a pharmaceutically acceptable salt thereof, wherein: —Ar is a substituted heteroaryl group bearing at least one nitro or azido group or is a benzoquinone, naphthoquinone or fused heterocyloquinone; -R1 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl or optionally substituted heteroaryl; -R2 is a glycoside, OH, optionally substituted alkyl, optionally substituted alkoxy, C | 08-13-2009 |
20090202572 | COMPOSITIONS AND METHODS FOR MODULATING BONE MASS - The instant invention relates to compositions and methods for treating or preventing bone diseases. In certain aspects, the invention provides compositions comprising a β-adrenergic antagonist or agonist associated to a bone-targeted molecule, as well as methods of modulating bone mass and/or growth in a mammal by administering a composition of the present invention. In other aspects, the invention provides methods of modulating bone mass and/or growth in a mammal by administering a composition comprising a β2-selective antagonist or agonist. | 08-13-2009 |
20090214576 | TYROSINE KINASE INHIBITOR COMPOSITIONS AND METHODS FOR MANUFACTURING AND USING THEM IN THE TREATMENT OF DISEASE - The invention is the method of using the soluble modified receptor erbB3 to treat breast cancer by competitively inhibiting ligands, such as heregulin, from binding to erbB3 tyrosine kinase receptors on cell surfaces. | 08-27-2009 |
20090226465 | MACROCYCLIC DEPSIPEPTIDE ANTIBODY-DRUG CONJUGATES AND METHODS - The present invention relates to antibody-drug conjugate compounds of Formula I: Ab (L D)p I where one or more macrocyclic depsipeptide drug moieties (D), selected from Aplidin, Didemnin B, Kahalalide F, and analogs and derivatives therefrom, are covalently attached by a linker (L) to an antibody (Ab) which binds to one or more tumor-associated antigens or cell-surface receptors. These compounds may be useful in methods of diagnosis or treatment of cancer, and other diseases and disorders. | 09-10-2009 |
20090252749 | Compositions and Methods for Producing a Composition - The invention provides for mammalian cells capable of producing recombinant CTLA4-Ig and variants thereof. The invention also provides for compositions comprising CTLA4-Ig and formulations thereof. The invention further provides for methods for mass-producing CTLA4-Ig from mammalian cells capable of producing this recombinant protein, and for purifying the CTLA4-Ig. | 10-08-2009 |
20090252750 | ANTIBODIES AND IMMUNOTOXINS THAT TARGET HUMAN GLYCOPROTEIN NMB - The invention provides high affinity antibodies suitable for forming immunotoxins that inhibit the growth of cells expressing human glycoprotein NMB, including glioblastoma multiform cells, anaplastic astrocytoma cells, anaplastic oligodendroglioma cells, oligodendroglioma cells, and melanoma cells. | 10-08-2009 |
20090258029 | Heparin Prodrugs and Drug Delivery Stents Formed Therefrom - A prodrug comprising a heparin and a drug is provided. The prodrug can be used to form a coating on a medical device. The prodrug can also be used with a polymeric material to form a coating on a medical device. The polymeric material can be a hydrophobic polymer, a hydrophilic polymer, a non-fouling polymer, or combinations thereof. The medical device can be implanted in a human being for the treatment of a disease such as atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, or combinations thereof. | 10-15-2009 |
20090274710 | TRANS-MEMBRANE-ANTIBODY INDUCED INHIBITION OF APOPTOSIS - Cell suicide (apoptosis) is associated with pathogenesis, for example, it is the major cause for the loss of neurons in Alzheimer's disease. Caspase-3 is critically involved in the pathway of apoptosis. Superantibody (SAT)-trans-membrane technology has been used to produce antibodies against the caspase enzyme in an effort to inhibit apoptosis in living cells. The advantage of using trans-membrane antibodies as apoptosis inhibitors is their specific target recognition in the cell and their lower toxicity compared to conventional apoptosis inhibitors. It is shown that a MTS-transport-peptide modified monoclonal anti-caspase-3 antibody reduces actinomycin D-induced apoptosis and cleavage of spectrin in living cells. These results indicate that antibodies conjugated to a membrane transporter peptide have a therapeutic potential to inhibit apoptosis in a variety of diseases. | 11-05-2009 |
20090274711 | LEVELS OF BLyS/APRIL HETEROTRIMERS IN SERUM AND USE IN DIAGNOSTIC METHODS - The present invention provides a method of measuring the levels of BLyS/APRIL heterotrimers (HT) in a biological sample, in a preferred embodiment, in serum. The diagnostic assays are useful in predicting an individual's likelihood of developing or currently suffering from an autoimmune disease, such as SLE and for methods for treating an individual clinically diagnosed with an autoimmune disease. This diagnostic test serves to predict a patient's likelihood to respond to a specific drug treatment, in particular treatment with HT antagonists, either singly or in combination with other immune suppressive drugs. | 11-05-2009 |
20090274712 | COMPOSITIONS FOR COATING CELL MEMBRANES AND METHODS OF USE THEREOF - In certain aspects, the invention relates to cell delivery compositions comprising a progenitor cell and a targeting moiety, and methods related thereto. Such compositions and methods may be used, for example, in administering a targeted cell therapy cell therapy to a subject. | 11-05-2009 |
20090280132 | COUPLING OF PERIPHERAL TOLERANCE TO ENDOGENOUS IL-10 PROMOTES EFFECTIVE MODULATION OF T CELLS AND AMELIORATES AUTOIMMUNE DISEASE - Immunomodulating agents comprising at least one Fc receptor ligand and at least one immunosuppressive factor are provided as are methods for their manufacture and use. The immunomodulating agents may be in the form of polypeptides or chimeric antibodies and preferably incorporate an immunosuppressive factor comprising a T cell receptor agonist or antagonist. The compounds and compositions of the invention may be used to selectively suppress the immune system to treat symptoms associated with immune disorders such as allergies, transplanted tissue rejection and autoimmune disorders including autoimmune diabetes, rheumatoid arthritis and multiple sclerosis. | 11-12-2009 |
20090280133 | PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF - Disclosed are compounds of Formula I effective as cytotoxic agents. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs. | 11-12-2009 |
20090285838 | USE OF SOLUBLE CD164 IN INFLAMMATION AND AUTOIMMUNE DISORDERS - The present invention relates to novel therapeutic uses of soluble proteins comprising the extracellular region of human CD164, in particular for treating inflammatory and/or autoimmune disorders. | 11-19-2009 |
20090285839 | Antigen uptake receptor for candida albicans on dendritic cells - Dendritic cells (DC) that express the type II C-type lectin DC-SIGN (CD209) are located in the submucosa of tissues, where they mediate HIV-1 entry. Interestingly, the pathogen | 11-19-2009 |
20090285840 | METHODS FOR TREATING PATHOLOGICAL NEOVASCULARIZATION - Provided herein are compositions and methods that inhibit expression of Adam9 gene products, such as ADAM9 mRNA and/or ADAM9 polypeptides, as a therapeutic approach for the treatment of pathological neovascularization and conditions associated with angiogenesis. | 11-19-2009 |
20090285841 | ANTITUMOR COMBINATIONS CONTAINING A VEGF-INHIBITING AGENT AND 5FU OR A DERIVATIVE THEREOF - This invention relates to antitumor combinations comprising a VEGF inhibitor combined with 5-fluorouracil or with a 5-fluoropyrimidine derivative that are therapeutically useful in the treatment of neoplastic diseases, and pharmaceutical compositions comprising such combinations. | 11-19-2009 |
20090291091 | USE OF THE GLOBULAR DOMAIN OF ACRP30 FOR THE PREPARATION OF A MEDICAMENT FOR THE PREVENTION AND/OR TREATMENT OF THROMBOSIS-RELATED DISEASES - It is the object of the present invention to provide novel means for the treatment and/or prevention of thrombosis, tumor implantation, tumor seeding and metastasis. More specifically, the present invention relates to the use of a polypeptide comprising the globular head of Acrp30 for the manufacture of a medicament for treatment and/or prevention of thrombosis-related disorder, an hypertensive disorder of the pregnancy, tumor implantation, tumor seeding and metastasis. | 11-26-2009 |
20090291092 | TREATMENT OF MITOCHONDRIAL DISEASES WITH AN ERYTHROPOIETIN MIMETIC - Methods of treating mitochondrial disorders that are not respiratory chain disorders using compositions comprising EPO mimetic compounds or compounds capable of increasing endogenous EPO levels or stimulating erythropoiesis are disclosed. Methods of treating Friedreich's ataxia, Leigh's syndrome, or other disorders by increasing the expression of frataxin with an EPO mimetic compound or a compound capable of increasing endogenous EPO levels or stimulating erythropoiesis are also disclosed. | 11-26-2009 |
20090304717 | Immuno-RNA-Constructs - Subject of the invention is a compound, consisting of a targeting moiety which specifically binds to a disease related cell surface marker, a nucleic acid which specifically induces cell death and a linker, wherein the linker covalently links the targeting moiety to the nucleic acid. Subject of the invention are also medicaments comprising the compound and their use as a medicament for the treatment of diseases, including proliferative diseases. | 12-10-2009 |
20090304718 | Antibody Molecules Specific for Fibroblast Activation Protein and Immunoconjugates Containing Them - Anti-FAP-antibodies and immunoconjugates, pharmaceutical compositions containing such conjugates, and their use in cancer therapy. | 12-10-2009 |
20090304719 | ACTIVATABLE BINDING POLYPEPTIDES AND METHODS OF IDENTIFICATION AND USE THEREOF - The present disclosure provides activatable binding polypeptides (ABPs), which contain a target binding moiety (TBM), a masking moiety (MM), and a cleavable moiety (CM). The present disclosure provides activatable antibody compositions, which contain a TBM containing an antigen binding domain (ABD), a MM and a CM. Furthermore the present disclosure also provides ABPs which contain a first TBM, a second TBM and a CM. The ABPs exhibit an “activatable” conformation such that at least one of the TBMs is less accessible to target when uncleaved than after cleavage of the CM in the presence of a cleaving agent capable of cleaving the CM. The disclosure further provides libraries of candidate ABPs, methods of screening to identify such ABPs, and methods of use. The disclosure further provides ABPs having TBMs that bind VEGF, CTLA-4, or VCAM, ABPs having a first TBM that binds VEGF and a second TBM that binds FGF, as well as compositions and methods of use. | 12-10-2009 |
20090311274 | NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 238P1B2 USEFUL IN TREATMENT AND DETECTION OF CANCER - A novel gene (designated 238P1B2) and its encoded protein, and variants thereof, are described wherein 238P1B2 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 238P1B2 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 238P1B2 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 238P1B2 can be used in active or passive immunization. | 12-17-2009 |
20090317408 | LIGAND CONJUGATED THERMOTHERAPY SUSCEPTORS AND METHODS FOR PREPARING SAME - Magnetic nanoparticles exhibiting enhanced heating ability in thermotherapeutic applications are described, as are several strategies to conjugate such nanoparticles. Methods for using conjugated nanoparticles are also provided. | 12-24-2009 |
20090324618 | NOVEL SIGNATURE SELF RENEWAL GENE EXPRESSION PROGRAMS - The present invention relates to compounds and methods which are useful in molecular investigations of target genes, as well as their encoded RNAs and protein, belonging to signature self renewal programs in leukemia and/or cancer stem cells. Data herein shows that leukemia stem cells can be generated from committed progenitors without widespread reprogramming of gene expression, and wherein a leukemia self-renewal associated signature is activated in the process. | 12-31-2009 |
20090324619 | Immunogenic Protein Carrier Containing An Antigen Presenting Cell Binding Domain and A Cysteine-Rich Domain - A protein carrier containing an antigen presenting cell binding domain and a cysteine-rich domain. Also described herein is an immunoconjugate containing the protein carrier with an antigen conjugated to multiple cysteine residues in the cysteine-rich domain, and an immune composition containing the immunoconjugate and an adjuvant, as well as their uses in eliciting immune responses. | 12-31-2009 |
20090324620 | CONJUGATES OF THERAPEUTIC OR CYTOTOXIC AGENTS AND BIOLOGICALLY ACTIVE PEPTIDES - The invention features conjugates of therapeutic or cytotoxic agents and biologically active peptides and methods of use thereof. | 12-31-2009 |
20100003266 | TARGETED IMMUNE CONJUGATES - Disclosed herein are materials and methods related to vaccines. Materials and methods for delivery of immunogens to the reticuloendothelial system via non-circulating lymphoid cells are provided. | 01-07-2010 |
20100008937 | TARGETED DELIVERY TO LEUKOCYTES USING NON-PROTEIN CARRIERS - Disclosed are delivery agents for selective delivery to leukocytes. The leukocyte-selective delivery agents comprise a targeting moiety that selectively binds LFA-I, a non-protein carrier moiety covalently linked to the targeting moiety and a therapeutic agent associated with the carrier moiety. The non-protein carrier moiety comprises a liposome, a micelle, or a polymeric nanoparticle comprised of PLA or PLGA. The delivery agent may be further selective for activated leukocytes by using a targeting moiety that selectively binds LFA-I in its activated conformation. The targeting moiety may comprise an antibody or functional fragment thereof such as an scFV. Appropriate therapeutic agents include a nucleic acid, a small molecule, a polypeptide, and an antibody or functional fragment thereof. Additional examples of therapeutic agents are a small RNA, an antagomir, an LNA, or an antisense oligonucleotide. One such therapeutic agent is an RNA interference molecule such as siRNA, dsRNA, stRNA, shRNA, miRNA. Specific delivery agents are provided. Methods for in vivo, in vitro and ex vivo leukocyte-selective delivery using the delivery agents are also disclosed. | 01-14-2010 |
20100008938 | SELF ASSEMBLING AMPHIPHILIC POLYMERS AS ANTIVIRAL AGENTS - There are provided amphiphilic biodegradable copolymers comprising a hydrophilic backbone with pendant aliphatic groups as the hydrophobic component. The polymers form nanoscale molecular aggregates in aqueous environments, which have hydrophobic interiors that are capable of solubilizing insoluble organic compounds and disrupting viral coat proteins. The polymers optionally feature reactive functional groups that provide attachment points for antibodies, ligands, and other targeting moieties which mediate adherence of the aggregate to a viral target. | 01-14-2010 |
20100015164 | Compositions and Methods for Modulating Osteoblast Cell Differentiation and Bone Generation Through HIF-1a - The present invention provides a novel screening tool for the determination of compounds capable of promoting bone healing, promoting osteoblast cellular differentiation, improving bone mass or volume, and/or promoting osteogenesis that could be used in the treatment of various bone-loss or bone density decreasing disorders. The present invention also provides a screening tool for the determination of compounds capable of inhibiting osteoblast cellular differentiation, decreasing bone mass or volume, and/or inhibiting osteogenesis. Also provided are compositions and methods for the treatment of various bone-loss or bone density decreasing disorders. | 01-21-2010 |
20100015165 | Two Step Miniemulsion Process - The present invention is directed to a method of producing nanoparticles and nanoparticles obtainable by that method. The invention further relates to a pharmaceutical composition, comprising said nanoparticles and the use of the nanoparticles for the treatment of diseases and conditions, requiring a pharmaceutical agent to cross one or more physiological barriers. | 01-21-2010 |
20100015166 | Therapeutic antibodies - A pharmaceutical comprising a therapeutic protein that hinds to a therapeutic target, the protein being modified with a compound that inhibits binding of the protein to the therapeutic target, the modified protein being effective for reducing an immune response against the protein and for producing a therapeutic effect by binding to the therapeutic target. The therapeutic protein may be an antibody that includes an antibody combining site that binds to the therapeutic target. | 01-21-2010 |
20100021480 | BIOACTIVE SUBSTANCE-BLOOD PROTEIN CONJUGATE AND STABILIZATION OF A BIOACTIVE SUBSTANCE USING THE SAME - This invention relates to a technology of modifying low-molecular-weight bioactive substances with short in vivo half-life and low stability in order to achieve a stable and efficient in vivo delivery thereof. More specifically, the present invention relates to a stable bioactive substance-blood protein conjugate, wherein a low-molecular-weight bioactive substance is ex vivo conjugated with a specific functional group on a blood protein through a reactive group, the low-molecular-weight bioactive substance is available as a drug for treatment and prevention in mammals including human and selected from the group consisting of a natural substance; and a method of a stable and efficient in vivo delivery of the low-molecular-weight bioactive substance based on the use of the bioactive substance-blood protein conjugate. | 01-28-2010 |
20100021481 | CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY - Conjugates of an anti-TNF antibody and one or more nonpeptidic water soluble polymers are provided. Typically, the nonpeptidic water soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided, among other things, are compositions comprising conjugates, methods of making conjugates, and methods of administering compositions to a patient. | 01-28-2010 |
20100021482 | NOVEL DEATH ASSOCIATED PROTEINS, AND THAP1 AND PAR4 PATHWAYS IN APOPTOSIS CONTROL - The invention relates to genes and proteins of the THAP (THanatos (death)-Associated Protein) family comprising a THAP domain, and their use in diagnostics, treatment of disease, and in the identification of molecules for the treatment of disease. The invention also relates to the Par4 protein and SLC chemokine pathways, including the interaction of Par4 and SLC with THAP family proteins, and the recruitment and localization of Par4 to PML nuclear bodies. | 01-28-2010 |
20100028366 | SYNERGISTIC EFFECT BETWEEN A CYANOGENIC SYSTEM AND ANOTHER OXIDATIVE INDUCING SYSTEM FOR TREATING TUMORS - The invention relates to a system capable of causing the death of tumor cells by activating caspase-independent apoptosis, comprising:
| 02-04-2010 |
20100028367 | SGP130/FC DIMERS - Described are polypeptide dimers comprising two soluble gp130 molecules wherein each of said molecules is fused to an Fc domain of an IgG1 protein and wherein the hinge region of the Fc domain is modified resulting in advantageous properties of the dimer. In a particularly preferred embodiment, the hinge region comprises the amino acid sequence motif Ala | 02-04-2010 |
20100028368 | SULFIDE, SULFOXIDE AND SULFONE CHALCONE ANALOGUES, DERIVATIVES THEREOF AND THERAPEUTIC USES THEREOF - Compounds useful as antiproliferative agents according to formula (I): wherein Ar | 02-04-2010 |
20100028369 | Hazardous substance removing material and method for removing hazardous substance - It is an object of the present invention to provide a hazardous substance removing material, which efficiently captures hazardous substances derived from microorganisms such as bacteria or viruses and rapidly inactivates them, so as to minimize the their influences on human bodies, and which is able to allow an antibody to be supported on a carrier by a simple method, and which has an improved antibody use efficiency. The present invention provides a hazardous substance removing material consisting of a carrier on which an antibody and a polymer material having an affinity for Fc region of the antibody are supported. | 02-04-2010 |
20100034836 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND ALLEVIATION OF TUMOR - The present invention is directed to methods of determining the presence of certain tumor-associated kinase polypeptides in a biological sample, and to compositions useful for the diagnosis and treatment of tumors in mammals | 02-11-2010 |
20100047258 | Drug Carriers, Their Synthesis, and Methods of Use Thereof - Drug carriers, methods of synthesizing, and methods of use thereof are provided. | 02-25-2010 |
20100047259 | FOLLISTATIN DOMAIN CONTAINING PROTEINS - The present invention relates to the use of proteins comprising at least one follistatin domain to modulate the level or activity of growth and differentiation factor-8 (GDF-8). More particularly, the invention relates to the use of proteins comprising at least one follistatin domain, excluding follistatin itself, for treating disorders that are related to modulation of the level or activity of GDF-8. The invention is useful for treating muscular diseases and disorders, particularly those in which an increase in muscle tissue would be therapeutically beneficial. The invention is also useful for treating diseases and disorders related to metabolism, adipose tissue, and bone degeneration. | 02-25-2010 |
20100055115 | COMPOSITIONS AND METHODS FOR STEM CELL DELIVERY - This invention provides compositions of matter, articles of manufacture and methods for delivering and/or affixing a stem cell to a target tissue. This invention also provides related nucleic acids, vectors, cell, methods of production, and kits. | 03-04-2010 |
20100062006 | Method and composition for the treatment of cancer by the enzymatic conversion of soluble radioactive toxic precipitates in the cancer - The invention features compositions and methods for treating or alleviating a symptom of cancer. The compositions and methods of the invention direct supra-lethal doses of radiation, called Hot-Spots, to virtually all cancer cell types. | 03-11-2010 |
20100062007 | MULTI-MODAL CANCER THERAPY USING VIRAL HITCH-HIKING - The present invention relates to an antibody fusion protein which specifically recognizes the VA, HN or F surface antigen of the New Castle Disease Virus (NDV), a surface molecule of a tumor-unspecific T cell or a surface molecule of a dendritic cell and an immunocytokine. Also encompassed by the present invention are polynucleotides encoding the aforementioned antibody fusion protein as well as tumor-unspecific key cells or dendritic cells bound by the antibody fusion protein. Moreover, the present invention relates to a method of treating a tumor in a subject comprising administering to the said subject the antibody fusion protein, the tumor-unspecific T cell, the dendritic cell or the polynucleotide of the invention. Preferably, the said tumor is a solid tumor. | 03-11-2010 |
20100068215 | Use of GDF traps to increase red blood cell levels - In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans. | 03-18-2010 |
20100080815 | MN Gene and Protein - A new gene—MN—and proteins/polypeptides encoded therefrom are disclosed. Recombinant nucleic acid molecules for expressing MN proteins/polypeptides and recombinant proteins are provided. Expression of the MN gene is disclosed as being associated with tumorigenicity, and the invention concerns methods and compositions for detecting and/or quantitating MN antigen and/or MN-specific antibodies in vertebrate samples that are diagnostic/prognostic for neoplastic and pre-neoplastic disease. Test kits embodying the immunoassays of this invention are provided. MN-specific antibodies are disclosed that can be used diagnostically/prognostically, therapeutically, for imaging, and/or for affinity purification of MN proteins/polypeptides. Also provided are nucleic acid probes for the MN gene as well as test kits comprising said probes. The invention also concerns vaccines comprising MN proteins/polypeptides which are effective to immunize a vertebrate against neoplastic diseases associated with the expression of MN proteins. The invention still further concerns antisense nucleic acid sequences that can be used to inhibit MN gene expression. | 04-01-2010 |
20100086558 | Protein Having Prolyl Oligopeptidase Activity, Nucleic Acid Encoding Same and Method for Producing and Using Same - Proteins isolated from | 04-08-2010 |
20100086559 | POLYPEPTIDE FORMULATION - The present invention relates to an aqueous pharmaceutical composition suitable for long-term storage of polypeptides containing an Fc domain of an immunoglobulin, methods of manufacture, methods of administration and kits containing same. | 04-08-2010 |
20100092494 | Composition and method for facilitating the internalization of a therapeutic agent into a cell - The present invention is a composition and method for facilitating the internalization of a therapeutic agent into a cell. Specifically, the invention relates to the use of the extracellular domain of basigin-2, cyclophilin, or anti-basigin-2 antibody or antibody fragment as a delivery moiety for internalization of a therape. | 04-15-2010 |
20100098716 | RECOMBINANT HUMAN EPO-FC FUSION PROTEINS WITH PROLONGED HALF-LIFE AND ENHANCED ERYTHROPOIETIC ACTIVITY IN VIVO - A recombinant fusion protein comprising a human erythropoietin peptide portion linked to an immunoglobulin peptide portion is described. The fusion protein has a prolonged half-life in vivo in comparison to naturally occurring or recombinant native human erythropoietin. In one embodiment of the invention, the protein has a half-life in vivo at least three fold higher than native human erythropoietin. The fusion protein also exhibits enhanced erythropoietic bioactivity in comparison to native human erythropoietin. In one embodiment, the fusion protein comprises the complete peptide sequence of a human erythropoietin (EPO) molecule and the peptide sequence of an Fc fragment of human immunoglobulin IgG1. The Fc fragment in the fusion protein includes the hinge region, CH2 and CH3 domains of human immunoglobulin IgG1. The EPO molecule may be linked directly to the Fc fragment to avoid extraneous peptide linkers and lessen the risk of an immunogenic response when administered in vivo. In one embodiment the hinge region is a human Fc fragment variant having a non-cysteine residue at amino acid 6. The invention also relates to nucleic acid and amino acid sequences encoding the fusion protein and transfected cell lines and methods for producing the fusion protein. The invention further includes pharmaceutical compositions comprising the fusion protein and methods of using the fusion protein and/or the pharmaceutical compositions, for example to stimulate erythropoiesis in subjects in need of therapy. | 04-22-2010 |
20100104588 | SERUM ALBUMIN BINDING PEPTIDES FOR TUMOR TARGETING - Peptide ligands having affinity for serum albumin are useful for tumor targeting. Conjugate molecules comprising a serum albumin binding peptide fused to a biologically active molecule demonstrate modified pharmacokinetic properties as compared with the biologically active molecule alone, including tissue (e.g., tumor) uptake, infiltration, and diffusion. | 04-29-2010 |
20100111976 | TARGETED BIOCIDES - The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as agriculture, medicine, and national defense. | 05-06-2010 |
20100111977 | Methods and compositions for treatment of myotonic dystrophy - In certain embodiments, the present invention provides compositions and methods for treating myotonic dystrophy. | 05-06-2010 |
20100119528 | Transport of Biologically Active Molecules into a Cell, Mitochondrion, or Nucleus - Novel carrier peptides are described, as well as methods of using the carrier peptides to transport biologically active molecules into a cell, mitochondrion, or nucleus, e.g., by formation of a complex of the carrier peptide non-covalently bound to a biologically active molecule. | 05-13-2010 |
20100129383 | BIFUNCTIONAL FUSION MOLECULES FOR THE DELIVERY OF ANTIGENS TO PROFESSIONAL ANTIGEN-PRESENTING CELLS - The invention provides a bifunctional fusion molecule comprising: a first functional domain comprising a first immunoglobulin variable region, a second immunoglobulin variable region and a linker for connecting the first and second variable regions; a second functional domain comprising a moiety for binding to an antigenic agent; wherein the first and second functional domains are linked; and wherein the first functional domain specifically binds to a surface molecule of a professional antigen-presenting cell, and uses thereof. | 05-27-2010 |
20100129384 | TACI-IMMUNOGLOBULIN FUSION PROTEINS - Molecules that interfere with the binding of a tumor necrosis factor receptor with its ligand, such as a soluble receptor, have proven usefulness in both basic research and as therapeutics. The present invention provides improved soluble transmembrane activator and calcium modulator and cyclophilin ligand-interactor (TACI) receptors. | 05-27-2010 |
20100136032 | TRIMERIC OX40-IMMUNOGLOBULIN FUSION PROTEIN AND METHODS OF USE - Compositions including a trimeric OX-40 fusion protein are disclosed. Also disclosed are methods for enhancing the immune response of a mammal to an antigen by engaging the OX-40 receptor on the surface of T-cells involving administering to the mammal a composition comprising a trimeric OX-40 fusion protein and a pharmaceutically acceptable carrier. | 06-03-2010 |
20100143387 | MULTIMERIC CONJUGATE - The present invention is directed to a multimeric agent and a multimeric conjugate formed from this multimeric agent and a biologically active agent. Said multimeric conjugates have a longer life time in vivo and an increased avidity compared to the unmodified biologically agent. The present invention is further directed to a pharmaceutical or diagnostic composition containing said conjugate as well as to a method of its production. The invention additionally provides the use of said conjugates for the detection, determination, separation and/or isolation of a specific binding partner and for the diagnosis, prophylaxis and treatment of diseases in which the specific binding partner is directly or indirectly involved. | 06-10-2010 |
20100143388 | Antibody Composition-Producing Cell - The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof. | 06-10-2010 |
20100150949 | METHODS AND COMPOSITIONS FOR MODULATING PROLINE LEVELS - Methods and compositions for modulating amino acid levels in a subject are provided herein. | 06-17-2010 |
20100150950 | HUMAN ANTIBODIES THAT BIND CD70 AND USES THEREOF - The present disclosure provides isolated monoclonal antibodies that specifically bind to CD70 with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human CD70. In certain embodiments, the antibodies are capable of being internalized into CD70-expressing cells or are capable of mediating antigen dependent cellular cytotoxicity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CD70, as well as methods for treating cancers, such as renal cancer and lymphomas, using an anti-CD7Q antibody of this disclosure. | 06-17-2010 |
20100158927 | ANTIBODIES, METHODS AND KITS FOR DIAGNOSING AND TREATING MELANOMA - A method of diagnosing melanoma and antibodies capable of same are disclosed. The method comprises contacting a cell of the subject with an antibody comprising an antigen recognition domain capable of binding to an MHC-I molecule being complexed with a tyrosinase peptide, wherein the antibody does not bind the MHC-I in the absence of the complexed peptide, and wherein the antibody does not bind the peptide in an absence of the MHC, under conditions which allow immunocomplex formation, wherein a presence of the immunocomplex or level thereof is indicative of the melanoma. Methods for treating melanoma and antibodies capable of same are also disclosed. Pharmaceutical compositions comprising antibodies are also disclosed. | 06-24-2010 |
20100158928 | IMMUNE RESPONSE MODIFIER COMPOSITIONS AND METHODS - The present invention provides an immune response modifier (IRM) composition that includes an IRM moiety and a second active moiety covalently linked to the IRM moiety, wherein the covalent link comprises a labile bond directly attached to the IRM moiety. | 06-24-2010 |
20100183633 | INTERLEUKIN 6 AND TUMOR NECROSIS FACTOR ALPHA AS BIOMARKERS OF JNK INHIBITION - Biomarkers for JNK inhibition are described that can be used for monitoring effectiveness of JNK inhibitors and monitoring treatment with JNK inhibitors. | 07-22-2010 |
20100183634 | MULTIFUNCTIONAL NUCLEIC ACID NANO-STRUCTURES - Compositions and methods are provided for constructing multi-functional nucleic acid nano-structures. Nano-structures are provided incorporating a built-in modularity, including nucleic acid modules. Modules contain moieties including detectible labels, nanoparticles, reactive moieties and other functional groups. Nano-structures can be used for delivery of target compounds, as well as identification of target nucleic acid molecules. | 07-22-2010 |
20100183635 | GLYCOSYLATED SPECIFICITY EXCHANGERS - The present invention is directed to ligand/receptor and antigen/antibody specificity exchangers comprising a saccharide or glycoconjugate. Methods of making these specificity exchangers and methods of using said specificity exchangers to treat or prevent human disease are described herein. | 07-22-2010 |
20100189726 | LPAAT-BETA INHIBITORS AND USES THEREOF - The invention relates to triazines and the use thereof to inhibit lysophosphatidic acid acyltransferase β (LPAAT-β) activity. The invention further relates to methods of treating cancer using said triazines. The invention also relates to methods for screening for LPAAT-β activity. | 07-29-2010 |
20100189727 | Masking Ligands For Reversible Inhibition Of Multivalent Compounds - Masking ligands for reversibly concealing the antigen-binding site of an antibody comprise epitopes of the antibody and a cleavable linker. Methods for making masking ligands comprise joining at least two copies of the epitope of an antibody to a cleavable polypeptide linker. | 07-29-2010 |
20100196403 | ANTIBODY CONJUGATES FOR CIRCUMVENTING MULTI-DRUG RESISTANCE - Conjugates of a cell permeability moiety coupled to an antibody against an intracellular epitope of a multi drug resistance (MDR) protein are provided. Also provided are pharmaceutical compositions that include these conjugates and methods for their use in preventing and inhibiting multi drug resistance to therapeutic agents, particularly to chemotherapeutic agents. | 08-05-2010 |
20100196404 | METHODS OF USE OF THE TACI/TACI-L INTERACTION - The invention discloses a novel interaction between a TNF receptor (TACI) and its interacting ligand (TACI-L). Also disclosed are methods of screening candidate molecules to determine potential antagonists and agonists of the TACI/TACI-L interaction. The use of the antagonists and agonists as therapeutics to treat autoimmune diseases, inflammation, and to inhibit graft vs. host rejections is further disclosed. | 08-05-2010 |
20100196405 | GLP-1 Fc FUSION PROTEIN FORMULATION - The invention provides a stable solution formulation comprising a therapeutically effective amount of a GLP-1-Fc fusion protein at about pH 6.5 in citrate buffer with polysorbate-80 and mannitol. The formulation is useful in treating diabetes and obesity as well as a variety of other conditions or disorders. | 08-05-2010 |
20100209440 | Targeted Delivery of siRNA - The present invention provides a method of delivering RNA interference molecules to a cell or a cell in a subject, which comprises contacting the cell with a protein-double stranded RNA complex, the complex comprising the double stranded RNA segment containing a double stranded RNA of interest and a protein, the protein comprising (1) a targeting moiety, which will specifically bind to a site on a target cell, and (2) a binding moiety linked thereto, which will bind to the double stranded RNA, wherein the double stranded RNA segment is delivered to a cell and effects RNA interference of the target RNA in the cell. | 08-19-2010 |
20100209441 | DRUG FOR SUPPRESSING PATHOGEN OCCURRING IN VIVO - To provide a drug for actively metabolizing or excreting a pathogen occurring in vivo. | 08-19-2010 |
20100215670 | Immunotoxin Fusions Comprising An Antibody Fragment and a Plant Toxin Linked by Protease Cleavable Linkers - Novel conjugates are disclosed which comprise (a) a ligand that binds to a surface molecule on a target cell, such as a cancer cell; (b) an effector molecule that is to be delivered into the cell, such as a toxin; and (c) a linker sequence that couples the ligand and the effector molecule wherein the linker comprises at least one protease cleavage site corresponding to a protease found in the intracellular trafficking pathway of the effector molecule; wherein the cleavage of the linker by the protease uncouples the effector molecule from the ligand. | 08-26-2010 |
20100215671 | Combination Therapy With Antibody-Drug Conjugates - Methods for the treatment of Hodgkin's lymphoma comprising administering both a chemotherapeutic regimen and an antibody-drug conjugate compound to a subject in need thereof are provided. | 08-26-2010 |
20100233189 | Crystal structure - This invention relates to a crystallisable composition comprising a TSHR polypeptide, to crystals comparing a TSHR polypeptide and to TSHR-related applications. | 09-16-2010 |
20100255012 | RECOMBINANT FUCOSE MODIFIED MONOVALENT HALF-ANTIBODIES OBTAINED BY MOLECULAR ENGINEERING - Glycosylated monovalent antibodies binding to selected antigens with a low or lacking fucose content, which are capable of inducing antibody dependent cellular cytotoxicity (ADCC) on cells expressing the selected antigens in the presence of effector cells, methods for producing the monovalent antibodies, pharmaceutical compositions comprising such monovalent antibodies and use thereof for different diagnostic and therapeutic applications. | 10-07-2010 |
20100255013 | GLYCOPROTEIN COMPOSITIONS - The present invention concerns compositions comprising a glycoprotein having an Fc region, wherein about 80-100% of the glycoprotein in the composition comprises a mature core carbohydrate structure which lacks fucose, attached to the Fc region of the glycoprotein. The preferred glycoprotein is an antibody or immunoadhesin. | 10-07-2010 |
20100260785 | SARP-1 Fusion Proteins and Uses Thereof - The invention relates to a fusion protein comprising a mature SARP-1 polypeptide without the Netrindomain, the fusion protein further comprising an Fc region of an immunoglobulin, wherein the fusion protein lacks certain N-terminal amino acids of the mature SARP-1 polypeptide. The invention further relates to the use of said fusion protein for treating cancer, a fibrotic disorder or a cardiovascular disorder. | 10-14-2010 |
20100266620 | Immunoconjugates for treatment of infectious diseases - The present invention features immunoconjugates which comprise therapeutic agents coupled to antibodies that specifically recognize pathogen surface antigens. These immunoconjugates can be used to treat or prevent infectious diseases. Upon administration of an immunoconjugate of the present invention to an infected host, the immunoconjugate binds to a specific antigen on the surface of the targeted pathogen (e.g., virus). As the pathogen enters the host cells, the therapeutic agent(s) in the immunoconjugate destroys the infected host cells (and, preferably, the bound pathogen), thereby preventing the replication and transmission of the pathogen. In one embodiment, the immunoconjugates of the present invention specifically recognize surface/envelope antigens of the following viruses: HIV, HBV, HCV, EBV, influenza virus, and SARS associated coronavirus. | 10-21-2010 |
20100272740 | MICRO- AND NANOSCALE DEVICES FOR DELIVERY OF ACTIVE FIBRONOLYTIC AGENTS - Disclosed are devices as may be used to deliver a fibrinolytic agent such as functional tPA to targeted sites. Disclosed devices include micro or nanosized particles as carriers of a fibrinolytic agent and a targeting polypeptide such as antifibrin antibody that specifically binds a component of a blood clot. A plurality of protein molecules can be bound to a single particle. In addition, the total number of protein molecules attached to each particle can be controlled as can the proportion of each different compound bound to a single particle. Disclosed devices can be utilized, for example, to deliver tPA to blood clots, for instance in postmyocardial infarction or ischemic stroke treatment, and can minimize systemic plasminemia compared to the use of free tPA. | 10-28-2010 |
20100291114 | Crystal structures and methods using same - The present invention relates generally to the fields of molecular biology and growth factor regulation. More specifically, the invention concerns modulators of FGFR3 function, and the identification and uses of said modulators. | 11-18-2010 |
20100303835 | PEPTOID LIGANDS FOR ISOLATION AND TREATMENT OF AUTOIMMUNE T-CELLS - The present invention provides for the identification of autoreactive T cell populations from individuals having autoimmune diseases, such as multiple sclerosis and EAE. Peptoids recognized by autoreactive T cells can be used to identify various types of autoimmune disease, and can also be used to target therapies against such populations. | 12-02-2010 |
20100310584 | Antigen - The present invention relates to a novel method for the delivery of agents to tumour cells. In particular it relates to a method for the specific delivery of agents to the interior of tumour cells. Uses of the method are also described. | 12-09-2010 |
20100316656 | CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE - The invention relates to novel tomaymicine derivatives comprising a linker. It also relates to the conjugate molecules that comprise one or more of said tomaymicine derivatives covalently linked to a cell binding agent through a linking group that is present on the linker of the tomaymycin derivative. It also relates to the preparation of the tomaymicine derivatives and of the conjugate molecules. | 12-16-2010 |
20100330107 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 24P4C12 PROTEINS - Antibody drug conjugates (ADC's) that bind to 24P4C12 protein and variants thereof are described herein. 24P4C12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer. | 12-30-2010 |
20110008373 | PRODRUGS OF CC-1065 ANALOGS - Prodrugs of analogs of the anti-tumor antibiotic CC-1065 having a cleavable protective group such as a piperazino carbamate, a 4-piperidino-piperidino carbamate or a phosphate, in which the protecting group confers enhanced water solubility and stability upon the prodrug, and in which the prodrug also has a moiety, such as a disulfide, that can conjugate to a cell binding reagent such as an antibody. The therapeutic use of such prodrug conjugates is also described; such prodrugs of cytotoxic agents have therapeutic use because they can deliver cytotoxic prodrugs to a specific cell population for enzymatic conversion to cytoxic drugs in a targeted fashion. | 01-13-2011 |
20110014216 | Drug Transfer Based on Coenzyme A and Acyl Carrier Protein - The invention relates to coenzyme A (CoA) type compounds carrying one or more drug entities and optionally a label detectable by a fluorescence detector, magnetic resonance imaging (MRI), positron emission tomography (PET) or scintigraphy, and/or a functional group which can be transformed into a drug or a detectable label. The invention further relates to a molecular shuttle which is a fusion protein comprising a proteinaceous binding entity directed to a target and an acyl carrier protein (ACP) or a fragment thereof, and carrying one or more drug entities. The proteinaceous binding entity is designed to bind to a target structure in vitro or in vivo, for example a cellular receptor. | 01-20-2011 |
20110020371 | POLY(BETA MALIC ACID) WITH PENDANT LEU-LEU-LEU TRIPEPTIDE FOR EFFECTIVE CYTOPLASMIC DRUG DELIVERY - The invention relates to the use of Polycefin-LLL nanoconjugate as a means of cytoplasmic delivery of drugs. In one embodiment, the present invention provides a drug delivery molecule, comprising a polymerized carboxylic acid molecular scaffold covalently linked to L-leucylleucylleucine. In another embodiment, the Polycefin-LLL includes drug antisense morpholino oligos, targeting antibodies, and a pH-sensitive endosome escape unit. In addition, the drug could be siRNA, microRNA, and aptamer. | 01-27-2011 |
20110045006 | LUCA2 and Antibodies That Bind Thereto - The invention provides the identification and characterization of disease and cancer-associated antigen, LUCA2. The invention also provides a family of monoclonal antibodies that bind to antigen LUCA2, methods of diagnosing and treating various human cancers and diseases that express LUCA2. | 02-24-2011 |
20110052609 | MAGNETIC TRANSDUCERS - Embodiments herein relate to the production of biocompatible magnetic nanoparticles with a high SAR-value which produce a large amount of heat when exposed to an alternating magnetic field. The produced heat can be used among others for therapeutic purposes, in particular for combating cancer. | 03-03-2011 |
20110052610 | ANTIBODY COMPOSITION EXHIBITING CELLULAR CYTOTOXICTY DUE TO GLYCOSYLATION - The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof. | 03-03-2011 |
20110052611 | PEPTIDE CONJUGATE COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF ALZHEIMER'S DISEASE - The invention provides compositions and methods for the treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient, such as Alzheimer's disease. Such methods entail administering an immunogenic fragment of Aβ, lacking a T-cell epitope, capable of inducing a beneficial immune response in the form of antibodies to Aβ. In another aspect, the immunogenic fragment of Aβ is capable of elevating plasma Aβ levels. The immunogenic fragments comprise linear or multivalent peptides of Aβ. Pharmaceutical compositions comprise the immunogenic fragment chemically linked to a carrier molecule which may be administered with an adjuvant. | 03-03-2011 |
20110059115 | ANTIBODY COMPOSITION EXHIBITING CELLULAR CYTOTOXICTY DUE TO GLYCOSYLATION - The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof. | 03-10-2011 |
20110064750 | METHOD AND KIT FOR TREATING NICOTINE ADDICTION - Described are methods and kits related to treating nicotine addiction and increasing the likelihood of nicotine abstinence. Methods and kits for reestablishing nicotine abstinence after a relapse to nicotine use are also described. | 03-17-2011 |
20110064751 | TARGETED IMMUNOCONJUGATES - The present invention relates to immunoconjugates. In particular embodiments, the present invention relates to immunoconjugates comprising at least one single-chain effector moiety and two or more antigen binding moieties. In addition, the present invention relates to nucleic acid molecules encoding such immunoconjugates, vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the immunoconjugates of the invention, and to methods of using these immunoconjugates in the treatment of disease. | 03-17-2011 |
20110064752 | EXTRACELLULAR TARGETED DRUG CONJUGATES - The present invention relates to, inter alia, extracellular drug conjugates (EDC) in which an antibody or other targeting agent (e.g. a targeting moiety) is linked to a drug through a linker (e.g. a non-cleavable linker). These conjugates are useful in the treatment of disease and/or as a tool in the evaluation of biological systems. | 03-17-2011 |
20110064753 | DRUG CONJUGATES AND THEIR USE FOR TREATING CANCER, AN AUTOIMMUNE DISEASE OR AN INFECTIOUS DISEASE - Drug-Linker-Ligand Conjugates are disclosed in which a Drug is linked to a Ligand via a peptide-based Linker unit. In one embodiment, the Ligand is an Antibody. Drug-Linker compounds and Drug compounds are also disclosed. Methods for treating cancer, an autoimmune disease or an infectious disease using the compounds and compositions of the invention are also disclosed. | 03-17-2011 |
20110064754 | Immunoconjugates Comprising Poxvirus-Derived Peptides and Antibodies Against Antigen-Presenting Cells for Subunit-Based Poxvirus Vaccines - The present invention concerns methods and compositions for subunit-based vaccines for inducing immunity against poxvirus infections, such as smallpox. Preferred embodiments concern immunoconjugates comprising one or more subunit antigenic peptides attached to an antibody or fragment thereof that targets antigen-producing cells (APCs). More preferably, the antibody binds to HLA-DR and the antigenic peptide is from an immunomodulating factor, such as the viral IL-18 binding protein (vIL18BP). However, mixtures of antigenic peptides from different viral proteins may also be used. The vaccine is capable of inducing immunity against poxvirus without risk of disseminated infection in immunocompromised hosts or transmission to susceptible contacts. | 03-17-2011 |
20110070248 | DR5 LIGAND DRUG CONJUGATES - Ligand Drug Conjugates are provided having a DR5 binding moiety attached via linking groups and/or spacers to a therapeutic agent and are effective in treatment of various cancers. | 03-24-2011 |
20110070249 | IMMUNIZING COMPOSITION AND METHOD FOR INDUCING AN IMMUNE RESPONSE AGAINST THE Beta-SECRETASE CLEAVAGE SITE OF AMYLOID PRECURSOR PROTEIN - The present invention is directed to an immunizing composition containing an antigenic product such as a multiple antigen peptide system (MAPS) or a filamentous bacteriophage displaying an AβPP epitope spanning the β-secretase cleavage site of AβPP and a method for inducing an immune response against the β-secretase cleavage site of AβPP using this immunizing composition. The present invention is also directed to antibodies against the β-secretase cleavage site of AβPP and their use in a method for inhibiting the formation of amyloid β. | 03-24-2011 |
20110076287 | NEMORUBICIN METABOLITE AND ANALOG REAGENTS, ANTIBODY-DRUG CONJUGATES AND METHODS - The present invention relates to antibody-drug conjugate compounds of Formula I: | 03-31-2011 |
20110086050 | GLYCOPROTEIN COMPOSITIONS - The present invention concerns compositions comprising a glycoprotein having an Fc region, wherein about 80-100% of the glycoprotein in the composition comprises a mature core carbohydrate structure which lacks fucose, attached to the Fc region of the glycoprotein. The preferred glycoprotein is an antibody or immunoadhesin. | 04-14-2011 |
20110097345 | NOVEL DOSING REGIMEN AND METHOD OF TREATMENT - This invention relates to a method of treatment and dosing regimen for treating disease, such as cancer and mammalian tumors, wherein therapy with a cytotoxic drug is suitable, by the administration of an antibody-toxin conjugate, such as a maytansinoid toxin, by infusion at an initial infusion rate of 1 mg/min or lower on a schedule selected from the group consisting of: (1) an amount of at least about 90 mg/m | 04-28-2011 |
20110104184 | ANTIBODIES FOR INHIBITING BLOOD COAGULATION AND METHODS OF USE THEREOF - Disclosed are antibodies that provide superior anti-coagulant activity by binding native human TF with high affinity and specificity. Also disclosed are methods of using such antibodies to reduce cancer cell tissue factor activity and to detect cancer cells that express TF. | 05-05-2011 |
20110104185 | ANTIBODY FRAGMENT-POLYMER CONJUGATES AND USES OF SAME - Described are conjugates formed by an antibody fragment covalently attached to a non-proteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD. The conjugates exhibit substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the underivatized parental antibody fragment. Also described are conjugates directed against human vascular endothelial growth factor (VEGF), human p185 receptor-like tyrosine kinase (HER2), human CD20, human CD18, human CD11a, human IgE, human apoptosis receptor-2 (Apo-2), human tumor necrosis factor-α (TNF-α), human tissue factor (TF), human α | 05-05-2011 |
20110117114 | Neovascular-Targeted Immunoconjugates - Immunoconjugates for treating diseases associated with neovascularization such as cancer, rheumatoid arthritis, the exudative form of macular degeneration, and atherosclerosis are described. The immunoconjugates typically consist of the Fc region of a human IgG1 immunoglobulin including the hinge, or other effector domain or domains that can elicit, when administered to a patient, a cytolytic immune response or cytotoxic effect against a targeted cell. The effector domain is conjugated to a targeting domain which comprises a factor VII mutant that binds with high affinity and specificity to tissue factor but does not initiate blood clotting such as factor VII having a substitution of alanine for lysine-341 or of alanine for serine-344. | 05-19-2011 |
20110123553 | Use of LINGO-4 Antagonists in the Treatment of Conditions Involving Demyelination - The invention provides methods of treating diseases, disorders or injuries involving demyelination and dysmyelination, including multiple sclerosis, by the administration of a LINGO-4 antagonist. | 05-26-2011 |
20110123554 | USES OF IMMUNOCONJUGATES TARGETING CD138 - Disclosed are methods and treatment regimes that include the administration of immunconjugates targeting CD138 to combat diseases. The immunoconjugate is either used as the sole active ingredient, as part of a treatment regime or as part of an anticancer combination. | 05-26-2011 |
20110129484 | IMMUNOTHERAPIES EMPLOYING SELF-ASSEMBLING VACCINES - Provided herein are self-assembling pharmaceutical compositions comprising a heat shock protein fused to a biotin-binding protein, wherein the biotin-binding protein is non-covalently bound to four biotinylated components, and further wherein at least two of the four biotinylated components are not identical. | 06-02-2011 |
20110135667 | ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE - The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same. | 06-09-2011 |
20110142859 | ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREFOR - Anti-CD22 antibodies and immunoconjugates thereof are provided. Methods of using anti-CD22 antibodies and immunoconjugates thereof are provided. | 06-16-2011 |
20110150907 | METHODS AND MATERIALS FOR GASTROINTESTINAL DELIVERY OF PATHOGEN/TOXIN BINDING AGENTS - The present disclosure relates generally to recombinant bacteria (e.g., | 06-23-2011 |
20110159018 | COMPLEMENT FACTOR H-DERIVED SHORT CONSENSUS REPEAT-ANTIBODY CONSTRUCTS - The present invention relates to a complement activating construct comprising a complement factor H-derived short consensus repeat (fH-derived SCR) and a binding molecule which specifically recognizes a pathogen. More specifically, the fH-derived SCR is selected from the group consisting of SCR7, SCR9, SCR13, SCR18-20 and artificial SCR (aSCR). Furthermore, an in vivo method for screening complement-based approaches for the treatment of the prevention, treatment or amelioration of an infection with a pathogen or a pathological condition associated with an infection with a pathogen is described. | 06-30-2011 |
20110165180 | Polypeptides capable of binding to CD64 comprising one or more heterologous T cell epitopes and their uses - The invention relates to the use of a polypeptide that comprises i) a first portion comprising the part of human Fc that binds to CD64, and ii) a second portion comprising one or more heterologous T cell epitopes for stimulating a cytotoxic T cell response. The polypeptide may be an antibody that may be used to stimulate a cytotoxic T cell response against pathogens and tumour cells in patients in need of such treatment. | 07-07-2011 |
20110165181 | RELAY VACCINE - The present invention provides a method and composition for raising an immune response in an animal. The method comprising administering to the animal a composition comprising a carrier and an antigen bound to a targeting moiety. The targeting moiety binds to at least one receptor that is upregulated on lymphocytes that home to MAdCAM | 07-07-2011 |
20110165182 | CONJUGATE OF AN ANTIBODY AGAINST CCR5 AND AN ANTIFUSOGENIC PEPTIDE - The current invention is related to a conjugate comprising one or more antifusogenic peptides and an anti-CCR5 antibody (mAb CCR5) characterized in that one to eight antifusogenic peptides are each conjugated to one terminus of the heavy and/or light chains of said anti-CCR5 antibody and to the pharmaceutical use of said conjugate. | 07-07-2011 |
20110177100 | TARGETING PAX2 FOR THE INDUCTION OF DEFB1-MEDIATED TUMOR IMMUNITY AND CANCER THERAPY - Provided is a method of treating cancer in a subject by inhibiting expression of PAX2. An example of a cancer treated by the present method is prostate cancer. In the cancer treatment methods disclosed, the method of inhibiting expression of PAX2 can be by administration of a nucleic acid encoding an siRNA for PAX2. A method of treating cancer in a subject by administering DEFB1 is also provided. Similarly, provided is a method of treating cancer in a subject by increasing expression of DEFB1 in the subject. | 07-21-2011 |
20110177101 | TARGETING PAX2 FOR THE INDUCTION OF DEFB1-MEDIATED TUMOR IMMUNITY AND CANCER THERAPY - Provided is a method of treating cancer in a subject by inhibiting expression of PAX2. An example of a cancer treated by the present method is prostate cancer. In the cancer treatment methods disclosed, the method of inhibiting expression of PAX2 can be by administration of a nucleic acid encoding an siRNA for PAX2. A method of treating cancer in a subject by administering DEFB1 is also provided. Similarly, provided is a method of treating cancer in a subject by increasing expression of DEFB1 in the subject. | 07-21-2011 |
20110177102 | TARGETED DOUBLE STRANDED RNA MEDIATED CELL KILLING - A method of killing a specific target cell/tissue is disclosed. The method comprises exposing the specific target cell/tissue to a composition-of-matter which comprises a double stranded RNA molecule associated with a targeting moiety selected capable of targeting to the specific target cell/tissue, thereby killing the specific target cell/tissue. | 07-21-2011 |
20110182919 | Immunoglobulin Chimeric Monomer-Dimer Hybrids - The invention relates to a chimeric monomer-dimer hybrid protein wherein said protein comprises a first and a second polypeptide chain, said first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and said second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention. | 07-28-2011 |
20110189206 | Antibody Targeting Through a Modular Recognition Domain - Antibodies containing one or more modular recognition domains (MRDs) used to target the antibodies to specific sites are described. The use of the antibodies containing one or more modular recognition domains to treat disease, and methods of making antibodies containing one or more modular recognition domains are also described. | 08-04-2011 |
20110189207 | METHODS FOR SOLUBLE ZALPHA11 CYTOKINE RECEPTORS - Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for soluble zalpha11 receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block zalpha11 Ligand activity in vitro and in vivo, and may be used in conjunction with zalpha11 Ligand and other cytokines to selectively stimulate the immune system. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto. | 08-04-2011 |
20110189208 | TB VACCINE - The invention relates to a vaccine useful in therapy and prevention of mycobacterial infections. | 08-04-2011 |
20110195077 | METHODS AND COMPOSITIONS USING FGF23 FUSION PPOLYPEPTIDES - The present disclosure is directed to methods, kits and compositions for preventing or treating age-related conditions or metabolic disorders. The fusion polypeptides of the disclosure include FGF23 or an active fragment thereof. In one embodiment, the fusion polypeptide comprises (a) a polypeptide comprising fibroblast growth factor 23 (FGF23), or a functionally active variant or derivative thereof, wherein FGF23 has a mutation at one or more of the positions Q156, C206 and C244; and (b) either a modified Fc fragment having decreased affinity for Fc-gamma-receptor and/or increased serum half-life, or a polypeptide comprising at least one extracellular subdomain of a Klotho protein, or a functionally active variant or derivative thereof; and, optionally (c) a linker. The Klotho fusion proteins are useful in the treatment and prevention of a variety of age-related conditions and metabolic disorders. In another embodiment, the fusion polypeptide comprises a FGF (such as FGF23), or a functionally active variant or derivative thereof; and a modified Fc fragment, or a functionally active variant or derivative thereof. In various embodiments of the fusion polypeptides, FGF23 has mutations which decrease aggregation and protease-mediated cleavage. | 08-11-2011 |
20110200622 | POLYPEPTIDE SPECIFICALLY BINDING TO VASCULAR ENDOTHELIAL GROWTH FACTOR, FUSION PROTEIN INCLUDING POLYPEPTIDE, AND METHODS THEREFOR - A polypeptide inhibiting binding between a vascular endothelial growth factor and a vascular endothelial growth factor receptor, a fusion protein including the same, and a method of preparing the fusion protein are disclosed. | 08-18-2011 |
20110200623 | POLYPEPTIDE COMPLEX COMPRISING NON-PEPTIDYL POLYMER HAVING THREE FUNCTIONAL ENDS - Disclosed is a protein complex, comprising a physiologically active polypeptide, a dimeric protein and a non-peptidyl polymer having three functional ends (3-arm), with the linkage of both the physiologically active polypeptide and the dimeric protein to the 3-arm non-peptidyl polymer via respective covalent bonds. The protein complex guarantees the long acting activity and biostability of a physiologically active polypeptide. Having the ability to maintain the bioactivity of physiologically active polypeptides or peptides highly and to significantly improve the serum half life of the polypeptides or peptides, the protein complex can be applied to the development of sustained release formulations of various physiologically active polypeptide drugs. Also, it utilizes raw materials including the physiologically active polypeptides without significant loss, thereby increasing the production yield. Further, it can be easily purified. | 08-18-2011 |
20110200624 | NOVEL PEPTIDES FOR USE IN TRANSFECTION - Novel peptides derived from antibody complementarity determining regions (CDRs) that enhance delivery of macromolecules into cells, particularly when used in combination with cationic lipids, are provided. The peptides can be combined with cationic lipids, and compositions of cationic lipids associated with enhancer elements, to provide reagents that can complex with macromolecules such as nucleic acids, proteins and peptides and permit introduction of these macromolecules into a variety of cells and tissues in vitro or in vivo with greatly enhanced efficiency compared to other lipid-based reagents. Methods for delivering macromolecules into target cells and tissues using the lipids and enhancer elements are provided. | 08-18-2011 |
20110206704 | Methods and compositions for modulating hepatocyte growth factor activator - The present invention relates generally to the fields of molecular biology and growth factor regulation. More specifically, the invention concerns modulators of hepatocyte growth factor activator function, and the identification and uses of said modulators. | 08-25-2011 |
20110206705 | B7-H3 AS A BIOMARKER FOR DIAGNOSING THE PROGRESSION AND EARLY LYMPH NODE METASTASIS OF CANCER - B7H3 is a ligand member of the immunoregulatory family of proteins on immune cells. In one embodiment, a method for diagnosing the progression of cancer with a high propensity of primary tumor metastasis to the lymph node or distant site is provided. Such a method may comprise obtaining a cancer tissue sample from a cancer patient, determining an expression level of B7-H3 present in the tissue sample, and diagnosing the progression of the cancer having a high propensity of primary tumor metastasis to the lymph node or distant site based upon the expression level, wherein an increased expression level correlates with an increased probability of having regional lymph nodes or organ site that are positive for metastases. | 08-25-2011 |
20110212114 | METHOD FOR MAKING TARGETED THERAPEUTIC AGENTS - Provided herein are methods and kits for making a targeted therapeutic for treating a disease or condition. The therapeutic agents can be targeted to patient-specific disease markers. In one of these methods, the method includes obtaining a biological sample from a patient having the disease or condition, or who is at risk for developing the disease or condition. In this particular method, the sample includes a population of diseased cells, screening a library comprising proteins linked to their cognate mRNAs to identify mRNA-protein pairs that bind to the diseased cells, isolating one or more proteins from the identified mRNA-protein pairs, and conjugating the isolated protein(s) to a therapeutic agent. Some of the methods further include preparing a library with proteins linked to their cognate mRNAs. In certain of these methods, the preparation of the library includes providing at least two candidate mRNA molecules in which each of the mRNA molecules includes a cross-linker, translating at least two of the candidate mRNA molecules to generate at least one translated protein, and linking at least one of the candidate mRNA molecules to its corresponding translated protein via the cross-linker to form at least one cognate pair. | 09-01-2011 |
20110217321 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 161P2F10B PROTEINS - Antibody drug conjugates (ADC's) that bind to 161P2F10B protein are described herein. 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer. | 09-08-2011 |
20110223183 | HUMAN NOTCH3 BASED FUSION PROTEINS AS DECOY INHIBITORS OF NOTCH3 SIGNALING - This invention provides a fusion protein comprising a signal peptide, EGF repeats 1-X of the extracellular domain of human Notch3 receptor protein wherein X is any integer from 12 to 34, and an Fc portion of an antibody bound thereto. This invention also provides a method for treating a subject having a tumor, a method for inhibiting angiogenesis in a subject, a method for treating a subject having ovarian cancer, and a method for treating a subject having a metabolic disorder, comprising administering to the subject an amount of the above fusion protein effective to treat the subject. This invention further provides uses of the above fusion protein for the preparation of a pharmaceutical composition for the treatment of a subject having a tumor, for inhibiting angiogenesis in a subject, for treating a subject having ovarian cancer, and for treating a subject having a metabolic disorder. | 09-15-2011 |
20110223184 | DKK2 PROTEIN AND USE THEREOF - The present invention provides DKK2 and DKK-Fc fusion protein with angiogesis promoting activity and methods of using the same. | 09-15-2011 |
20110223185 | CHIMERIC HEPATITIS C VIRUS ANTIGENS FOR ELICITING AN IMMUNE RESPONSE - Disclosed herein are chimeric antigens, comprising an hepatitis C virus (HCV) antigen and a Fc fragment of an immunoglobulin for eliciting an immune response against said antigen. The immune response is enhanced by presenting the host immune system with an immune response domain (HCV antigen from HVC core, envelope, or non-structural protein fragments) and a target binding domain (an Fc fragment). By virtue of the target binding domain, antigen presenting cells internalize and process the chimeric antigens for antigen presentation, thereby eliciting both a humoral and cellular immune response. | 09-15-2011 |
20110229497 | Modulating the Alternative Complement Pathway - Provided herein are compositions, including pharmaceutical compositions, and methods for modulating, i.e., stimulating or inhibiting, activity of the alternative complement pathway, and methods of identifying factor H-binding proteins. | 09-22-2011 |
20110236403 | TARGETING PAX2 FOR THE INDUCTION OF DEFB1-MEDIATED TUMOR IMMUNITY AND CANCER THERAPY - Provided is a method of treating cancer in a subject by inhibiting expression of PAX2. An example of a cancer treated by the present method is prostate cancer. In the cancer treatment methods disclosed, the method of inhibiting expression of PAX2 can be by administration of a nucleic acid encoding an siRNA for PAX2. A method of treating cancer in a subject by administering DEFB1 is also provided. Similarly, provided is a method of treating cancer in a subject by increasing expression of DEFB1 in the subject. | 09-29-2011 |
20110243966 | SINGLE CHAIN Fc (ScFc) REGIONS, BINDING POLYPEPTIDES COMPRISING SAME, AND METHODS RELATED THERETO - The present invention features inter alia polypeptides comprising an Fc region comprising genetically-fused Fc moieties. In addition, the instant invention provides, e.g., methods for treating or preventing a disease or disorder in subject by administering the binding polypeptides of the invention to said subject. | 10-06-2011 |
20110243967 | MOLECULAR COMPLEXES WHICH MODIFY IMMUNE RESPONSES - Extracellular domains of transmembrane heterodimeric proteins, particularly T cell receptor and major histocompatibility complex proteins, can be covalently linked to the heavy and light chains of immunoglobulin molecules to provide soluble multivalent molecular complexes with high affinity for their cognate ligands. The molecular complexes can be used, inter alia, to detect and regulate antigen-specific T cells and as therapeutic agents for treating disorders involving immune system regulation, such as allergies, autoimmune diseases, tumors, infections, and transplant rejection. | 10-06-2011 |
20110250214 | DRUG DELIVERY SYSTEM TOWARD DEMYELINATING LESION AND BIOCHEMICAL MARKER OF DEMYELINATING LESION - It is intended to provide a drug delivery system toward a demyelinating lesion. It is also intended to provide a biochemical marker of a demyelinating lesion. A delivery system for a prophylactic and/or therapeutic agent for a demyelinating disease characterized in that a substance capable of specifically recognizing Contactin is conjugated to an active ingredient of a prophylactic and/or therapeutic agent for a demyelinating disease is provided. Also provided is a method of evaluating and/or differentiating a demyelinating disease, including measuring the expression of Contactin in a body fluid. | 10-13-2011 |
20110250215 | STRUCTURALLY-RELATED RELAXIN-FUSION PROTEINS WITH EXTENDED IN VIVO HALF-LIVES - Disclosed are human relaxin-Fc fusion proteins having an increased serum half-life, polynucleotides encoding the same, and intermediates formed during the fusion protein biosynthesis. The fusion proteins may include a linker portion or other sections as well. Suitable fusion proteins are also those predicted to have the same effect as human relaxin in vivo, based, for example, on structural modeling. The fusion protein is useful in the treatment of a number of diseases and conditions, including heart disease, vascular disease, wound healing, fibrosis, fibromyalgia, and promoting angiogenesis. | 10-13-2011 |
20110256156 | TRANSFERRIN/TRANSFERRIN RECEPTOR-MEDIATED siRNA DELIVERY - The invention provides interfering RNA molecule-ligand conjugates useful as a delivery system for delivering interfering RNA molecules to a cell in vitro or in vivo. The conjugates comprise a ligand that can bind to a transferrin receptor (TfR). Therapeutic uses for the conjugates are also provided. | 10-20-2011 |
20110262466 | COMPOSITIONS CONTAINING THROMBOMODULIN DOMAINS AND USES THEREOF - Compositions are provided comprising a thrombomodulin domain linked to a targeting moiety that binds to a determinant on the surface of a target endothelial cell or red blood cell, wherein the thrombomodulin domain may be the extracellular domain, the N-terminal lectin-like domain, or an epidermal growth factor (EGF)-like domain. The targeting moiety may be a single chain antigen-binding domain (scFv), and the targeting moiety and thrombomodulin domain of the composition may be linked as a continuous polypeptide chain. Methods of delivery and use of a composition described herein are provided, as well as methods of treating or preventing thrombosis, inflammation, tissue ischemia, sepsis, acute lung injury (ALI), acute myocardial infarction (AMI), ischemic stroke, cerebrovascular disease, pulmonary embolism, or ischemic peripheral vascular disease is provided. | 10-27-2011 |
20110280889 | HIGH AFFINITY T CELL RECEPTOR AND USE THEREOF - The present invention is directed to a high affinity T cell receptor (TCR) against a tumor-associated antigen, an isolated nucleic acid molecule encoding same, a T cell expressing said TCR, and a pharmaceutical composition for use in the treatment of diseases involving malignant cells expressing said tumor-associated antigen. | 11-17-2011 |
20110280890 | PRODRUGS OF CC-1065 ANALOGS - The present invention provides prodrugs of analogs of the anti-tumor antibiotic CC-1065 having a cleavable protective group containing a sulfonic acid containing phenyl carbamate, in which the protecting group confers enhanced water solubility upon the prodrug, and in which the prodrug also has a moiety, such as a sulfide or a disulfide, that can conjugate to a cell binding reagent such as an antibody, and for the therapeutic use of such prodrug and conjugates, and for processes for preparing such prodrugs and conjugates. | 11-17-2011 |
20110287032 | NOVEL CTLA4-IG IMMUNOADHESINS - The present application relates to CTLA4-Ig immunoadhesins that target CD80 and CD86, and their use, particularly for therapeutic purposes. | 11-24-2011 |
20110287033 | USE OF FERRITIN TO TREAT IRON DISORDERS - Methods and compositions for treating an iron disorder in a patient are presented, including methods for delivering a therapeutically effective amount of iron to the brain. Iron disorders that may be treated by these methods include iron deficiency disorders and iron overload disorders. A recombinant yeast expressing human H-ferritin and a composition for treating an iron disorder comprising this recombinant yeast are also presented. | 11-24-2011 |
20110287034 | THERAPEUTIC AND DIAGNOSTIC METHODS RELATING TO CANCER STEM CELLS - Genes that are deregulated in cancer stem cells (e.g., melanoma stem cells) are disclosed. Methods which involve modulating (e.g., inducing, inhibiting, etc.) the activity of the cancer stem cell associated genes are used to treat individuals having melanoma. Cell surface genes that are upregulated in melanoma stem cells are targeted for the selective isolation, detection, and killing of cancer stem cells in melanoma. | 11-24-2011 |
20110287035 | METHOD AND COMPOSITION FOR HYPERTHERMALLY TREATING CELLS - A method and composition for hyperthermally diagnosing and monitoring treatment of cells in an animal with photoacoustic sound and nanoparticles. The heat (temperature) and photoacoustic sound wave production inside the target tissue is measured. The desired temperature is achieved using a laser and photoacoustic imaging technique. Hyperthermia treatment of tissue in a target site applies a heat source to kill cells without protein denaturation. The method introduces an encapsulated dye that is released at a selected temperature in the target site to indicate that a threshold temperature has been reached to hyperthermally treat the tissue. In one embodiment, the composition releases the dye at a temperature of 42° C. to 56° C., and preferably about 45° C. to 49° C. The composition which can be a liposome composition encapsulating the dye can be introduced to the bloodstream of the patient to flow through the target site. | 11-24-2011 |
20110305716 | TARGETED CYTOKINE FOR TREATMENT OF DISEASES - Provided are proteins and polynucleotides, complexes and compositions containing the proteins, and methods for their use in administration to subjects and for disease treatment. Among the provided proteins and complexes are complexes containing a TGF-beta associated with immunoglobulins (such as IgGs) or functional portions thereof including Fc portions, such as by non-covalent bonds. The provided complexes include those in which the immunoglobulin portion binds to inhibitory Fcγ receptors to a greater degree than to activating Fcγ receptors. The provided complexes further include those in which the immunoglobulin portion bind to activating Fcγ receptors to a greater degree than to inhibitory Fcγ receptors. The complexes and compositions can be used for administration to subjects, such as for increasing immunity or decreasing inflammation, such as for treating diseases including autoimmune diseases and cancer. | 12-15-2011 |
20110311558 | Recombinant Bone Marrow Stromal Antigen-2 in the Treatment of Autoimmune Diseases - Methods, compositions and kits are disclosed for inhibiting interferon production and modulating immune responses, particularly an autoimmune response. In certain embodiments, the methods involve administering an effective amount of a BST2 protein or a nucleic acid encoding an BST2 protein to treat an autoimmune disease or disorder. | 12-22-2011 |
20110318370 | CXCL4L1 AS A BIOMARKER OF PANCREATIC CANCER - The invention relates to the use of CXCL4L1 as a biomarker of pancreatic cancer in a patient. More particularly, the invention relates to a method for detecting a pancreatic cancer and/or pancreatic metastasis in a patient, said method comprising determining the expression level of the CXCL4L1 gene in a biological sample obtained from said patient. | 12-29-2011 |
20110318371 | Novel serpentine transmembrane antigens expressed in human cancers and uses thereof - Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (Six Transmembrane Epithelial Antigens of the Prostate). Four particular human STEAPs are described and characterized herein. The prototype member of the STEAP family, STEAP-1, appears to be a type IIIa membrane protein expressed predominantly in prostate cells in normal human tissues. Structurally, STEAP-1 is a 339 amino acid protein characterized by a molecular topology of six transmembrane domains and intracellular N- and C-termini, suggesting that it folds in a “serpentine” manner into three extracellular and two intracellular loops. STEAP-1 protein expression is maintained at high levels across various stages of prostate cancer. Moreover, STEAP-1 is highly over-expressed in certain other human cancers. | 12-29-2011 |
20120009205 | Modified Fc Molecules - Disclosed is a process for preparing a pharmacologically active compound, in which at least one internal conjugation site of an Fc domain sequence is selected that is amenable to conjugation of an additional functional moiety by a defined conjugation chemistry through the side chain of an amino acid residue at the conjugation site. An appropriate amino acid residue for conjugation may be present in a native Fc domain at the conjugation site or may be added by insertion (i.e., between amino acids in the native Fc domain) or by replacement (i.e., removing amino acids and substituting different amino acids). In the latter case, the number of amino acids added need not correspond to the number of amino acids removed from the previously existing Fc domain. This technology may be used to produce useful compositions of matter and pharmaceutical compositions containing them. A DNA encoding the inventive composition of matter, an expression vector containing the DNA, and a host cell containing the expression vector are also disclosed. | 01-12-2012 |
20120014974 | METHODS OF MODULATING CELL DEATH BASED ON THE BIT1/AES REGULATORY PATHWAY - The present invention provides a method of identifying an effective agent that alters the association of a Bit1 polypeptide with an AES polypeptide. The method is practiced by contacting a Bit1 polypeptide, or active fragment thereof, and an AES polypeptide, or active fragment thereof, with an agent under conditions that allow the Bit1 polypeptide or active fragment thereof to associate with the AES polypeptide or active fragment thereof; and detecting an altered association of the Bit1 polypeptide or active fragment thereof and the AES polypeptide or active fragment thereof, where an altered association indicates that the agent is an effective agent that alters the association of a Bit1 polypeptide with an AES polypeptide. Such an effective agent can modulate apoptosis and can be a useful therapeutic agent. | 01-19-2012 |
20120027781 | Neuroprotective and neurorestorative method and compositions - The invention relates to methods and products for preventing and treating neuronal cell death-associated diseases and/or conditions. The products and methods are useful for research and for clinical applications relating to neuronal cell-death associated diseases and/or conditions. | 02-02-2012 |
20120027782 | MONOCLONAL ANTIBODY PARTNER MOLECULE CONJUGATES DIRECTED TO PROTEIN TYROSINE KINASE 7 (PTK7) - The present disclosure relates to antibody-partner molecule conjugates directed to PTK7. Also described are methods for treating or preventing a disease characterized by growth of tumor cells expressing PTK7 using the antibody-partner molecule conjugates. | 02-02-2012 |
20120027783 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS - Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo. | 02-02-2012 |
20120027784 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS - Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo. | 02-02-2012 |
20120058131 | PTA089 PROTEIN - The present invention provides methods and compositions for treatment, screening, diagnosis and prognosis of bladder cancer, colorectal cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, prostate cancer or skin cancer, for monitoring the effectiveness of bladder cancer, colorectal cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, prostate cancer or skin cancer treatment, and for drug development. | 03-08-2012 |
20120064097 | Enhanced Binding of Pro-Inflammatory Cytokines by Polysaccharide-Antibody Conjugates - We provide monoclonal antibodies against interleukin-1β and tumor necrosis factor-α that remain biologically active in vitro when conjugated to high molecular weight polysaccharides. We report enhanced binding of these cytokines when their monoclonal antibodies are conjugated to alginate compared to non-conjugated monoclonal antibodies. In cell assays, polysaccharide-antibody constructs of the invention inhibited cytokine signaling to comparable levels as that of unmodified antibodies. Conjugation of cytokine-neutralizing antibodies to high molecular weight polymers enhances the affinities cytokine-binding moieties used as anti-inflammatory therapeutics. | 03-15-2012 |
20120064098 | Intracoronary Device And Method Of Use Thereof - Engraftment of therapeutic cells and agents to a target site in an organism is enhanced by mechanical, chemical and biological methods and systems. | 03-15-2012 |
20120070451 | METHODS AND COMPOSITIONS FOR MODULATING CARDIAC CONTRACTILITY - Provide is a Ca | 03-22-2012 |
20120076804 | CANCER TARGETED INNATE IMMUNITY - Provided is a cancer therapeutic agent comprising a cancer targeting molecule linked to a CpG oligodeoxynucleotide. Also provided are methods of reducing the size of a tumor or inhibiting the growth of cancer cells in an individual or inhibiting the development of metastatic cancer, comprising administering an effective amount of the cancer therapeutic agent. The methods may also include reducing immunoregulatory T cell activity in the individual. | 03-29-2012 |
20120082685 | Dock-and-Lock (DNL) Constructs for Human Immunodeficiency Virus (HIV) Therapy - The present invention concerns methods and compositions for treatment of HIV infection in a subject, utilizing a DNL complex comprising at least one anti-HIV therapeutic agent, attached to an antibody, antibody fragment or PEG. In a preferred embodiment, the antibody or fragment binds to an antigen selected from gp120, gp41, CD4 and CCR5. In a more preferred embodiment the antibody is P4/D10 or 2G12, although other anti-HIV antibodies are known and may be utilized. In a most preferred embodiment, the anti-HIV therapeutic agent is a fusion inhibitor, such as T20, T61, T651, T1249, T2635, CP32M or T-1444, although other anti-HIV therapeutic agents are known and may be utilized. The DNL complex may be administered alone or may be co-administered with one or more additional anti-HIV therapeutic agents. | 04-05-2012 |
20120082686 | Neovascular-Targeted Immunoconjugates - Immunoconjugates for treating diseases associated with neovascularization such as cancer, rheumatoid arthritis, the exudative form of macular degeneration, and atherosclerosis are described. The immunoconjugates typically consist of the Fc region of a human IgG1 immunoglobulin including the hinge, or other effector domain or domains that can elicit, when administered to a patient, a cytolytic immune response or cytotoxic effect against a targeted cell. The effector domain is conjugated to a targeting domain which comprises a factor VII mutant that binds with high affinity and specificity to tissue factor but does not initiate blood clotting such as factor VII having a substitution of alanine for lysine-341 or of alanine for serine-344. | 04-05-2012 |
20120093840 | TARGETED DELIVERY OF FACTOR VIII PROTEINS TO PLATELETS - The invention described herein relates to novel molecules and polypeptides comprising at least one amino acid sequence having significant identity with (homology to) human Factor VIII or biologically active portion(s) thereof, related molecules (such as nucleic acids encoding such polypeptides), compositions (such as pharmaceutical formulations) comprising such polypeptides, and methods of making and using such polypeptides. | 04-19-2012 |
20120100159 | ANTI-TAT226 ANTIBODIES AND IMMUNOCONJUGATES - Anti-TAT226 antibodies and immunoconjugates thereof are provided. Methods of using anti-TAT226 antibodies and immunoconjugates thereof are provided. | 04-26-2012 |
20120107331 | GEMM RIBOSWITCHES, STRUCTURE-BASED COMPOUND DESIGN WITH GEMM RIBOSWITCHES, AND METHODS AND COMPOSITIONS FOR USE OF AND WITH GEMM RIBOSWITCHES - Disclosed is the crystal structure of a GEMM riboswitch from | 05-03-2012 |
20120114673 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR - The invention is directed to antibody drug conjugate compositions of matter useful for the diagnosis and treatment of tumors in mammals and to methods of using those compositions of matter for the same. | 05-10-2012 |
20120121613 | PROTEIN CONJUGATE HAVING AN ENDOPEPTIDASE- CLEAVABLE BIOPROTECTIVE MOIETY - The invention is directed to a procoagulant conjugate having an endopeptidase-activatable procoagulant protein moiety and one or more bioprotective moieties, which are conjugated to one another by a linker that is cleaved by an endopeptidase in situ to release the bioprotective moiety. The invention is also directed to therapeutic uses of the procoagulant conjugate and methods of making the conjugate. | 05-17-2012 |
20120121614 | METHODS AND COMPOSITIONS FOR BI-SPECIFIC TARGETING OF CD19/CD22 - Methods and composition involving genetically engineered targeting conjugates with reversed orientation of VL and VH chains are provided. For example, in certain aspects targeting conjugates comprising VL and VH chains of anti-CD22 and anti-CD19 are described. In a further aspect, the invention provides methods and targeting conjugates comprising therapeutic agents or diagnostic agents for delivery to B cells. | 05-17-2012 |
20120128700 | CONSTRUCTS FOR DELIVERY OF THERAPEUTIC AGENTS TO NEURONAL CELLS - A non-toxic polypeptide, for delivery of a therapeutic agent to a neuronal cell, comprises a binding domain that binds to the neuronal cell, and a translocation domain that translocates the therapeutic agent into the neuronal cell, wherein the translocation domain is not a H | 05-24-2012 |
20120135012 | TRANS-MEMBRANE-ANTIBODY INDUCED INHIBITION OF APOPTOSIS - Cell suicide (apoptosis) is associated with pathogenesis, for example, it is the major cause for the loss of neurons in Alzheimer's disease. Caspase-3 is critically involved in the pathway of apoptosis. Superantibody (SAT)-trans-membrane technology has been used to produce antibodies against the caspase enzyme in an effort to inhibit apoptosis in living cells. The advantage of using trans-membrane antibodies as apoptosis inhibitors is their specific target recognition in the cell and their lower toxicity compared to conventional apoptosis inhibitors. It is shown that a MTS-transport-peptide modified monoclonal anti-caspase-3 antibody reduces actinomycin D-induced apoptosis and cleavage of spectrin in living cells. These results indicate that antibodies conjugated to a membrane transporter peptide have a therapeutic potential to inhibit apoptosis in a variety of diseases. | 05-31-2012 |
20120148608 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS - Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo. | 06-14-2012 |
20120148609 | INTRACORONARY DEVICE AND METHOD OF USE THEREOF - Engraftment of therapeutic cells and agents to a target site in an organism is enhanced by mechanical, chemical and biological methods and systems. | 06-14-2012 |
20120156227 | PROTEINS MODIFIED WITH (AMINO) MONOSACCHARIDE-BIOTIN ADDUCT - A protein covalently linked to, or coated with, a non-immunogenic molecule selected from an amino monosaccharide-biotin adduct or a monosaccharide-biotin adduct is disclosed, wherein the coated protein, which has diminished immuno-genicity relative to the uncoated protein and intact biological activity, enables, for example, cross-species vaccination | 06-21-2012 |
20120177667 | Metal Abstraction Peptide (MAP) Tag and Associated Methods - Compositions comprising a tripeptide having the sequence XC | 07-12-2012 |
20120183566 | Aldehyde-Tagged Immunoglobulin Polypeptides and Methods of Use Thereof - The present disclosure provides aldehyde-tagged immunoglobulin (Ig) polypeptides that can be converted by a formylglycine-generating enzyme to produce a 2-formylglycine (FGly)-modified Ig polypeptide. An FGly-modified Ig polypeptide can be covalently and site-specifically bound to a moiety of interest to provide an Ig conjugate. The disclosure also encompasses methods of production of such aldehyde-tagged Ig polypeptides, FGly-modified Ig polypeptides, and Ig conjugates, as well as methods of use of same. | 07-19-2012 |
20120183567 | PROCESS FOR PRODUCING WATER-SOLUBLE HYALURONIC ACID MODIFICATION - The present invention provides a water-soluble modified HA practically used as a drug carrier and a production method thereof. The present invention provides: a water-soluble modified hyaluronic acid, the residence time in blood of which is elongated to a practical level, which is produced by introducing a substituent into the carboxy group of the glucuronic acid of hyaluronic acid or a derivative thereof, via an amide bond, at a lower limit of an introduction ratio of 5 mole % or more, using a BOP condensing agent in an aprotic polar solvent; and a production method thereof. Moreover, by cross-linking the modified hyaluronic acid, the present invention provides a hyaluronic acid gel capable of extremely long drug sustained-release even at the same cross-linking functional group introduction ratio as that of the conventionally known gel. | 07-19-2012 |
20120189644 | ANTI-MESOTHELIN IMMUNOCONJUGATES AND USES THEREFOR - The present invention provides immunoconjugates composed of antibodies, e.g., monoclonal antibodies, or antibody fragments that bind to mesothelin, that are conjugated to cytotoxic agents, e.g., maytansine, or derivatives thereof, and/or co-administered or formulated with one or more additional anti-cancer agents. The immunoconjugates of the invention can be used in the methods of the invention to treat and/or diagnose and/or monitor cancers, e.g. solid tumors. The immunoconjugates comprise antibodies and functional fragments containing such antigen-binding regions that are specific for the membrane-anchored, 40 kDa mesothelin polypeptide, which is overexpressed in several tumors, such as pancreatic and ovarian tumors, mesothelioma and lung cancer cells. | 07-26-2012 |
20120225088 | COMPOSITIONS AND METHODS FOR TREATING CANCER AND OTHER DISEASES - Aptamers and improved aptamers are provided with enhanced efficacy for binding to target molecules in vivo or for treating cancer or other diseases. Such improvements in aptamers are provided that enhance in vivo efficacy such as binding to the target molecule or enhancing anti-cancer activity. Such improvements also include stability to serum nucleases, reduced binding to a soluble form of the target molecule, increased avidity, affinity or specificity to the target molecule on a cell surface, increased lifetime in circulation, or any combination of the foregoing. Improvements are provided by truncation, multimerization, including at least one non-natural nucleic acid, adding a 3′ or 5′ polyethylene glycol, or any combination thereof. Aptamers for treatment of autoimmune diseases are also provided. | 09-06-2012 |
20120231022 | GLP-1 RECEPTOR AGONIST COMPOUNDS FOR SLEEP ENHANCEMENT - The disclosure provides, among other things, the use of GLP-1 receptor agonist compounds to enhance sleep, increase the duration and/or intensity of non-rapid eye movement (NREM) sleep, treat NREM sleep disorders, and to treat circadian rhythm sleep disorders. The GLP-1 receptor agonist compounds may be exendins, exendin analogs, GLP-1(7-37), GLP-1(7-37) analogs (e.g., GLP-1(7-36)-NH | 09-13-2012 |
20120231023 | Novel Vaccine Adjuvants Based on Targeting Adjuvants to Antibodies Directly to Antigen-Presenting Cells - The present invention includes compositions and methods for enhancing an immune response with an adjuvant composition comprising: an anti-dendritic cell (DC)-specific antibody or fragment thereof conjugated to at least a portion of Toll-Like Receptor (TLR) agonist, more specifically a TLR7 ligand (TLR7L), and a pharmaceutically acceptable carrier, wherein the conjugate and agonist are each comprised in an amount such that, in combination with the other, are effective to produce the immune response in a human or animal subject in need of immunostimulation. | 09-13-2012 |
20120231024 | MONOCLONAL ANTIBODIES AND SINGLE CHAIN ANTIBODY FRAGMENTS AGAINST CELL-SURFACE PROSTATE SPECIFIC MEMBRANE ANTIGEN AS DIAGNOSTIC AND THERAPEUTIC TOOLS FOR PROSTATE CANCER - Isolated monoclonal antibodies or an antigen binding portion thereof which bind to prostate specific membrane antigen in its native form occurring on the surface of tumor cells characterized in that it is linked to a label or a cytotoxic agent or constructed as a part of a bispecific antibody or a recombinant diabody. | 09-13-2012 |
20120237531 | TOPOISOMERASE INHIBITORS - The invention provides compounds of formula I: (I) wherein A, B, W, Y, Z, R | 09-20-2012 |
20120237532 | PHARMACEUTICAL FORMULATION CONTAINING IMMUNOGLOBULIN - A set of at least two different protein conjugate preparations, each protein conjugate preparation comprising histidine as a buffering agent and a protein conjugate comprising one or more immunoglobulin moieties conjugated to a carrier protein; wherein the immunoglobulin moieties of each element of said set of protein conjugate preparation have identical complementarity determining regions (CDRs); and wherein different protein conjugate preparations differ in that the immunoglobulin moieties of the protein conjugates have different CDRs. | 09-20-2012 |
20120251557 | GalNAc-SPECIFIC BINDING MOLECULES AND USES THEREOF - The present invention provides, among others, means and methods for detecting terminal GalNAc-containing molecules. A preferred molecule for detecting the structures is a molecule comprising a carbohydrate binding part of MGL. | 10-04-2012 |
20120258124 | ANTIGEN-ANTIBODY COMPLEXES AS HIV-1 VACCINES - The present relation relates to antigen-antibody complexes for use as prophylactic and therapeutic vaccines for infectious diseases of AIDS. The present invention encompasses the preparation and purification of immunogenic antibody-antigen complexes which are formulated into the vaccines of the present invention. | 10-11-2012 |
20120263738 | MULTIPLEX DICER SUBSTRATE RNA INTERFERENCE MOLECULES HAVING JOINING SEQUENCES - The present invention is based, in part, upon the insight that compound DsiRNA agents can be generated using site-specific RNase H-cleavable double-stranded nucleic acid regions to attach, e.g., one DsiRNA moiety to another DsiRNA moiety and/or one DsiRNA moiety to a functional group and/or payload. Because such double-stranded nucleic acid joining sequences are site-specifically RNase H-cleavable, the bifunctional molecule is cleaved into DsiRNAs bearing terminal ends that orient dicer cleavage. Detrimental impacts of administering a single double-stranded nucleic acid RNAi agent of longer than 30-35 nucleotides (e.g., provocation of interferon response) is minimized, as once administered to a subject or RNase H-containing cell, RNase H cleavage produces a shortened, active DsiRNA agent(s). The invention provides bifunctional DsiRNA agents that are joined by double-stranded DNA extension joining sequences, which do not provoke RNase H cleavage. | 10-18-2012 |
20120263739 | ANTI INTEGRIN ANTIBODIES LINKED TO NANOPARTICLES LOADED WITH CHEMOTHERAPEUTIC AGENTS - The invention relates to anti-integrin antibodies which are covalently linked to nanoparticles, wherein these nanoparticles were prior loaded with chemotherapeutic/cytotoxic agents. The antibody-chemotherapeutic agent-nanoparticle conjugates according to the invention, especially wherein the antibody is MAb DI17E6 and the cytotoxic agent is doxorubicin show a significant increase of tumor cell toxicity. | 10-18-2012 |
20120269827 | Compositions and Methods for Treatment of Ovarian, Peritoneal, and Fallopian Tube Cancer - The present invention relates to highly effective anti-cancer drug combinations, pharmaceutical compositions comprising the same, and uses thereof in the treatment of ovarian, peritoneal, or fallopian tube cancer. In particular, the present invention is based on the discovery that the administration of a CD56 antibody linked to a cytotoxic compound (e.g., an immunoconjugate) in combination with a chemotherapeutic agent (in particular a gemcitabine compound, a topotecan compound, and a doxorubicin compound), improves the therapeutic index in the treatment of ovarian, peritoneal, or fallopian tube cancer over and above the additive effects of the anticancer agents used alone. In one embodiment of the invention, combinations of the CD56 antibody, or fragment thereof, linked to a cytotoxic compound plus an additional chemotherapeutic agent have a synergistic effect in the ovarian cancer therapeutic index. | 10-25-2012 |
20120269828 | ANTI-DRUG VACCINES - The present invention relates to anti-drug vaccines based on conjugates between the drug and a non-immunogenic carrier protein. In preferred embodiments, it provides for anti-cocaine vaccines and their use to diminish the effects and/or use of cocaine in a subject. | 10-25-2012 |
20120269829 | Inhibitors of Phosphatase and Tensin Homolog (PTEN) Compositions, Uses and Methods - Described herein are isolated polypeptides having phosphatase and tensin homolog (PTEN) inhibitory activity, vectors and cells for the expression thereof and methods for their use in treating diseases associated with cytotoxic stress, such as spinal cord injury, stroke, traumatic brain injury, multiple sclerosis, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), Parkinson's disease, and Huntington's disease. | 10-25-2012 |
20120269830 | CONJUGATES WITH IMPROVED PHARMACOKINETIC PROPERTIES - The present invention concerns methods and means for modulating pharmacokinetic properties of molecules, such as biologically active molecules. More specifically, the present invention concerns conjugates comprising a biologically active moiety and a moiety conjugated to and modulating at least one pharmacokinetic property of the biologically active moiety (pharmacokinetic property modulating moiety). | 10-25-2012 |
20120269831 | SUBSTITUTED PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES AND THERAPEUTIC USES THEREOF - Compounds useful as antiproliferative agents according to Formula (I), wherein n, A, R | 10-25-2012 |
20120276124 | MAYTANSINOIDS AND THE USE OF SAID MAYTANSINOIDS TO PREPARE CONJUGATES WITH AN ANTIBODY - The invention relates to a compound of formula (I): | 11-01-2012 |
20120276125 | NOVEL IMMUNOCONJUGATES - The present invention generally relates to antigen-specific immunoconjugates for selectively delivering effector moieties that influence cellular activity. More specifically, the invention provides novel immunoconjugates comprising a first antigen binding moiety, an Fc domain and a single effector moiety. In addition, the present invention relates to polynucleotides encoding such immunoconjugates, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the immunoconjugates of the invention, and to methods of using these immunoconjugates in the treatment of disease. | 11-01-2012 |
20120282279 | Anti-Diabetic Compounds - The present invention provides a FGF21 molecule covalently attached to the combining site of an antibody via a linker, wherein the linker is covalently attached to the side chain of a linking residue within FGF21. Various uses of the compounds are provided, including methods to prevent or treat diabetes or diabetes-related conditions. | 11-08-2012 |
20120282280 | BI-SPECIFIC DIGOXIGENIN BINDING ANTIBODIES - This invention relates to bispecific antibodies and antibody fragments against a target protein and a hapten, wherein the hapten is PEG or biotin, most preferably digoxigenin, methods for their production, their use as a delivery platform for therapeutic or diagnostic agents, pharmaceutical 5 compositions containing said antibodies, and uses thereof. | 11-08-2012 |
20120282281 | Agents that Engage Antigen-Presenting Cells Through Dendritic Cell Asialoglycoprotein Receptor (DC-ASGPR) - The present invention includes compositions and methods for making and using anti DC-ASGPR antibodies that can, e.g., activate DCs and other cells. | 11-08-2012 |
20120288511 | GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS - Provided herein are glucagon analogs comprising a modified amino acid sequence of native human glucagon (SEQ ID NO: 2) that exhibit activity at the glucagon receptor, activity at the GLP-I receptor, or activity at each of the glucagon receptor and the GLP-I receptor. In some embodiments, the glucagon analog exhibits at least 100% or more of the activity of native glucagon at the glucagon receptor and/or at least 100% or more of the activity of native GLP-I at the GLP-I receptor. In some embodiments, the glucagon analog has an EC50 at the GLP-I receptor which is within 50-fold or less than the EC50 at the glucagon receptor. In some embodiments, the glucagon analog has an EC50 at the GLP-I receptor which is two- to ten-fold greater than the EC50 at the glucagon receptor. Related conjugates, dimers and multimers, and pharmaceutical compositions, and uses thereof, are further provided. | 11-15-2012 |
20120308583 | USE OF GCC LIGANDS - Proliferation of colorectal, gastric and esophageal cancer cells is inhibited by administering ST receptor ligand. The number of ST receptor molecules on the surface of a colorectal cell or metastasized colorectal cancer cell are increased by administering an ST receptor ligand such that ligand comes into contact with an ST receptor on the surface of the colorectal cell. Pharmaceutical compositions comprise sterile, pyrogen free ST receptor ligand and a pharmaceutically acceptable carrier or diluent. Metastasized colorectal cancer is treated or imaged by increasing the number of ST receptor molecules on the surface of a metastasized colorectal cancer cell and then administering a pharmaceutical composition containing components that target the ST receptor for delivery of a therapeutic agent or imaging agent. Methods of detecting metastasized colorectal cancer are disclosed. Methods of delivering active compounds to a colorectal cell in an individual are disclosed. | 12-06-2012 |
20120315288 | LOW DENSITY LIPOPROTEIN RECEPTOR-MEDIATED siRNA DELIVERY - The invention provides interfering RNA molecule-ligand conjugates useful as a delivery system for delivering interfering RNA molecules to a cell in vitro or in vivo. The conjugates comprise a ligand that can bind to a low density lipoprotein receptor (LDLR) or LDLR family member. Therapeutic uses for the conjugates are also provided. | 12-13-2012 |
20120321647 | STRUCTURED RNA MOTIFS AND COMPOUNDS AND METHODS FOR THEIR USE - Disclosed are compositions and methods involing riboswitches and RNA motifs. For example, disclosed are compositions and methods involving glutamine-responsive riboswitches, S-adenosylmethionine-repsonsive riboswitches, S-adenosylhomocysteine-repsonsive riboswitches, glutamine riboswitches, SAM/SAH riboswitches, glnA riboswitches, Downstream-peptide riboswitches, crcB riboswitches, pfl riboswitches, yjdF riboswitches, manA riboswitches, wcaG riboswitches, epsC riboswitches, ykkC-III riboswitches, psaA riboswitches, psbA riboswitches, PhotoRC-I riboswitches, PhotoRC-II riboswitches, and psbNH riboswitches. | 12-20-2012 |
20130004522 | PHOTOTRIGGERED NANOPARTICLES FOR CELL AND TISSUE TARGETING - The present invention relates, in part, to a novel and simple particulate system that targets and binds any tissue selectively upon light illumination. The particulate system can be used for targeted delivery of substances to predefined cells or tissues in an individual. | 01-03-2013 |
20130004523 | THERAPEUTIC COMPOSITIONS AND METHODS FOR DELIVERY OF ACTIVE AGENTS CLEAVABLY LINKED TO NANOPARTICLES - Various embodiments of the present invention pertain to therapeutic compositions that comprise: ( | 01-03-2013 |
20130011418 | Antibody-Drug Conjugates - Disclosed are anti-5T4 antibody drug conjugates and methods for preparing and using the same. | 01-10-2013 |
20130017210 | DISPLAY OF ANTIBODY FRAGMENTS ON VIRUS-LIKE PARTICLES OF RNA BACTERIOPHAGES - The invention enables the display of antibody single-chain variable fragments (scFv's on virus-like particles (VLPs) of bacteriophages such as MS2. The VLPs encapsidate mRNA encoding the coat protein from which it assembles, enabling the recovery by reverse transcription and PGR of affinity-selected sequences from scFv libraries. Related virus-like particles, method for constructing a library of scFv-VLPs, drug delivery vehicles comprising one or more pharmaceutically-active ingredients, biomedical imaging agents, assays, and kits are also provided. | 01-17-2013 |
20130028917 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF - Conjugates and compounds for making conjugates which are PBD molecules linked via the N10 position are disclosed, along with the use of the conjugates for treating proliferative diseases, including cancer. | 01-31-2013 |
20130034572 | COMPOSITIONS AND METHODS FOR BRAIN DELIVERY OF ANALGESIC PEPTIDES - The present invention relates to non-invasive brain delivery technology for centrally-acting analgesic peptides. Specifically, the invention is directed to compounds comprising an antibody or fragment thereof capable of transmigrating across the blood brain barrier (BBB) and an analgesic peptide. Compositions and methods of using the compounds or compositions are also provided. | 02-07-2013 |
20130039931 | Antibodies Against A Cancer-Associated Epitope of Variant HNRNPG and Uses Thereof - The present application provides the amino acid and nucleic acid sequences of heavy chain and light chain complementarity determining regions of a cancer specific antibody. In addition, the application provides cancer specific antibodies and immunoconjugates comprising the cancer specific antibody attached to a toxin or label, and methods and uses thereof. The application also relates to diagnostic methods and kits using the cancer specific antibodies disclosed herein. Further, the application provides novel cancer-associated epitopes and antigens, and uses thereof. | 02-14-2013 |
20130058962 | Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein - Methods, compositions and kits are provided for treating a subject exposed to or at risk for exposure to a disease agent using a pharmaceutical composition including at least one recombinant heteromultimeric neutralizing binding protein including two or multiple binding regions, such that the binding regions are not identical, and each binding region specifically binds a non-overlapping portion of the disease agent, thereby treating the subject for exposure to the disease agent. In a related embodiment, the heteromultimeric neutralizing binding protein includes two or multiple binding regions that neutralize a plurality of disease agents. In certain embodiments, the disease agent includes a bacterium, a bacterial protein, a virus, a viral protein, a cancer cell, and a protein or molecule produced therefrom. In certain embodiments, the disease agent is a plurality of different disease agents. | 03-07-2013 |
20130071412 | METHODS AND COMPOSITIONS FOR STABLE LIQUID DRUG FORMULATIONS - The invention features a powdered composition including a pharmaceutically active compound and a protein or a hydrolyzed protein. In particular, the powdered composition forms a stable solution or dispersion suitable for oral administration in which the protein or the hydrolyzed protein is bound to the pharmaceutically active compound. The invention also provides a method of administering the composition, such as to a patient with dysphasia; liquid or semi-solid formulations of the composition; methods for preparing the composition; and kits including the composition. | 03-21-2013 |
20130071413 | TARGETED IMMUNE CONJUGATES - Disclosed herein are materials and methods related to vaccines. Materials and methods for delivery of immunogens to the reticuloendothelial system via non-circulating lymphoid cells are provided. | 03-21-2013 |
20130084302 | Methods of binding TNF-alpha using Anti-TNF-alpha antibody fragment-polymer conjugates - Described are conjugates formed by an antibody fragment covalently attached to a nonproteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD. The conjugates exhibit substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the underivatized parental antibody fragment. Also described are conjugates directed against human vascular endothelial growth factor (VEGF), human p185 receptor-like tyrosine kinase (HER2), human CD20, human CD18, human CD11a, human IgE, human apoptosis receptor-2 (Apo-2), human tumor necrosis factor-α (TNF-α), human tissue factor (TF), human α | 04-04-2013 |
20130101607 | Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR1) Single Chain FV Antibody Fragment Conjugates and Methods of Use Thereof - Compositions including an antibody single-chain variable fragment (scFv) conjugate that specifically binds to ROR1 tumor-associated antigen are provided. The anti-ROR1 scFv antibody and conjugates may include a biologically-active molecule. Such conjugates may comprise a chimeric receptor to direct T cells to respond to ROR1 cancer cells, Methods to use the scFV conjugates to target cells expressing ROR1 for therapeutic and diagnostic purposes are also provided. | 04-25-2013 |
20130101608 | HUMAN ANTIBODY DRUG CONJUGATES AGAINST TISSUE FACTOR - Antibody drug conjugates against tissue factor. Also disclosed are pharmaceutical compositions comprising the antibodies and antibody drug conjugates, and therapeutic and diagnostic methods for using the antibodies and antibody drug conjugates. | 04-25-2013 |
20130108653 | BIVALENT MOLECULES FOR HIV ENTRY INHIBITION | 05-02-2013 |
20130108654 | TELOMERASE ACTIVITY INHIBITING PEPTIDE AND MANUFACTURING METHOD AND APPLICATION THEREOF | 05-02-2013 |
20130115230 | DELIVERY PROTEINS - Disclosed herein are materials and methods related to vaccines. Materials and methods for delivery of a payload, e.g., an immunogen, to the reticuloendothelial system via non-circulating lymphoid cells are provided. | 05-09-2013 |
20130122022 | SEQUENCE OF STRO-1 ANTIBODY VARIABLE REGION - The amino acid sequence of the heavy chain polypeptide and the light chain polypeptide of the STRO-1 antibody is disclosed. Also disclosed are methods for detecting and isolating cells expressing the STRO-1 cell surface protein. | 05-16-2013 |
20130122023 | NOVEL LONG-ACTING GLUCAGON CONJUGATE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME FOR THE PREVENTION AND TREATMENT OF OBESITY - Disclosed is a novel long-acting glucagon conjugate in which glucagon or its derivative is covalently linked to a polymer carrier via a non-peptide linker, and a pharmaceutical composition comprising the same as an effective ingredient useful for the prevention and treatment of obesity. Since the long-acting glucagon conjugate of the present invention shows improved in vivo durability and stability, when used in combination with an anti-obesity drug, it is possible to induce synergistic effects on the loss of body weight and decrease in food intake without causing any side-effects such as fluctuation in blood glucose level. Accordingly, the long-acting peptide conjugate of the present invention is very effective for the prevention and treatment of obesity. | 05-16-2013 |
20130129752 | TARGETED DELIVERY TO LEUKOCYTES USING PROTEIN CARRIERS - Disclosed herein are is a leukocyte-selective delivery agent comprising, a targeting moiety that selectively binds LFA-I, a protein carrier moiety covalently linked to the targeting moiety, and a therapeutic agent associated with the carrier moiety. The delivery agent may be further selective for activated leukocytes, wherein the targeting moiety selectively binds LFA-I in its activated conformation. The targeting moiety comprises an antibody or functional fragment thereof, such as an scFV. Examples of antibodies or fragments thereof which selectively bind LFA-I activated conformation bind to the locked open I domain of LFA-I, or binds to the leg domain of the β2 subunit of LFA-I ((ILP2)—The antibody or functional fragment thereof may alternatively bind non-selectively to both low affinity and high affinity LFA-I. Examples of a non-protein carrier are a basic polypeptide such as protamine or a functional fragment thereof. One such fragment is RSQSRSRYYRQRQRSRRRRRRS. The therapeutic agent may comprise one or more of a nucleic acid, a small molecule, a polypeptide, and an antibody or functional fragment thereof. An example of a nucleic acid delivery agent comprises an RNA interference molecule. Examples of RNA interference molecules are siRNA, dsRNA, StRNA, shRNA, miRNA, and combinations thereof. Specific siRNAs are provided. Other examples of a nucleic acid delivery agent are a small RNA, an antagomir, an LNA, and an antisense oligonucleotide. Methods for leukocyte-selective delivery, or activated leukocyte-selective delivery in vivo, in vitro and ex vivo are also provided. | 05-23-2013 |
20130136756 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 24P4C12 PROTEINS - Antibody drug conjugates (ADC's) that bind to 24P4C12 protein and variants thereof are described herein. 24P4C12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer. | 05-30-2013 |
20130164310 | ANTI-DIABETIC COMPOUNDS - The present invention provides a composition of the formula: [FGF21-1 | 06-27-2013 |
20130177580 | TRANSFERRIN/TRANSFERRIN RECEPTOR-MEDIATED siRNA DELIVERY - The invention provides interfering RNA molecule-ligand conjugates useful as a delivery system for delivering interfering RNA molecules to a cell in vitro or in vivo. The conjugates comprise a ligand that can bind to a transferrin receptor (TfR). Therapeutic uses for the conjugates are also provided. | 07-11-2013 |
20130183323 | TARGETED ANTIBIOTIC AND ANTIMICROBIAL TREATMENTS FOR PERSONALIZED ADMINISTRATION - A solution for the bottleneck issues in antibiotic treatment is to use novel antibiotic formulas with targeted delivery customized based on the nature of the infection and resistance profile of the infectious agent(s). | 07-18-2013 |
20130189286 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS - Antibody drug conjugates (ADC's) that bind to 191P4D12 protein and variants thereof are described herein. 191P4D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer. | 07-25-2013 |
20130202625 | USE OF HUMAN ERYTHROCYTES FOR PREVENTION AND TREATMENT OF CANCER DISSEMINATION AND GROWTH - The technology relates in part to methods of preventing and treating diseases and conditions associated with cancer, including methods, compositions, and kits used for preventing and treating cancer dissemination and growth. | 08-08-2013 |
20130209493 | BIOMAKERS FOR CIRCULATING TUMOR CELLS - Provided are methods for detecting circulating tumor cells (CTCs) in a subject. The methods may include detecting the expression of at least one epithelial mesenchymal transition (EMT) biomarker. Further provided are kits for detecting CTCs. The kits may include antibodies to at least one EMT biomarker. Further provided are methods of predicting the responsiveness of a subject to a cancer drug, methods of targeting delivery of a cancer drug in a subject, methods of providing a cancer prognosis to a subject, and methods for following the progress of cancer in a subject. | 08-15-2013 |
20130209494 | ENEDIYNE COMPOUNDS, CONJUGATES THEREOF, AND USES AND METHODS THEREFOR - Enediyne compounds having a structure according to formula (I), where R | 08-15-2013 |
20130209495 | ErbB3 ANTIBODIES - Antibodies are disclosed which bind to ErbB3 protein and further possess any one or more of the following properties: an ability to reduce heregulin-induced formation of an ErbB2-ErbB3 protein complex in a cell which expresses ErbB2 and ErbB3; the ability to increase the binding affinity of heregulin for ErbB3 protein; and the characteristic of reducing heregulin-induced ErbB2 activation in a cell which expresses ErbB2 and ErbB3. | 08-15-2013 |
20130224226 | INSECT BINDING ANTIBODIES - Described is a binding domain, preferably an antigen binding domain, more preferably an antigen binding domain that specifically binds a binding site on an insect. More specifically, described are antigen binding domains comprising an amino acid sequence that comprises 4 framework regions and 3 complementary determining regions, whereby the antigen binding domains are capable to bind specifically to an insect as a whole, preferably to a binding site on the insect surface. Further described is the use of the binding domain to deliver a compound, preferably a biologically active agent to the insect, and to insecticidal compositions comprising the binding domain. | 08-29-2013 |
20130230542 | ROS-Activated Compounds as Selective Anti-Cancer Therapeutics - Provided are compounds according to the following Formula I: | 09-05-2013 |
20130230543 | ENGINEERED POLYPEPTIDE CONJUGATES AND METHODS FOR MAKING THEREOF USING TRANSGLUTAMINASE - The present invention provides engineered polypeptide conjugates (e.g., antibody-drug-conjugates, toxin-(biocompatible polymer) conjugates, antibody-(biocompatible polymer) conjugates, and bispecific antibodies) comprising acyl donor glutamine-containing tags and amine donor agents. In one aspect, the invention provides an engineered Fc-containing polypeptide conjugate comprising the formula (Fc-containing polypeptide)-T-A, wherein T is an acyl donor glutamine-containing tag engineered at a specific site or comprises an endogenous glutamine made reactive by the Fc-containing polypeptide engineering, wherein A is an amine donor agent, and wherein the amine donor agent is site-specifically conjugated to the acyl donor glutamine-containing tag or the endogenous glutamine. The invention also provides methods of making engineered polypeptide conjugates using transglutaminase. | 09-05-2013 |
20130243796 | GENETIC PRODUCTS DIFFERENTIALLY EXPRESSED IN TUMORS AND USE THEREOF - The invention relates to the identification of genetic products that are expressed in association with a tumor and the nucleic acid coding therefor. The invention relates to the therapy and diagnosis of diseases in which the genetic products that are expressed in association with a tumor are expressed in an aberrant manner. The invention also relates to proteins, polypeptides, and peptides which are expressed in association with a tumor and the nucleic acids coding therefor. | 09-19-2013 |
20130259879 | VACCINE COMPOSITION COMPRISING COMPLEXED IMMUNOSTIMULATORY NUCLEIC ACIDS AND ANTIGENS PACKAGED WITH DISULFIDE-LINKED POLYETHYLENEGLYCOL/PEPTIDE CONJUGATES - The present invention is directed to an inventive composition or vaccine composition comprising a) an adjuvant component comprising or consisting of at least one immunostimulatory nucleic acid sequence, complexed with a complexing agent; b) an antigen, preferably a protein or peptide antigen and/or a nucleic acid sequence encoding said antigen; and c) a carrier molecule for combined packaging the adjuvant component and the antigen. The present invention is also directed to the first medical use of such an inventive composition or vaccine composition and to the second medical use of such an inventive composition or vaccine composition or components thereof for the treatment of diseases, such as infectious or cancer or tumour diseases as defined herein. The present invention furthermore discloses kits comprising such a composition or vaccine composition. | 10-03-2013 |
20130273080 | SIALOADHESIN-RELATED COMPOSITIONS AND METHODS - Methods of delivering a cargo moiety to a cell is provided that include contacting a cell expressing sialoadhesin with a conjugate including a sialoadhesin binding moiety and a cargo moiety. The sialoadhesin binding moiety binds to the sialoadhesin expressed by the cell and is internalized along with the cargo, delivering the cargo moiety to the cell. Particular methods include induction or enhancement of sialoadhesin expression in a cell which naturally produces little or no sialoadhesin. Induction or enhancement of sialoadhesin expression includes transfection of a sialoadhesin expression construct and/or administration of an agent effective to induce or enhance sialoadhesin expression. Methods and compositions for stimulating an immune response in a subject are detailed. Particular methods and compositions for stimulating an immune response to a virus are provided herein. | 10-17-2013 |
20130280280 | ANTIGEN BINDING PROTEINS - The present invention concerns antigen binding proteins and fragments thereof which specifically bind B Cell Maturation Antigen (BCMA), particularly human BCMA (hBCMA) and which inhibit the binding of BAFF and APRIL to the BCMA receptor. Further disclosed are pharmaceutical compositions, screening and medical treatment methods. | 10-24-2013 |
20130287800 | IMMUNIZATION WITH AMYLOID-BETA OLIGOMERS - The present invention provides methods of immunization against Alzheimer's Disease and compositions for use in such methods. | 10-31-2013 |
20130287801 | BIOMARKERS, USES OF BIOMARKERS AND A METHOD OF IDENTIFYING BIOMARKERS - The invention relates to the use of one or more of protein myoferlin, protein latent-transforming growth factor beta binding protein 2, protein transforming growth factor beta induced protein ig-h3, protein adipocyte enhancer-binding protein 1, protein EMILIN1, protein periostin, protein CD97, protein prolargin, protein Thy-1 membrane glycoprotein, protein growth hormone inducible transmembrane protein, protein biglycan, protein EPCAM and protein EMILIN2 as a biomarker for colorectal carcinoma (CRC) liver metastasis, or a predisposition thereto. The invention also relates to ligands directed to the above-mentioned biomarkers, for use in the therapeutic and/or prophylactic treatment of CRC liver metastasis. | 10-31-2013 |
20130295120 | VACCINES BASED ON TARGETING ANTIGEN TO DCIR EXPRESSED ON ANTIGEN-PRESENTING CELLS - The present invention includes compositions and methods for increasing the effectiveness of antigen presentation using a DCIR-specific antibody or fragment thereof to which an antigen is attached that forms an antibody-antigen complex, wherein the antigen is processed and presented by a dendritic cell that has been contacted with the antibody-antigen complex. | 11-07-2013 |
20130302357 | NOVEL BENZODIAZEPINE DERIVATIVES - The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepines of formula (I) and (II), in which the diazepine ring (B) is fused with a heterocyclic ring (CD), wherein the heterocyclic ring is bicyclic or a compound of formula (III), in which the diazepine ring (B) is fused with a heterocyclic ring (C), wherein the heterocyclic ring is monocyclic. The invention provides cytotoxic dimers of these compounds. The invention also provides conjugates of the monomers and the dimers. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention. The invention further relates to methods of using the compounds or conjugates for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions. | 11-14-2013 |
20130302358 | MORPHOLOGICALLY AND SIZE UNIFORM MONODISPERSE PARTICLES AND THEIR SHAPE-DIRECTED SELF-ASSEMBLY - Monodisperse particles having: a single pure crystalline phase of a rare earth-containing lattice, a uniform three-dimensional size, and a uniform polyhedral morphology are disclosed. Due to their uniform size and shape, the monodisperse particles self assemble into superlattices. The particles may be luminescent particles such as down-converting phosphor particles and up-converting phosphors. The monodisperse particles of the invention have a rare earth-containing lattice which in one embodiment may be an yttrium-containing lattice or in another may be a lanthanide-containing lattice. The monodisperse particles may have different optical properties based on their composition, their size, and/or their morphology (or shape). Also disclosed is a combination of at least two types of monodisperse particles, where each type is a plurality of monodisperse particles having a single pure crystalline phase of a rare earth-containing lattice, a uniform three-dimensional size, and a uniform polyhedral morphology; and where the types of monodisperse particles differ from one another by composition, by size, or by morphology. In a preferred embodiment, the types of monodisperse particles have the same composition but different morphologies. Methods of making and methods of using the monodisperse particles are disclosed. | 11-14-2013 |
20130315935 | OLIGOMERIC RECEPTOR LIGAND PAIR MEMBER COMPLEXES - This invention concerns an oligomeric receptor-ligand pair member in general and an oligomeric MHC-peptide complex in particular and a method of labeling, detecting and separating mammalian T cells according to the specificity of their antigen receptor by use of the oligomer. The invention further concerns a method of targeting the oligomeric receptor-ligand pair member complexes to target molecules of the surface of a target cell in order to present antigens on the target cell. The invention further concerns related pharmaceutical and diagnostic compositions and processes. | 11-28-2013 |
20130315936 | METHOD FOR NON-INVASIVE TREATMENT OF CEREBRAL ANEURYSMS - Described herein is a method for non-invasive detection and treatment of intra-cranial aneurysms. Antibodies are provided to specifically react/bind with antigens of the cerebral aneurism wall. The antibodies may be bound to a label and/or to a therapeutic agent for diagnosis and/or for treatment purposes thereof. Intra-cranial aneurysms are thus non-invasively detected before rupture occurs and are specifically treated. | 11-28-2013 |
20130336994 | EXTRACELLULAR TARGETED DRUG CONJUGATES - The present invention relates to, inter alia, extracellular drug conjugates (EDC) in which an antibody or other targeting agent (e.g. a targeting moiety) is linked to a drug through a linker (e.g. a non-cleavable linker). These conjugates are useful in the treatment of disease and/or as a tool in the evaluation of biological systems. | 12-19-2013 |
20130336995 | PHOTOSENSITIZING ANTIBODY-FLUOROPHORE CONJUGATES - The present disclosure relates to compositions and methods of killing cells in vitro or in vivo. In particular examples, the method includes contacting a cell having a cell surface protein with a therapeutically effective amount of an antibody-IR700 molecule, wherein the antibody specifically binds to the cell surface protein. In particular examples the antibody recognizes a tumor-specific antigen on the surface of a tumor cell. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm at a dose of at least 1 J cm | 12-19-2013 |
20140004132 | IMMUNOTHERAPY OF CANCER USING GENETICALLY ENGINEERED GD2-SPECIFIC T CELLS | 01-02-2014 |
20140017262 | CRIPTO BINDING MOLECULES - The invention pertains to humanized forms of an anti-CRIPTO antibody and portions thereof and their use in treating disorders, such as cancer either alone or in combination with other agents. | 01-16-2014 |
20140017263 | Delivery Agents for Targeted Treatment of Elastin Degradation - Methods and delivery agents for treatment of connective tissue that includes elastic fibers are described. Delivery agents are nano- or micro-sized particles that include a biologically active compound useful in treatment of degraded elastic fibers and an anchoring agent at a surface that binds at or near the area of degraded elastic fibers. The delivery agents may be utilized for targeted delivery of biologically active compounds to degraded elastic fibers so as to maintain and/or regenerate the elastin component of connective tissue, and prevent further degradation and/or rehabilitate the structural architecture of the connective tissue. | 01-16-2014 |
20140017264 | DOSAGE AND ADMINISTRATION OF BISPECIFIC SCFV CONJUGATES - Disclosed are methods for the therapeutic administration of bispecific scFv conjugates as single doses at at least weekly intervals. In certain embodiments the conjugate is MM-111 and is administered at intervals of every two weeks or every three weeks. In other embodiments a single loading dose of MM-111 is administered to a human patient followed at at least weekly intervals by a least a single maintenance dose of MM-111. The loading dose is larger than the maintenance dose. | 01-16-2014 |
20140023664 | Activatable Antibodies Having Non-Binding Steric Moieties and Methods of Using the Same - The invention relates generally to activatable antibodies and methods of making and using these activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications. | 01-23-2014 |
20140023665 | NOVEL MAYTANSINOID DERIVATIVES WITH SULFOXIDE LINKER - The invention relates to novel maytansinoid compounds having sulfoxide linkers and more specifically to novel maytansinoid compounds of structural formula (I) and (II). The invention also provides conjugates of the maytansinoid compounds linked to a cell-binding agent. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention. | 01-23-2014 |
20140030277 | IMMUNOMODULATING COMPOSITIONS AND METHODS OF USE THEREOF - This invention is directed to β-1-6-glucans, compositions and devices comprising the same, and methods of use thereof in modulating immune responses. The β-1-6-glucans of certain embodiments of the invention are enriched for O-acetylated groups and/or conjugated to a solid support or linked to a targeting moiety. | 01-30-2014 |
20140037656 | Treatment for Tauopathies - A method is described to treat tauopathies by extracorporeally treating a patient's cerebrospinal fluid (CSF). The method includes introducing an antibody into the CSF that is targeted to an antigen associated with tauopathies. The antibody can include an albumin moiety, and targets the removal of antigens such as tau protein, phosphorylated tau (pTau) protein, Ubiquitin and PKN. The antibody-antigen complex can be removed from the CSF and the CSF can be returned to the patient. | 02-06-2014 |
20140050744 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR - The invention is directed to antibody drug conjugate compositions of matter useful for the diagnosis and treatment of tumors in mammals and to methods of using those compositions of matter for the same. | 02-20-2014 |
20140056924 | GLP-1 RECEPTOR AGONIST COMPOUNDS FOR OBSTRUCTIVE SLEEP APNEA - The disclosure provides, among other things, the use of GLP-1 receptor agonist compounds to treat obstructive sleep apnea. The GLP-1 receptor agonist compounds may be exendins, exendin analogs, GLP-1(7-37), GLP-1(7-37) analogs (e.g., GLP-1(7-36)-NH | 02-27-2014 |
20140056925 | Methods of Reducing Myocardial Injury Following Myocardial Infarction - The present invention discloses methods of reducing injury resulting from cardiovascular disease, such as myocardial infarction, and/or promoting myocardial repair. The methods include administering an ephrin and pharmaceutical compositions including ephrins to a subject. Kits useful for accomplishing the same are also provided. | 02-27-2014 |
20140072586 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS - Antibody drug conjugates (ADC's) that bind to 158P1D7 protein and variants thereof are described herein. 158P1D7 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in glioblastoma, lung cancer, bladder cancer, and breast cancer. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer. | 03-13-2014 |
20140072587 | USE OF ANTI-CD19 MAYTANSINOID IMMUNOCONJUGATE ANTIBODY FOR THE TREATMENT OF B-CELL MALIGNANCIES SYMPTOMS - An anti-CD19 maytansinoid immunoconjugate is used for treating B-cell malignancies symptom, in particular Non-Hodgkin's lymphoma. | 03-13-2014 |
20140086941 | SUBSTITUTED 2-BENZYLIDENE-2H-BENZO[b][1,4]THIAZIN-3(4H)-ONES, DERIVATIVES THEREOF, AND THERAPEUTIC USES THEREOF - The present invention relates to compounds according to Formula I: | 03-27-2014 |
20140105920 | COMPOSITIONS AND METHODS TO TREAT DISEASE CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS - Described herein are compositions and methods for preventing and/or treating diseases involving aberrant angiogenesis employing one or more benzo[c]chromen-6-one derivatives. | 04-17-2014 |
20140112943 | METHOD OF DEVELOPING A VACCINE USING PEPTIDE-POLY IC COMPLEXES - The invention describes the development of more potent peptide vaccines to prevent or treat infections or cancer. Small synthetic peptides from the known sequences of viral, bacterial, parasitic or tumor antigens are modified so they can spontaneously form complexes with a synthetic nucleic acid, such as Poly IC, that functions as an immunological adjuvant. The peptide-nucleic acid complexes are dramatically more immunogenic as compared to the separate components. The procedure for developing the vaccine involves the conjugation of a synthetic peptide containing a C residue to poly-K using a bi-functional cross-linking reagent (SMCC). The peptide/poly-K complex was then formulated with CMC and poly-IC to produce a self-adjuvant vaccine that was 36-fold more effective as compared to the same peptide administered mixed with the same adjuvant (but not complexed to it). | 04-24-2014 |
20140112944 | COMPOSITIONS AND METHODS FOR TREATING CANCER - This invention generally relates to compositions and methods for targeted delivery of chemotherapeutic agents to cancerous and pre-cancerous cells, thereby treating a cancer in a subject. | 04-24-2014 |
20140120118 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF - A compound which is selected from A: | 05-01-2014 |
20140120119 | PHOTOSENSITIZING ANTIBODY-FLUOROPHORE CONJUGATES - The present disclosure relates to compositions and methods of killing cells. In particular examples, the method includes contacting a cell having a cell surface protein with a therapeutically effective amount of an antibody-IR700 molecule, wherein the antibody specifically binds to the cell surface protein, such as a tumor-specific antigen on the surface of a tumor cell. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm at a dose of at least 1 J cm | 05-01-2014 |
20140134191 | TCR Mimic Antibodies as Vascular Targeting Tools - The present invention includes a method of delivering a therapeutic agent into and across an endothelial cell (EC) in a subject in need thereof, comprising: attaching to a T Cell receptor mimic (TCR mimic) an active agent to form a therapeutic agent; and administering to the subject the therapeutic agent in a pharmaceutically acceptable carrier, wherein the therapeutic agent effectively crosses the EC microvascular barrier. Furthermore, the present invention relates to methods of treating diseases (particularly neuronal diseases) or conditions comprising identifying a subject in need of such a treatment and administering to said subject a composition comprising a TCR mimic conjugated to an active agent. | 05-15-2014 |
20140134192 | Methods and Compositions For Wound Treatment - The present disclosure relates to methods for identifying proteins or peptide motifs of intracellular, extracellular, or extracellular matrix proteins specifically exposed in wound sites, as well as compositions for treating wounds, and methods for their use. | 05-15-2014 |
20140141022 | SINGLE-CHAIN MULTIVALENT BINDING PROTEINS WITH EFFECTOR FUNCTION - Multivalent binding peptides, including bi-specific binding peptides, having immunoglobulin effector function are provided, along with encoding nucleic acids, vectors and host cells as well as methods for making such peptides and methods for using such peptides to treat or prevent a variety of diseases, disorders or conditions, as well as to ameliorate at least one symptom associated with such a disease, disorder or condition. | 05-22-2014 |
20140141023 | NOVEL ANTIGEN BINDING PROTEIN AND ITS USE AS ADDRESSING PRODUCT FOR THE TREATMENT OF CANCER - The present invention relates to a novel antigen binding protein, in particular a monoclonal antibody, capable of binding specifically to the protein Axl as well as the amino and nucleic acid sequences coding for said protein. From one aspect, the invention relates to a novel antigen binding protein, or antigen binding fragments, capable of binding specifically to Axl and, by inducing internalization of Axl, being internalized into the cell. The invention also comprises the use of said antigen binding protein as an addressing product in conjugation with other anti-cancer compounds, such as toxins, radio-elements or drugs, and the use of same for the treatment of certain cancers. | 05-22-2014 |
20140141024 | COMBINATION OF ANTI-CTLA4 ANTIBODY WITH DIVERSE THERAPEUTIC REGIMENS FOR THE SYNERGISTIC TREATMENT OF PROLIFERATIVE DISEASES - Compositions and methods are disclosed which are useful of the treatment and prevention of proliferative disorders. | 05-22-2014 |
20140147452 | METHOD FOR REMOVAL OF TOXINS FROM MUCOSAL MEMBRANES - The present invention provides novel mucoadhesive compounds useful in the prevention of diseases and disorders of or which are associated with the mucosal membrane. | 05-29-2014 |
20140154271 | Methods of Treating Glucose Metabolism Disorders - Methods of treating individuals with a glucose metabolism disorder, and compositions thereof, are provided. | 06-05-2014 |
20140161827 | COMPOSITIONS AND METHODS FOR TREATING CANCER - The present invention provides combination therapies useful for treating cancer, particularly breast cancer. The invention provides, in various embodiments, methods of treating a cancer, comprising administering to a patient afflicted therewith of an effective amount an immunoconjugate comprising a monoclonal antibody moiety and a first pro-apoptotic drug moiety linked thereto; and administering to the patient an effective amount of a second pro-apoptotic drug. The monoclonal antibody moiety of the immunoconjugate can act to target receptors of hormone-resistant breast cancer cells, such as HER2. Synergistic effects can be seen when the two pro-apoptotic drugs, acting by a common molecular mechanism (vertical modulation) or different molecular mechanisms (horizontal modulation) are administered to patients afflicted by breast cancer, such as hormone-resistant breast cancer. | 06-12-2014 |
20140170171 | TARGETED CYTOKINE FOR TREATMENT OF MUSCULOSKELETAL DISEASES - Provided are proteins and polynucleotides, complexes and compositions containing the proteins, and methods for their use in administration to subjects and for disease treatment. Among the provided proteins and complexes are complexes containing a TGF-beta associated with immunoglobulins (such as IgGs) or functional portions thereof including Fc portions, such as by non-covalent bonds. The complexes and compositions can be used for administration to subjects, such as for treating a subject with a musculoskeletal disease such as osteoarthritis and/or degenerative joint disease. The complexes and compositions can be used in different mammals, including dogs, horses, and humans. | 06-19-2014 |
20140170172 | Tat-Based Tolerogen Compositions and Methods for Making and Using Same - A Tat-based tolerogen composition comprising at least one immunogenic antigen coupled to at least one human immunodeficiency virus (HIV) trans-activator of transcription (Tat) molecule wherein the immunogenic antigen can be a foreign or endogenous antigen or fragments thereof. Additionally methods of suppressing organ transplant rejection and methods of treating autoimmune diseases are provided. | 06-19-2014 |
20140193435 | METHOD FOR INTEGRATING LARGE SCALE BIOLOGICAL DATA WITH IMAGING - There is disclosed a method of extracting large scale biological, biochemical or molecular information about an index disease, biological state, or systems from imaging by correlating the imaging features associated with said disease, state or system with corresponding large scale biological data. | 07-10-2014 |
20140193436 | EXTRACELLULAR TARGETED DRUG CONJUGATES - Extracellular-targeted drug conjugates (EDC) in which a targeting moiety targeting a protein associated with the Na,K-ATPase is linked to a drug that interacts with the Na,K-ATPase through a linker a stable linker are useful in the treatment of disease and as tools for the evaluation of biological systems. | 07-10-2014 |
20140212440 | CONJUGATE COMPRISING OXYNTOMODULIN AND AN IMMUNOGLOBULIN FRAGMENT, AND USE THEREOF - The present invention relates to a conjugate comprising oxyntomodulin, an immunoglobulin Fc region, and non-peptidyl polymer wherein the conjugate being obtainable by covalently linking oxyntomodulin to immunoglobulin Fc region via non-peptidyl polymer, and a pharmaceutical composition for the prevention or treatment of obesity comprising the conjugates. The conjugate comprising oxyntomodulin and the immunoglobulin Fc of the present invention reduces food intake, suppresses gastric emptying, and facilitates lipolysis without side-effects, unlike native oxyntomodulin, and also shows excellent receptor-activating effects and long-term sustainability, compared to native oxyntomodulin. Thus, it can be widely used in the treatment of obesity with safety and efficacy. | 07-31-2014 |
20140220044 | METHOD FOR THE PRODUCTION OF HYDROLYZED ALLERGENS - A method for the production of hydrolyzed allergens from allergens comprising the steps of:
| 08-07-2014 |
20140220045 | Compositions of a Peptide Targeting System for Treating Cancer - This invention describes a protein nanoparticle system for targeting siRNA or other drugs into tumors. The basis of the protein system is elastin-like peptides that self-assemble once exposed to the nucleic acid of the siRNA. Specific targeting peptides are fused to the core ELP structure by standard genetic engineering techniques. These targeting peptides confer specific binding of the nanoparticle to receptors on the surface of tumor cells and allow for uptake of the nanoparticle into the tumor cells. | 08-07-2014 |
20140242096 | COMPOSITIONS AND METHODS RELATED TO GRAFT VERSUS HOST DISEASE AND TREATMENTS THEREOF - Embodiments of the present invention illustrate methods of treating and preventing transplantation and side effects associated with transplantation. In particular, the present invention relates to compositions and methods for inhibition of graft rejection and promotion of graft survival. Thus, the invention relates to modulation of cellular activities, including graft rejection, promotion of graft survival, graft versus host rejection and conditions commonly associated with graft rejection. More particularly, the present invention relates to the inhibitory compounds comprising naturally occurring and man-made inhibitors of serine protease and inducers of other alpha1-antitrypsin activities. | 08-28-2014 |
20140242097 | METHODS - A method for promoting entry of an agent (introduced agent) into a cell, the method comprising the step of complexing the introduced agent in the presence of an entry-promoting agent and then exposing to cells, wherein the entry-promoting agent comprises a linear and/or branched or cyclic polymonoguanide/polyguanidine, polybiguanide, analogue or derivative thereof according to the following Formula 1a & b. The method also provides a means for formation of nanoparticles formed between the entry promoting agent and the introduced agent. wherein: “n”, refers to number of repeating units in the polymer, and n can vary from 2 to 1000, for example from 2 or 5 to 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800 or 900; G | 08-28-2014 |
20140248295 | GLYCAN-MODIFIED ANTI-CD4 ANTIBODIES FOR HIV PREVENTION AND THERAPY - Disclosed herein are glycan-modified anti-CD4 monoclonal antibodies with N-linked glycans attached to the variable region. Expression vectors and cell lines useful for the production of such antibodies, and use of such antibodies for HIV prevention and therapy are also disclosed. | 09-04-2014 |
20140271687 | Methods of Targeting T-Cells to Tumors - The invention provides a method of targeting T-cells to tumor cells using a tumor-associated antigen (TAA) specific antibody and a T-cell specific antibody, wherein the two antibodies can bind to each other through a high affinity avidin/biotin or streptavidin/biotin connection. The invention further provides methods to target activated T-cells to different tumor types by using a T-cell specific antibody that is specific to an activated T-cell surface molecule like CTLA-4. | 09-18-2014 |
20140286968 | ANTIBODY DRUG CONJUGATE (ADC) PURIFICATION - The invention provides methods for obtaining compositions having antibody drug conjugates (ADCs) with specified drug to antibody ratios (DARs). Included in the invention is a method for purifying an ADC mixture having ADCs with a drug loaded species of 6 or more by contacting the mixture with a hydrophobic resin such that a composition comprising less than 15% of the 6 or more drug loaded species is obtained. The invention also provides a composition wherein 70% or more of the ADCs present have a drug loaded species of 4 or less, wherein the ADC comprises an anti-EGFR antibody and an auristatin. | 09-25-2014 |
20140294863 | SERUM ALBUMIN BINDING PEPTIDES FOR TUMOR TARGETING - Peptide ligands having affinity for serum albumin are useful for tumor targeting. Conjugate molecules comprising a serum albumin binding peptide fused to a biologically active molecule demonstrate modified pharmacokinetic properties as compared with the biologically active molecule alone, including tissue (e.g., tumor) uptake, infiltration, and diffusion. | 10-02-2014 |
20140294864 | DRUG CONJUGATE COMPOSITION - The invention provides a liquid composition and a lyophilized composition comprising a therapeutically effective amount of a conjugate comprising an antibody chemically coupled to a maytansinoid. The invention further provides a method for killing a cell in a human comprising administering to the human either of the compositions such that the antibody binds to the surface of the cell and the cytotoxicity of the maytansinoid is activated, whereby the cell is killed. | 10-02-2014 |
20140322247 | CELL PROLIFERATION INHIBITORS AND CONJUGATES THEREOF - Disclosed herein are immunoconjugates comprising an inhibitor of Eg5 linked to an antigen binding moiety such as an antibody, that are useful for treating cell proliferative disorders. Also disclosed are novel inhibitors of Eg5 that can be used either alone or as part of an immunoconjugate to treat cell proliferation disorders. The Eg5 inhibitors include compounds of this formula as described herein: | 10-30-2014 |
20140328865 | Immune Modulation Via C-Type Lectin - The invention relates to the regulation of the immune system, and in particular to the finding that the CLEC9a molecule is a marker for dendritic cells which are capable of cross-presenting extracellular antigens via the MHC class I pathway. This makes them particularly suitable for generation of cytotoxic T lymphocyte responses. Materials and methods are provided both for the induction of immune responses against target antigens, and for the inhibition or suppression of undesirable immune responses in which these cells are involved. | 11-06-2014 |
20140328866 | Peptide-Mediated Non-Covalent Delivery of Active Agents Across the Blood-Brain Barrier - The peptides described herein can function as carrier peptides. These peptides can associate with (e.g., non-covalently bind) biologically active molecules or imaging agents to transport the biologically active molecules or imaging across the blood-brain barrier. In some cases, such transport may increase the effectiveness of the biological molecules or imaging agents. | 11-06-2014 |
20140335107 | ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE - The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same. | 11-13-2014 |
20140335108 | UTILITY OF INSULIN-LIKE 6 (INSL6) FOR THE TREATMENT OF AUTOIMMUNE DISEASES - The present invention is directed to compositions and methods to treat an autoimmune disease in a subject, comprising an insulin-like 6 (Insl6) agent, such as an Insl6 polypeptide or variant or fragment thereof, or a nucleic acid encoding Insl6 poly peptide or variant or fragment thereof. Aspects of the present invention relate to use of Insl6 agents to reduce T-regulatory (Treg) cells in the subject and to reduce pro-inflammatory cytokines in a subject with an autoimmune disease such as a muscle autoimmune disease. The present invention also relates to methods and kits for the treatment of autoimmune diseases in a subject, and methods to diagnose a subject with an autoimmune disease such as myositis. | 11-13-2014 |
20140356381 | METHODS OF PURIFYING HETERODIMERIC PROTEINS USING IMMUNOGLOBULIN CLASS SWITCHING - The present invention describes novel immunoglobulin compositions that co-engage at least two antigens, e.g. a first and second antigen, or, as outlined herein, three or four antigens can be bound, in some of the scaffold formats described herein. First and second antigens of the invention are herein referred to as antigen-1 and antigen-2 respectively (or antigen-3 and antigen-4, if applicable. As outlined herein, a number of different formats can be used, with some scaffolds relying combinations of monovalent and bivalent bindings. | 12-04-2014 |
20140356382 | Exosomes for Delivery of Biotherapeutics - The present invention relates to exosomes, loaded with biotherapeutic protein and/or peptide and methods of producing them and to the use of such exosomes for delivering protein and/or peptide in vivo, in particular the use of such exosomes in methods of therapy. | 12-04-2014 |
20140363451 | Anti-FOLR1 Immunoconjugate Dosing Regimens - Methods of administering immunoconjugates that bind to FOLR1 are provided. The methods comprise administering an anti-FOLR1 immunoconjugate to a person in need thereof, for example, a cancer patient, at a therapeutically effective dosing regimen that results in minimal adverse effects. | 12-11-2014 |
20140370034 | SDF-1 Binding Nucleic Acids and the Use Thereof - The present invention is related to a nucleic acid molecule binding to SDF-1, whereby the nucleic acid molecule influences migration of cells. | 12-18-2014 |
20140370035 | METHODS OF REDUCING IMMUNOGENICITY AGAINST FACTOR VIII IN INDIVIDUALS UNDERGOING FACTOR VIII THERAPY - The present disclosure provides methods of administering chimeric and hybrid Factor VIII (FVIII) polypeptides comprising FVIII and Fc to subjects at risk of developing inhibitory FVIII immune responses, including anti-FVIII antibodies and/or cell-mediated immunity. The administration is sufficient to promote coagulation and to induce immune tolerance to FVIII. The chimeric polypeptide can comprise full-length FVIII or a FVIII polypeptide containing a deletion, e.g., a full or partial deletion of the B domain. | 12-18-2014 |
20140370036 | COMPOSITIONS OF, AND METHODS FOR, ALPHA-1 ANTITRYPSIN FcFUSION MOLECULES - A novel method of treating and preventing bacterial diseases is provided. In particular, the present invention relates to compositions and methods for inhibition of Gram negative, Gram positive and acid fast bacilli in general and tuberculosis (TB), | 12-18-2014 |
20140377287 | ANTI-TROP-2 ANTIBODY-DRUG CONJUGATES AND USES THEREOF - Described herein are compositions and methods of use of antibody-drug conjugates (ADCs) comprising an anti-Trop-2 antibody or antigen-binding fragment thereof, conjugated to one or more cytotoxic drugs. Preferably, the antibody is an RS7, 162-46.2 or MAB650 antibody. More preferably, the antibody is humanized. Preferably the drug is SN-38, pro-2-pyrrolinodoxorubicin, paclitaxel, calichemicin, DM1, DM3, DM4, MMAE, MMAD or MMAF. The compositions and methods are of use to treat Trop-2 expressing cancers, such as breast, ovarian, cervical, endometrial, lung, prostate, colon, stomach, esophageal, bladder, renal, pancreatic, thyroid, epithelial or head-and-neck cancer. Preferably, the cancer is one that is resistant to one or more standard cancer therapies. More preferably, the anti-Trop-2 antibody binds to Trop-2 expressed on normal cells, but administration of the anti-Trop-2 ADC to human cancer patients at a therapeutically effective dosage produces only limited toxicity. | 12-25-2014 |
20140377288 | COMPOSITIONS AND METHODS RELATED TO DNA DAMAGE REPAIR - The present invention provides compositions and methods for treating a cancer associated with elevated expression and/or activity of receptor tyrosine kinases (e.g., Eph receptors), such as EphA5. In some embodiments, the present invention provides compositions and methods for identifying elevated expression or activity of receptor tyrosine kinases (e.g., Eph receptors), such as EphA5. | 12-25-2014 |
20140377289 | Metallodrugs Having Improved Pharmacological Properties, and Methods of Manufacture and Use Thereof - It is an object of the present invention to provide improved pharmacological properties to molecules which bind to a target with low affinity (hereinafter referred to as a “ligand moiety”) through linkage of such molecules to a metal binding moiety, thereby generating a combination molecule commonly referred to as a “metallodrug” or “metallotherapeutic.” The metal binding domain of metallodrugs typically catalyzes oxido-reductase chemistry or acts as a Lewis-Acid catalyst, resulting in modification of proteins and nucleic acids that are in close proximity due to binding of the ligand moiety to its target. | 12-25-2014 |
20150010584 | Targeted Delivery Of Autoantigens To B Cell Populations - The present invention is related to compositions and methods to stimulate the immune system. For example, antigen-specific antibodies may be produced by stimulating B cell populations with specific antigenic compounds, such as an adjuvant comprising a macromolecule capable of activating a Toll-Like receptor (TLR). For example, a BCR adapter IgM (BCRAM) is described to exemplify delivery of autoantigens to polyclonal B cell populations resulting in immunoactivation by TLR activation. Alternatively, a compound is described that inhibits TLR activation. | 01-08-2015 |
20150010585 | IMMUNOCONJUGATES TARGETING SYNDECAN-1 EXPRESSING CELLS AND USE THEREOF - Immunoconjugates comprising a targeting agent selectively targeting cell-surface expressed syndecan-1 and at least one effector molecule as well as in vitro and in vivo methods of using those immunocomjugates are disclosed. The effector molecule may have, in its native form, high non-selective cytotoxicity, but substantially no non-selective cytotoxicity when part of said immunoconjugate. Targeting agents include the antibody B-B4 as well as other agents that bind cell-surface expressed syndecan-1. | 01-08-2015 |
20150017186 | Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and methods of use - Provided are compositions and combinations containing an organophosphorus bioscavenger and a hyaluronan-degrading enzyme. The provided compositions and combinations can be used to treat or prevent organophosphorus poisoning, including nerve agent poisoning and pesticide poisoning. | 01-15-2015 |
20150017187 | ANTIBODIES COMPRISING MULTIPLE SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE - Provided herein are antibodies comprising multiple non-natural amino acid residues at site-specific positions, compositions comprising the antibodies, methods of their production and methods of their use. The antibodies are useful for methods of treatment and prevention, methods of detection and methods of diagnosis. | 01-15-2015 |
20150030616 | NOVEL BENZODIAZEPINE DERIVATIVES - The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepines of formula (I) and (II), in which the diazepine ring (B) is fused with a heterocyclic ring (CD), wherein the heterocyclic ring is bicyclic or a compound of formula (III), in which the diazepine ring (B) is fused with a heterocyclic ring (C), wherein the heterocyclic ring is monocyclic. The invention provides cytotoxic dimers of these compounds. The invention also provides conjugates of the monomers and the dimers. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention. The invention further relates to methods of using the compounds or conjugates for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions. | 01-29-2015 |
20150037359 | XTEN CONJUGATE COMPOSITIONS AND METHODS OF MAKING SAME - The present invention relates to extended recombinant polypeptide (XTEN) compositions, conjugate compositions comprising XTEN and XTEN linked to cross-linkers useful for conjugation to pharmacologically active payloads, methods of making highly purified XTEN, methods of making XTEN-linker and XTEN-payload conjugates, and methods of using the XTEN-cross-linker and XTEN-payload compositions. | 02-05-2015 |
20150056218 | P97 FRAGMENTS WITH TRANSFER ACTIVITY - The present invention is related to fragments of human melanotransferrin (p97). In particular, this invention relates to treatment of diseases through the introduction of the melanotransferrin fragment conjugated to a therapeutic or diagnostic agent to a subject. | 02-26-2015 |
20150056219 | METHODS AND COMPOSITIONS FOR CANCER THERAPY USING MUTANT LIGHT MOLECULES WITH INCREASED AFFINITY TO RECEPTORS - Methods and compositions are disclosed to target tumor cells with embodiments of the LIGHT proteins linked fused or conjugated to a targeting agent. These compositions bind to both human and mouse receptors with affinity sufficient to conduct preclinical and clinical trials, and with increased affinity as compared to the wild type human LIGHT protein. The targeting of embodiments of LIGHT to tumor cells reduces tumor growth and reduces metastases. | 02-26-2015 |
20150056220 | METHODS FOR IDENTIFICATION OF SITES FOR IGG CONJUGATION - The present disclosure relates to immunoglobulins and immunoglobulin conjugates with reduced oligomerization and efficient labeling and compositions, methods of generating such immunoglobulins and immunoglobulin conjugates and methods of using such immunoglobulin conjugates particularly in the treatment and prevention of disease. | 02-26-2015 |
20150056221 | ANTI-PRLR ANTIBODIES AND USES THEREOF - The present invention provides antibodies that bind to prolactin receptor (PRLR) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human PRLR with high affinity. In certain embodiments, the invention includes antibodies that bind PRLR and block prolactin-mediated cell signaling. In other embodiments, the invention includes antibodies that bind PRLR but do not block prolactin-mediated cell signaling. The antibodies of the invention may be fully human antibodies. The invention includes anti-PRLR antibodies conjugated to a cytotoxic agent, radionuclide, or other moiety detrimental to cell growth or proliferation. The antibodies of the invention are useful for the treatment of various cancers as well as other PRLR-related disorders. The present invention also includes antibody drug conjugates comprising an antibody or antigen-binding fragment thereof that specifically binds a class I cytokine receptor, wherein the antibody or antigen-binding fragment thereof is conjugated to a cytotoxic agent. | 02-26-2015 |
20150056222 | ANTI-PRLR ANTIBODIES AND USES THEREOF - The present invention provides antibodies that bind to prolactin receptor (PRLR) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human PRLR with high affinity. In certain embodiments, the invention includes antibodies that bind PRLR and block prolactin-mediated cell signaling. In other embodiments, the invention includes antibodies that bind PRLR but do not block prolactin-mediated cell signaling. According to certain embodiments, the invention includes antibodies that bind to the first fibronectin-like type III domain of the extracellular domain of PRLR. The antibodies of the invention may be fully human antibodies. The invention includes anti-PRLR antibodies conjugated to a cytotoxic agent, radionuclide, or other moiety detrimental to cell growth or proliferation. The antibodies of the invention are useful for the treatment of various cancers as well as other PRLR-related disorders. The present invention also includes antibody drug conjugates comprising an antibody or antigen-binding fragment thereof that specifically binds a class I cytokine receptor, wherein the antibody or antigen-binding fragment thereof is conjugated to a cytotoxic agent. | 02-26-2015 |
20150064205 | ENHANCEMENT OF PATHOGEN-SPECIFIC MEMORY TH17 CELL RESPONSES - Compositions and methods for enhancing Th1/Th17 cell responses and decreasing Th2 cell responses are disclosed herein. In various embodiments the present invention describes activation of human dendritic cells and enhancement of antigen-specific T cell responses in a Dectin-1-expressing human dendritic cells comprising an anti-Dectin-1-specific antibody or fragment thereof fused with one or more antigens. TLR2 ligands may also be included to enhance the activation and for enhancement of T-cell responses. Further, the invention also includes methods based on the compositions described herein for the treatment of pathogenic infections. | 03-05-2015 |
20150071948 | NOVEL IMMUNOGLOBULIN VARIANTS - The present invention relates to Fc variants with optimized Fc ligand binding properties, methods for their generation, Fc polypeptides comprising Fc variants with optimized Fc ligand binding properties, and methods for using same. | 03-12-2015 |
20150079114 | DR5 LIGAND DRUG CONJUGATES - Ligand Drug Conjugates are provided having a DRS binding moiety attached via linking groups andor spacers to a therapeutic agent that are effective in treatment of various cancers. In some embodiments, the Ligand Drug Conjugate has the formula: L-(LU-D)p, where L is a Ligand unit, LU is a Linker unit and D is a Drug unit (or cytotoxic agent). The subscript p is an integer of from 1 to 20. Accordingly, the Ligand Drug Conjugates comprise a Ligand unit covalently linked to at least one Drug unit. The Drug units can be covalently linked directly or via a Linker unit (-LU-). The Ligand unit is a DR5 binding agent, such as an anti-DRS antibody. | 03-19-2015 |
20150079115 | Compositions and Methods for Preventing or Relieving Symptoms of Infections - Food products and/or pharmaceutical preparations including (i) viral neutralizing antibodies or antibody fragments anchored to a probiotic microorganism and (ii) a carrier medium for delivering the viral neutralizing antibodies or antibody fragments anchored to probiotic microorganisms to the gut of a mammal. Also provided are methods of making food products and/or pharmaceutical preparations, which can be used to treat existing viral infections or prevent the spread or transmission of viral infection. | 03-19-2015 |
20150093399 | CNS-TARGETED CONJUGATES HAVING MODIFIED FC REGIONS AND METHODS OF USE THEREOF - Provided are central nervous system (CNS)-targeted antibody or therapeutic Fc-fusion polypeptide conjugates having modified Fc regions, and related methods of use thereof, for instance, to facilitate delivery of therapeutic and/or diagnostic polypeptides across the blood-brain barrier (BBB), and thereby treat and/or diagnose conditions associated with the CNS, including cancer, pain, and various neuropathologies, such as neuroinflammatory, auto-immune, and/or neurodegenerative disorders. | 04-02-2015 |
20150098953 | METHODS OF TREATING A PATIENT HAVING AN AUTOIMMUNE DISORDER BY ADMINISTERING A BAFF ANTAGONIST - Therapeutic regimens for administration of BAFF antagonists for treatment of immunologic and related disorder are described. Regimens involve a short-term BAFF antagonist administration course followed by an extended no-treatment period prior the round or administration. | 04-09-2015 |
20150110814 | COMBINATION THERAPIES WITH PSMA LIGAND CONJUGATES - Compositions and methods related to inhibiting the proliferation of or killing of prostate-specific membrane antigen (PSMA)-expressing cells are provided herein. In some embodiments, PSMA-expressing cells are contacted with (i) a compound that increases cell surface expression of PSMA and (ii) a PSMA ligand conjugate. In other embodiments, the PSMA-expressing cells are contacted with (i) prednisone and (ii) a PSMA ligand conjugate. In some of these embodiment ts, the PSMA-expressing cells are further contacted with (iii) a compound that increases cell surface expression of PSMA. | 04-23-2015 |
20150110815 | DRUG CONJUGATE COMPRISING DRUG LINKED TO HUMAN C-MET ANTIBODY, AND USE THEREFOR - The present invention relates to a drug conjugate comprising a cytotoxic drug conjugated to a c-Met specific human antibody. More specifically, the present invention relates to: a drug conjugate comprising a cytotoxic drug conjugated to a c-Met specific human antibody; a pharmaceutical composition for cancer treatment comprising the drug conjugate; and a cancer treatment method comprising a step in which the drug conjugate or pharmaceutical composition is administered to an individual. | 04-23-2015 |
20150118255 | LIQUID FORMULATION OF HIGHLY CONCENTRATED LONG-ACTING HUMAN GROWTH HORMONE CONJUGATE - The present invention relates to a liquid formulation of highly concentrated long-acting human growth hormone conjugate, comprising a pharmaceutically effective amount of the long-acting human growth hormone conjugate in which human growth hormone (hGH) is linked to an immunoglobulin Fc region, and an albumin-free stabilizer, said stabilizer comprising a buffer, a non-ionic surfactant, a sugar alcohol, and sodium chloride as an isotonic agent, and a method for preparing the same. | 04-30-2015 |
20150125472 | ANTI-EFNA4 ANTIBODY-DRUG CONJUGATES - The present invention provides for anti-EFNA4 antibody-drug conjugates and methods for preparing and using the same. | 05-07-2015 |
20150132323 | Anti-FOLR1 Immunoconjugate Dosing Regimens - Methods of administering immunoconjugates that bind to FOLR1 are provided. The methods comprise administering an anti-FOLR1 immunoconjugate to a person in need thereof, for example, a cancer patient, at a therapeutically effective dosing regimen that results in minimal adverse effects. | 05-14-2015 |
20150140019 | Compositions and Methods for Regulating CAR T Cells - The present invention provides compositions and methods for inhibiting the depletion of healthy tissue during CAR T cell therapy. In another embodiment, the invention includes a drug-molecule conjugate which is administered to a subject receiving CAR T cell therapy, where the conjugate binds to the CAR resulting in internalization of the conjugate and inhibition of T cell activity and/or death of the T cell. | 05-21-2015 |
20150140020 | PHARMACEUTICAL COMPOSITION FOR TREATING ADVERSE REACTIONS DUE TO ADMINISTRATION OF SPIEGELMERS - The invention relates to the use of an L-ribozyme, which is capable of splitting an L-RNA in the region of a target sequence of the L-RNA, in order to produce a pharmaceutical composition for trating undesired physiological adverse reactions due to the administration of a therapeautic modecule containing the L-RNA. Alternatively, an endogeneous target RNA may also be split by the L-ribozyme. | 05-21-2015 |
20150140021 | Therapeutic Biologic for Treatment of Hepatocellular Carcinoma - The invention provides, inter alia, conjugates comprising a coagulating agent conjugated to an antibody, where the antibody specifically binds an extracellular domain epitope of a mammalian PLVAP protein. These agents specifically target HCC tumors and treat the HCC. The invention also provides methods of using these conjugates, such as methods of treating HCC by administering the conjugates provided by the invention or compositions provided by the invention, such as pharmaceutical compositions. | 05-21-2015 |
20150290324 | LIQUID FORMULATION OF PROTEIN CONJUGATE COMPRISING THE OXYNTOMODULIN AND AN IMMUNOGLOBULIN FRAGMENT - Disclosed are an albumin-free liquid formulation including a long-lasting oxyntomodulin conjugate in which an oxyntomodulin peptide comprising a derivative, variant, precursor or fragment of oxyntomodulin is linked to an immunoglobulin Fc region, which can increase the duration of physiological activity of the long-lasting oxyntomodulin conjugate and maintain the in vivo stability thereof for an extended period of time, as compared to native oxyntomodulin, and a method for preparing the liquid formulation. The liquid formulation contains a buffer, a sugar alcohol and a nonionic surfactant and does not contain a human serum albumin and factors that are potentially harmful to the human body, and thus is not susceptible to viral infection. The oxyntomodulin conjugate contains oxyntomodulin linked to an immunoglobulin Fc region, and thus has a large molecular weight, prolonged physiological activity, and excellent storage stability, compared to native oxyntomodulin. | 10-15-2015 |
20150291657 | TUBULYSIN DERIVATIVES - Novel tubulysin derivatives which may be useful as cytotoxic agents to provide therapeutic benefits in the treatment of various types of cancers, alone, as drug conjugates or in combination with other chemotherapies are provided. | 10-15-2015 |
20150291702 | CONJUGATED ANTI-CD38 ANTIBODIES - Isolated antibodies that bind to human CD38 and cynomolgus CD38 are disclosed. Also disclosed are pharmaceutical compositions comprising the disclosed antibodies, and therapeutic and diagnostic methods for using the disclosed antibodies. | 10-15-2015 |
20150297674 | SUBSTANCES AND METHODS FOR THE TREATMENT OF CEREBRAL AMYLOID ANGIOPATHY RELATED CONDITIONS OR DISEASE - A substance for treating a cerebral amyloid angiopathy related condition or disease affecting cerebrovasculature in a patient, comprising an inhibitor that causes inhibition of the formation of membrane attack complex of the complement system; and a vehicle for transporting the inhibitor into the cerebrovasculature; where the inhibition by the inhibitor is sufficient to decrease the incidence of or to prevent the incidence of cytolysis of the smooth muscle cells. A method for treating a cerebral amyloid angiopathy related condition or disease affecting cerebrovasculature in a patient, comprising: a) identifying a patient with a cerebral amyloid angiopathy related condition or disease; b) providing one or more than one substance that comprises an inhibitor that causes inhibition of the formation of membrane attack complex of the complement system, c) administering one or more than one dose of the one or more than one substance to the patient. | 10-22-2015 |
20150297745 | Agents and Methods - The invention provides an agent comprising: (i) a T cell antigen, and (ii) a binding partner for any of CD22, CD23, CD30, CD74, CD70, CD43, CD44, CD47, CD54, CD58, CD62L, CD95, HLA-DR, CD59, CD55, wherein, following binding of the agent to a cell that expresses any of CD22, CD23, CD30, CD74, CD70, CD43, CD44, CD47, CD54, CD58, CD62L, CD95, HLA-DR, CD59, CD55, the agent is internalised and the T cell antigen is presented on the surface of the cell in a form that can be recognised by a T cell. | 10-22-2015 |
20150301059 | B7-H3 AS A BIOMARKER FOR DIAGNOSING THE PROGRESSION AND EARLY LYMPH NODE METASTASIS OF CANCER - B7H3 is a ligand member of the immunoregulatory family of proteins on immune cells. In one embodiment, a method for diagnosing the progression of cancer with a high propensity of primary tumor metastasis to the lymph node or distant site is provided. Such a method may comprise obtaining a cancer tissue sample from a cancer patient, determining an expression level of B7-H3 present in the tissue sample, and diagnosing the progression of the cancer having a high propensity of primary tumor metastasis to the lymph node or distant site based upon the expression level, wherein an increased expression level correlates with an increased probability of having regional lymph nodes or organ site that are positive for metastases. | 10-22-2015 |
20150306246 | MAGNETIC NANOPARTICLES, COMPOSITES, SUSPENSIONS AND COLLOIDS WITH HIGH SPECIFIC ABSORPTION RATE (SAR) - Iron oxide nanoparticles and nanocomposites with organic molecules embedded in their structure, having exceptionally high SAR values, are provided for biological, medical (for example, drug delivery, hyperthermia, etc.) and other uses. | 10-29-2015 |
20150307620 | LINKED IMMUNOTHERAPEUTIC AGONISTS THAT COSTIMULATE MULTIPLE PATHWAYS - Described herein are modified immunotherapeutic agents including a first monoclonal antibody covalently linked to a second monoclonal antibody generating a single new immunotherapeutic agent. The first and second monoclonal antibodies stimulate different anti-tumor pathways. Advantageously, the modified single immunotherapeutic agent is capable of activating both anti-tumor pathways. Also included herein are methods of treating cancer with the modified immunotherapeutic agents. | 10-29-2015 |
20150315592 | TRANSFERRIN/TRANSFERRIN RECEPTOR-MEDIATED siRNA DELIVERY - The invention provides interfering RNA molecule-ligand conjugates useful as a delivery system for delivering interfering RNA molecules to a cell in vitro or in vivo. The conjugates comprise a ligand that can bind to a transferrin receptor (TfR). Therapeutic uses for the conjugates are also provided. | 11-05-2015 |
20150322160 | ANTI-MESOTHELIN IMMUNOCONJUGATES AND USES THEREFOR - The present invention provides immunoconjugates composed of antibodies, e.g., monoclonal antibodies, or antibody fragments that bind to mesothelin, that are conjugated to cytotoxic agents, e.g., maytansine, or derivatives thereof, and/or co-administered or formulated with one or more additional anti-cancer agents. The immunoconjugates of the invention can be used in the methods of the invention to treat and/or diagnose and/or monitor cancers, e.g. solid tumors. recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for the membrane-anchored, 40 kDa mesothelin polypeptide, which is overexpressed in several tumors, such as pancreatic and ovarian tumors, mesothelioma and lung cancer cells | 11-12-2015 |
20150335669 | CHEMICALLY MODIFIED TARGETING PROTEIN AND USE THEREOF - Provided is a chemically modified targeting protein, a pharmaceutical composition including the chemically modified targeting protein, a conjugate including the chemically modified targeting protein and a drug, and methods for preparing the same. | 11-26-2015 |
20150343042 | ANTI-DRUG VACCINES - The present invention relates to anti-drug vaccines based on conjugates between the drug and a non-immunogenic carrier protein. In preferred embodiments, it provides for anti-cocaine vaccines and their use to diminish the effects and/or use of cocaine in a subject. | 12-03-2015 |
20150343081 | ANTI-EPHA2 ANTIBODIES AND METHODS OF USE THEREOF - Antibodies that bind to tumor associated antigen CD44 or to tumor associated antigen EphA2, are disclosed herein, as well as related compositions and methods of use. Methods of use encompass cancer therapies, diagnostics, and screening methods. | 12-03-2015 |
20150343088 | ANTIBODY RECOGNIZING FOLATE RECEPTORS ALPHA AND BETA - The object of the present invention is to provide an antibody capable of immunologically and specifically binding to a folate receptor α and a folate receptor β. Specifically, the present invention relates to an antibody or a fragment thereof, in which the amino acid sequences of CDRH1, CDRH2, and CDRH3 of a heavy chain variable region (VH) are SEQ ID NOs: 2, 4, and 6, respectively, and the amino acid sequences of CDRL1, CDRL2, and CDRL3 of a light chain variable region (VL) are SEQ ID NOs: 10, 12, and 14, respectively. | 12-03-2015 |
20150352225 | Anti-Her2 Antibody-Maytansine Conjugates and Methods of Use Thereof - The present disclosure provides anti-HER2 antibody-maytansine conjugate structures. The disclosure also encompasses methods of production of such conjugates, as well as methods of using the same. | 12-10-2015 |
20150366986 | INTRANUCLEAR PROTEIN TRANSDUCTION THROUGH A NUCLEOSIDE SALVAGE PATHWAY - Provided herein are conjugate molecules containing a substrate for a nucleoside transport pathway linked to an active agent, wherein the conjugate can be transported into a cell or into the nucleus of a cell via a cellular nucleoside transport pathway. Further provided are methods of delivering a conjugate molecule to a target cell expressing a nucleoside transport pathway, wherein the conjugate contains a substrate for the nucleoside transport pathway linked to an active agent. Also provided are methods for screening for conjugates that are transported by nucleoside transport pathways. Further provided are methods of treating a patient having a disease or disorder affecting tissues expressing nucleoside transport pathways, in which a conjugate containing an agent effective in treating the disorder is administered to the patient. Also provided are methods of treating a patient having an autoimmune disorder involving administering to the patient a compound that inhibits a nucleoside transport pathway. | 12-24-2015 |
20150366989 | ANTI-TAT226 ANTIBODIES AND IMMUNOCONJUGATES - Anti-TAT226 antibodies and immunoconjugates thereof are provided. Methods of using anti-TAT226 antibodies and immunoconjugates thereof are provided. | 12-24-2015 |
20150368355 | ANTI-DLL3 ANTIBODY - It is intended to disclose an antibody which binds to DLL3 protein. Preferably, the antibody of the present invention recognizes a region from amino acids 216 to 492 in human DLL3 having the amino acid sequence as set forth in SEQ ID NO: 1. The present invention also provides a pharmaceutical composition, for example, an anticancer agent, comprising the antibody of the present invention as an active ingredient. The present invention further discloses a method for diagnosing cancer using the antibody of the present invention and a diagnostic drug for cancer comprising the antibody of the present invention. | 12-24-2015 |
20150374692 | METHODS AND COMPOSITIONS RELATING TO THE TREATMENT OF CANCER - The compositions and methods described herein relate to the treatment of cancer, e.g. by reducing the regression of cancer cells from regressing into cancer stem cell-like phenotypes and/or reducing the development of drug-resistant cancer cells. In some embodiments, the compositions and methods relate to inhibitors of PI3K pathway kinases and Src family kinases. | 12-31-2015 |
20150374809 | TUMOR VACCINES AND METHODS OF USE THEREOF - The present invention provides a therapeutic agent comprising an antibody-recognition epitope (ARE) covalently bound to a tumor cell, wherein the ARE is bound to an antibody that is specific for the ARE, to form a tumor cell:ARE:antibody complex, and kits and methods of using these tumor cell:ARE:antibody complexes. | 12-31-2015 |
20160000932 | MODIFIED Fc MOLECULES - Disclosed is a process for preparing a pharmacologically active compound, in which at least one internal conjugation site of an Fc domain sequence is selected that is amenable to conjugation of an additional functional moiety by a defined conjugation chemistry through the side chain of an amino acid residue at the conjugation site. An appropriate amino acid residue for conjugation may be present in a native Fc domain at the conjugation site or may be added by insertion (i.e., between amino acids in the native Fc domain) or by replacement (i.e., removing amino acids and substituting different amino acids). In the latter case, the number of amino acids added need not correspond to the number of amino acids removed from the previously existing Fc domain. This technology may be used to produce useful compositions of matter and pharmaceutical compositions containing them. A DNA encoding the inventive composition of matter, an expression vector containing the DNA, and a host cell containing the expression vector are also disclosed. | 01-07-2016 |
20160008480 | FUSION PROTEIN COMPRISING TARGETING MOIETY, CLEAVAGE SITE, AND CELL MEMBRANE PENETRATING DOMAIN, AND USE THEREOF | 01-14-2016 |
20160008486 | DUOCARMYCIN ADCS SHOWING IMPROVED IN VIVO ANTITUMOR ACTIVITY | 01-14-2016 |
20160008487 | DUOCARMYCIN ADCS FOR USE IN TREATMENT OF ENDOMETRIAL CANCER | 01-14-2016 |
20160015728 | TARGETING TUMOR CELLS WITH CHEMOTHERAPEUTIC AGENTS CONJUGATED TO MATRIPTASE ANTIBODIES - The present invention relates to matriptase antibodies and immunoconjugates of matriptase antibodies with cytotoxic agents and the use thereof for killing or inhibiting the growth of matriptase-expressing cancer cells, such as those of multiple myeloma and breast cancers. In particular, immunoconjugates comprising a matriptase monoclonal antibody and anticancer agents such as doxorubicin (DOX) are introduced, which are equipotent to anticancer agents used in free form but exhibit significantly reduced cardiotoxicity and almost no adverse effects on normal bone marrow-derived mesenchymal stromal cells that do not express matriptase. The present invention also provides compositions comprising these new immunoconjugates and use of them for treatment of malignancies comprising cells that express matriptase. In addition, administration of a matriptase antibody or immunoconjugates of a matriptase antibody and a cytotoxic agent in combination with administration of an immunomodulatory agent, such as thalidomide or an analog thereof, provides a more effective treatment of these cancers. | 01-21-2016 |
20160015732 | COMPOSITIONS AND METHODS FOR INDUCING APOPTOSIS - In an aspect, the invention relates to compositions, methods, and kits for inducing apoptosis. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 01-21-2016 |
20160015822 | Intranasal Administration of Guanidinylated Aminoglycosides - This disclosure relates to intranasal administration of conjugates comprising guanidinylated aminoglycosides (“guanidinoglycosides”) and a polypeptide (e.g., an enzyme, antibody, or polypeptide growth factor). For example, such administration methods are useful for delivering a polypeptide to the brain and/or cerebrospinal fluid. Such methods are useful for treating a lysosomal storage disease through intranasal administration of a conjugate comprising one or more guanidinoglycosides and an enzyme useful for treating a lysosomal storage disease. | 01-21-2016 |
20160024209 | ANTIGEN BINDING CONSTRUCTS TO CD8 - Antigen binding constructs that bind to CD8, for example antibodies, including antibody fragments (such as scFv, minibodies, and cys-diabodies) that bind to CD8, are described herein. Methods of use are described herein. | 01-28-2016 |
20160031988 | MULTIVARIABLE ANTIGENS COMPLEXED WITH TARGETING HUMANIZED MONOCLONAL ANTIBODY - The present invention includes compositions and methods for designing, making and using modular recombinant antibodies or fragments thereof with one half of a cohesin-dockerin pair that permits the rapid assembly of multivariant antigen conjugates. | 02-04-2016 |
20160046725 | NOVEL ANTIGEN BINDING PROTEINS AND THEIR USE AS ADDRESSING PRODUCT FOR THE TREATMENT OF CANCER - The present invention relates to novel antigen binding proteins, in particular monoclonal antibodies, capable of binding to the protein Axl as well as the amino and nucleic acid sequences coding for said proteins. From one aspect, the invention relates to novel antigen binding proteins, or antigen binding fragments, capable of binding to Axl and, by inducing internalization of Axl, being internalized into the cell. The invention also comprises the use of said antigen binding proteins as addressing products in conjugation with other anti-cancer compounds, such as toxins, radio-elements or drugs, and the use of same for the treatment of certain cancers. | 02-18-2016 |
20160051693 | Cellular Delivery of DNA Intercalating Agents - Compositions and methods for targeted delivery of active agents to cells are provided. The compositions comprise a wholly or partially double-stranded synthetic DNA carrier, and an active agent intercalated in double-stranded portions of the DNA carrier. The DNA carrier may also be linked to a targeting agent. The compositions are useful for delivering an active agent into a targeted cell type, for example a cytotoxic agent. | 02-25-2016 |
20160051694 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO CD37 PROTEINS - Antibody drug conjugates (ADC's) that bind to CD37 protein and variants thereof are described herein. CD37 exhibits a distinct and limited expression pattern in normal adult tissue(s), and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention in some embodiments provide a therapeutic composition for the treatment of cancer. | 02-25-2016 |
20160051696 | POLYPEPTIDE COMPLEX COMPRISING NON-PEPTIDYL POLYMER HAVING THREE FUNCTIONAL ENDS - Disclosed is a protein complex, comprising a physiologically active polypeptide, a dimeric protein and a non-peptidyl polymer having three functional ends (3-arm), with the linkage of both the physiologically active polypeptide and the dimeric protein to the 3-arm non-peptidyl polymer via respective covalent bonds. The protein complex guarantees the long acting activity and biostability of a physiologically active polypeptide. Having the ability to maintain the bioactivity of physiologically active polypeptides or peptides highly and to significantly improve the serum half life of the polypeptides or peptides, the protein complex can be applied to the development of sustained release formulations of various physiologically active polypeptide drugs. Also, it utilizes raw materials including the physiologically active polypeptides without significant loss, thereby increasing the production yield. Further, it can be easily purified. | 02-25-2016 |
20160060341 | T-CELL-SPECIFIC HUMANIZED SINGLE FRAGMENT ANTIBODY DELIVERY VEHICLE - The present invention relates to a humanized scFv delivery vehicle targeted to be human T-cell specific, and provides: a humanized scFv which comprises a heavy-chain variable region (VH) consisting of a polypeptide comprising an amino acid sequence given by sequence number 32 and comprises a light-chain variable region (VL) consisting of a polypeptide comprising an amino acid sequence given by sequence number 34; and a T-cell-specific drug or marker delivery vehicle comprising the humanized scFv. The humanized scFv of the present invention has minimalised antigenicity and has an effect which does not give rise to an immune reaction even when used in the human body, and thus can advantageously be used as a delivery vehicle for specifically delivering a target substance such as a siRNA gene or an immune reaction regulating protein to T-cells. | 03-03-2016 |
20160067273 | Compositions and methods for preparation of synthetic alpha-gal nanoparticles and for their clinical use - The present invention is related to the field of healing of internal injuries. In particular, the present invention provides compositions and methods comprising molecules and nanoparticles with linked α-gal epitopes from synthetic origin for induction of recruitment and activation of macrophages within or surrounding injured tissue of treated patients. These macrophages further recruit stem cells into the injured tissues. The recruited macrophages and stem cells promote the repair and regeneration of the treated injured tissue. This invention further teaches methods and compositions comprising molecules and nanoparticles with linked α-gal epitopes of synthetic origin for inducing recruitment and activation of macrophages into biomaterial implants for improving the conversion of such implants into functional tissues and organs within treated patients. | 03-10-2016 |
20160067348 | METHOD OF PREVENTING AND TREATING TYPE 1 DIABETES, ALLOGRAFT REJECTION AND LUNG FIBROSIS (BY TARGETING THE ATP/P2X7R AXIS) - The present invention relates to the role of purinergic receptors and ATP in T cell activation and autocrine system signaling. In one embodiment, the present invention provides a method of preventing or treating diabetes by administering a therapeutically effective inhibitor of ATP to a subject. In another embodiment, the present invention provides a method of preventing or treating fibrosis by administering a P2X7R soluble fusion protein. In another embodiment, the present invention provides a method of preventing or treating graft rejection by administering an inhibitor of P2X receptor signaling. | 03-10-2016 |
20160074472 | Inhibitors of Phosphatase and Tensin Homolog (PTEN) Compositions, Uses and Methods - Described herein are isolated polypeptides having phosphatase and tensin homolog (PTEN) inhibitory activity, vectors and cells for the expression thereof and methods for their use in treating diseases associated with cytotoxic stress, such as spinal cord injury, stroke, traumatic brain injury, multiple sclerosis, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), Parkinson's disease, and Huntington's disease. | 03-17-2016 |
20160075735 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME - Compounds having cytotoxic and/or anti-mitotic activity are disclosed. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed. Also disclosed are compositions having the structure: (T)-(L)-(D), wherein (T) is a targeting moiety, (L) is an optional linker, and (D) is a compound having cytotoxic and/or anti-mitotic activity. | 03-17-2016 |
20160090598 | ANTISENSE COMPOUNDS AND USES THEREOF - The present disclosure provides compounds comprising modified oligonucleotides and anti-CD22 antibodies. Certain such modified oligonucleotides conjugated to anti-CD22 antibodies are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell. | 03-31-2016 |
20160096902 | CHIMERIC ANTIGEN RECEPTOR-TARGETING MONOCLONAL ANTIBODIES - Provided are monoclonal antibodies that detect CD 19 CAR-modified immune cells and CAR-modified immune cells irrespective of the tumor associated antigen they target. Methods of using these functional monoclonal antibodies include, but are not limited to, detection, quantification, activation, and selective propagation of CAR-modified immune cells. | 04-07-2016 |
20160106862 | Re-Directed Immunotherapy - The invention provides an agent for preventing or treating a condition characterised by the presence of unwanted cells, the agent comprising: (i) a targeting moiety that is capable of targeting to the unwanted cells; and (ii) a T cell antigen, wherein the T cell antigen can be released from the targeting moiety by selective cleavage of a cleavage site in the agent in the vicinity of the unwanted cells. | 04-21-2016 |
20160114056 | ENZYMATIC CONJUGATION OF POLYPEPTIDES - One embodiment relates to methods for the enzymatic functionalization of immunoglobulins, in particular with drugs. Also disclosed herein are linking reagents, functionalized antibodies, pharmaceutical compositions, and method of treating disease and/or conditions. | 04-28-2016 |
20160114057 | MODULAR PROTEIN DRUG CONJUGATE THERAPEUTIC - The invention provides modular antibody-therapeutic agent conjugates and antibody-detectable-agent conjugates, and methods of using said conjugates in therapeutic and diagnostic procedures. | 04-28-2016 |
20160115232 | TARGETING AGENT ANTIBODY CONJUGATES AND USES THEREOF - Methods, compositions and uses are provided for bispecific antibodies comprising one or more unnatural amino acids. The bispecific antibodies may bind to two or more different receptors, co-receptors, antigens, or cell markers on one or more cells. The bispecific antibodies may be used to treat a disease or condition (e.g., cancer, autoimmune disease, pathogenic infection, inflammatory disease). The bispecific antibodies may be used to modulate (e.g., stimulate or suppress) an immune response. | 04-28-2016 |
20160120977 | PROTEINS MODIFIED WITH (AMINO) MONOSACCHARIDE-BIOTIN ADDUCT - A protein, e.g. an antibody, coated with a non-immunogenic molecule selected from an amino-monosaccharide-biotin adduct or a monosaccharide-biotin adduct is disclosed, wherein the coated protein, which has diminished immunogenicity relative to the uncoated protein and intact biological activity, enables, for example, cross-species vaccination. | 05-05-2016 |
20160120999 | COMPOSITIONS AND METHODS OF USE FOR TREATING METABOLIC DISORDERS - A complex comprising a GDF15 polypeptide is described. Methods of treating individuals with a metabolism disorder, such as, glucose metabolism disorder and/or a body weight disorder, and compositions associated therewith, are provided. | 05-05-2016 |
20160129096 | GASTRIN PEPTIDE IMMUNOGENIC COMPOSITION - The invention provides for an immunogenic composition comprising a. a directed adjuvant comprising at least an anti-CD32 moiety linked to a TLR9 ligand and a first peptidic alpha-helix; and b. a gastrin-17 peptide immunogen linked to a second peptidic alpha-helix coiled to the first alpha-helix, which peptide immunogen is any of (i) human gastrin-17 comprising the amino acid sequence of SEQ ID 1, or a fragment thereof comprising the amino acid sequence of SEQ ID 2, or at least the 4 N-terminal amino acids of SEQ ID 2; (ii) an analog of (i), preferably of rhesus monkey or murine origin; and/or (iii) a functionally active variant of any of (i) or (ii), with one, two, three or four point mutations in the amino acid sequence of SEQ ID 2. The invention further provides a kit for producing such immunogenic composition, a vaccine comprising such immunogenic composition and its medical use, such as for treating gastrin dependent diseases. | 05-12-2016 |
20160129109 | UNIVERSAL ANTI-TAG CHIMERIC ANTIGEN RECEPTOR-EXPRESSING T CELLS AND METHODS OF TREATING CANCER - The present invention provides a universal, yet adaptable, anti-tag chimeric antigen receptor (AT-CAR) system which provides T cells with the ability and specificity to recognize and kill target cells, such as tumor cells, that have been marked by tagged antibodies. As an example, αFITC-CAR-expressing T cells have been developed that specifically recognize various human cancer cells when those cells are bound by cancer-reactive FITC-labeled antibodies. The activation of αFITC-CAR-expressing T cells is shown to induce efficient target lysis, T cell proliferation, and cytokine/chemokine production. The system can be used to treating subjects having cancer. | 05-12-2016 |
20160136294 | BIFUNCTIONAL PROTEIN ANCHORS - The disclosure relates to the areas of immunology and vaccine delivery. More specifically, it relates to a bacterial vaccine delivery technology with built-in immunostimulatory properties which allow the immobilization of any antigen of interest, without prior antigen modification. Provided is an antigen-loaded immunogenic carrier complex comprising at least one bifunctional polypeptide attached to an immunogenic carrier, the bifunctional polypeptide comprising a peptidoglycan binding domain (PBD) through which the polypeptide is attached to the carrier, fused to an antigen binding domain (ABD) to which at least one antigen of interest is bound. Also described is a pharmaceutical (e.g., vaccine) composition comprising an antigen-loaded immunogenic carrier complex. | 05-19-2016 |
20160136295 | BIOMARKERS FOR TREATMENT WITH ANTI-TUBULIN CHEMOTHERAPEUTIC COMPOUNDS - Provided herein are biomarkers for predicting sensitivity to treating cancer with anti-tubulin chemotherapeutic agents. | 05-19-2016 |
20160137736 | ANTI-CTLA4, ANTI-GLUT2 PROTEIN FOR THE TREATMENT OF TYPE 1 DIABETES - The disclosure relates to a protein composed of a first polypeptide or polypeptide domain having a first specific binding activity for Cytotoxic T-lymphocyte Antigen 4 (CTLA-4) expressed on a T-cell cell surface and a second specific binding activity for Glucose Transporter 2 (GLUT2) or an extracellular ectodomain thereof expressed on a pancreatic β-cell surface, wherein binding of the first polypeptide or polypeptide domain to CTLA-4 induces a CTLA-4 specific agonist response in the T-cell, and binding of the second polypeptide or polypeptide domain to GLUT2 or an ectodomain thereof does not inhibit GLUT2 glucose transporter function, wherein said agonist response in the T-cell induces a response that reduces immunoreactivity against pancreatic β-cells. | 05-19-2016 |
20160138021 | COMPOSITIONS AND METHODS FOR TREATING CANCER AND OTHER DISEASES - Aptamers and improved aptamers are provided with enhanced efficacy for binding to target molecules in vivo or for treating cancer or other diseases. Such improvements in aptamers are provided that enhance in vivo efficacy such as binding to the target molecule or enhancing anti-cancer activity. Such improvements also include stability to serum nucleases, reduced binding to a soluble form of the target molecule, increased avidity, affinity or specificity to the target molecule on a cell surface, increased lifetime in circulation, or any combination of the foregoing. Improvements are provided by truncation, multimerization, including at least one non-natural nucleic acid, adding a 3′ or 5′ polyethylene glycol, or any combination thereof. Aptamers for treatment of autoimmune diseases are also provided. | 05-19-2016 |
20160158318 | METHODS FOR TREATING SCLERODERMA BY ADMINISTERING A SOLUBLE CTLA4 MOLECULE - The present invention relates to compositions and methods for treating autoimmune diseases by administering to a subject a CTLA4 molecule that block endogenous B7 molecules from binding their ligands. | 06-09-2016 |
20160158368 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HISTIOCYTOSIS - The present application provides methods of treating CD163 | 06-09-2016 |
20160186260 | CANCER VACCINATION WITH ANTIGEN EVOLUTION - The invention provides methods for treating with cancer vaccines patients whose cancers undergo clonal evolution. The invention makes use of a series of cancer vaccines to stimulate a patient's immune system to mount both a humoral and cellular immune response against cancer cells as cancer-specific antigens on the cancer cells change by clonal evolution. Vaccines used in the invention are derived from antigens unique to the cancer. In one aspect of the invention, such unique antigens are determined by generating sequence-based profiles of cancer related nucleic acids. In some embodiments, cancer antigens may be identified in sequence-based profiles of exon sequences from a sample suspected of containing cancer cells; in other embodiments in which lymphoid or myeloid cancers are being treated, cancer antigens may be identified in sequence-based clonotype profiles. | 06-30-2016 |
20180021440 | BISPECIFIC ANTIBODY CAPABLE OF BEING COMBINED WITH IMMUNE CELLS TO ENHANCE TUMOR KILLING CAPABILITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 01-25-2018 |
20190142857 | METHODS | 05-16-2019 |
20190142966 | Functionalized Nanoparticles and Compositions for Cancer Treatment and Methods | 05-16-2019 |
20190144443 | ASYMMETRIC CONJUGATE COMPOUNDS | 05-16-2019 |
20220135692 | CONJUGATES FOR TREATING INFLAMMATORY DISEASE AND IDENTIFICATION OF PATIENTS LIKELY TO BENEFIT FROM SUCH TREATMENT - The present invention relates to a conjugate that specifically targets a calcineurin inhibitor to T cells, such as Th17 cells, for use in a method for the treatment of an inflammatory disease. The invention also relates to a method for treating an inflammatory disease by administering a conjugate that specifically targets a calcineurin inhibitor to T cells, such as Th17 cells. In addition, the invention relates to a method for identifying a subject likely to be resistant to steroid treatment, as well as a subject likely to benefit from treatment with a calcineurin inhibitor. | 05-05-2022 |